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ABSTRACT
Adenoviruses have been extensively researched for use as vectors for both gene therapy and 
vaccination. Gene therapy is the delivery of transgenes in order to treat genetic disease, whereas 
vaccination with viral vectors is primarily to induce immune responses to transgenes and in some cases 
the vector itself. While immune reactions against the adenovirus backbone can be desirable in 
vaccination strategies, this has proved to be a particular problem in gene therapy settings. The most 
fully investigated human adenoviruses (HAds) are serotypes 2 and 5, which are endemic in the 
population with most people harbouring neutralising antibodies to them. Quantifying the levels of 
neutralising antibodies to adenoviral vectors in patients is important as these may impede vector 
efficiency upon administration. Recent research has shown that tins can be overcome by the use of 
alternative vectors based on less prevalent HAds and adenoviruses from heterologous species. 
However, before such alternatives can be used it is first necessary to investigate whether these viruses 
can express genes in cells of the target species. For development as a live vaccine vector their ability to 
infect cells of the target species is of interest.
Canine adenovirus type 1 (CAV-1) is a candidate vector for both gene therapy and vaccination. In its 
canine host CAV-1 causes a number of diseases including hepatitis. It has the ability to infect a wide 
range of tissues in the dog and cells from several animal species (Koptopoulos & Cornwell, 1981). In 
addition, limited investigations have shown CAV-1 capable of infecting human cells (Gehle & Smith, 
1969). One of the aims of the presented work was to investigate CAV-1 infection in cells of two 
candidate species: cats and humans, using sensitive modern techniques including real-time PCR and 
RT-PCR. This would determine the suitability of CAV-1 as a vector in these species, primarily for 
vaccination in cats and gene therapy in humans.
In feline cells CAV-1 infection was productive with growth kinetics similar to CAV-1 infection of 
canine cells. In addition, transgene expression was demonstrated from a replication competent CAV-1 
vector. DNA replication and transcription were demonstrated in human cells, as was transgene 
expression. Classical adenoviral cytopathic effect was not observed in human cells, however, in A549 
cells CAV-1 infection resulted in the limited production of de novo infectious virus. These findings 
indicate that CAV-1 has potential for development as a vector for use in both species.
One of the features that initially attracted researchers to the development of adenoviral vectors was 
their ability to infect a wide variety of tissues. However, the promiscuous tropism of these vectors can 
lead to limited transgene expression in target tissues. Untargeted vectors can cause a number of 
problems such as toxicity in non-target tissues and high dosage requirements, which can lead to 
harmful immune responses. The fibre mediates initial adenovirus attachment to host cells and research
has shown that adenoviruses can be targeted through modification of this protein. A second aim of this 
work was proof-of-principle experiments to investigate whether CAV-1 could tolerate the fibre of 
another adenovirus serotype. CAV-1 vectors that were pseudotyped with CAV-2 and HAd5 were 
created that grew to high titres and displayed altered tropism in preliminary investigations. As such, a 
vector system was developed that will facilitate targeting tlnough exploitation of existed targeted HAd5 
fibres in their entirety or tlnough knob exchange. In addition, fibre deleted vectors were developed. 
Infection of MDCK cells with these viruses did not result in cytotoxicity. However, fibre expressing 
cell lines allowed productive infection.
Finally, it is important to determine the levels of pre-existing antibodies in target species and therefore 
the neutralisation of CAV-1 by human and feline serum samples was determined. None of the feline 
samples had neutralising activity against CAV-1. Only 22% of human serum samples were able to 
neutralise CAV-1 compared with the neutralisation of HAd5 by 46% of samples. The same human 
samples were investigated for the ability to neutralise CAV-1 vector pseudotyped with the HAd5 fibre. 
The results showed that neutralisation of tins vector by human sera was related to that of CAV-1 and 
HAd5.
In conclusion these results demonstrate that CAV-1 can express transgenes in feline and human cells, 
that there is potential to modify its existing tropism and that there are low (or no) neutralising 
antibodies to it in both species investigated.
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CHAPTER 1
: ' jIntroduction
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1.1 INTRODUCTION
Gene therapy in its broadest sense is the amelioration of disease by delivery of 
genes to target cells and tissues. There are over 4000 known genetic disorders, of 
which only a few can be treated by conventional medicine and where treatments 
exist they are often inefficient. The aim of therapeutic gene therapy is to deliver 
and express transgenes without causing further disease. Another application of 
gene therapy is in the treatment of cancer either by targeting genes or lytic 
viruses to tumour cells, which will lead to their destruction, or by stimulating the 
immune system to reject tumours. Another example of gene therapy working 
with the immune system is in the administration of vaccine vectors.
CuiTent research explores the delivery of genes to patients by both viral and non- 
viral processes. Non-viral gene therapy involves briefly disrupting the cell 
membrane by either chemical or physical methods in order to allow direct 
delivery of the therapeutic DNA to the cell, where the transgene is expressed. In 
contrast, virus based gene therapy utilises the natural ability of viruses to target 
specific cells in the body, cross the plasma membrane and enter the cell, where, 
integration into the host chromosome or genomic persistence occurs and viral 
gene expression occurs. Manipulation of virus genomes to accommodate 
heterologous genes allows the delivery and expression of these transgenes in host 
cells.
Non-viral vectors are usually only capable of low levels of gene expression, 
which is typically transient. For the treatment of certain genetic diseases and 
forms of cancer, short-term gene expression is sufficient, however, other diseases 
demand long-term expression. Transient gene expression is a feature of some 
viral vectors, however, some viruses integrate their genome into that of their host 
cells or maintain episomal copies part of their normal life-cycle and are 
maintained for the lifetime of the cell. This attribute is being exploited in the 
development of vectors for the treatment of patients that require stable 
expression from a therapeutic gene. However, immune responses against virus 
vectors continue to cause problems and the search for improved gene delivery
systems is ongoing. Both non-viral and viral vectors have a great deal to offer 
gene therapy and the choice of vector is determined by the nature of the disease. 
This chapter investigates some examples of these vectors and their applications.
1.2 NON-VIRAL GENE THERAPY
Around 20% of gene therapy trials to date have used non-viral vectors (Journal 
of Gene Medicine 2001). In general, non-viral vectors have a high safety profile, 
but low efficacy, in comparison with viral vectors. The various methods include 
chemical transfection, injection of purified DNA, DNA transfer mediated by 
carrier lipids, electroporation, ultrasound and gene gun.
Chemical transfection is a relatively simple method of gene delivery, achieved by 
complexing DNA with a chemical such as calcium phosphate. The complex 
causes disruptions in the cell membrane and enters the cell, where expression of is
the gene takes place (Loyter et al, 1982). Results by Werner et al, in 1990 
showed that DNA could be transfected into, not only dividing, but also non­
dividing primary postmitotic chick embryo cells m vivo. This treatment did not 
affect cell survival but it was found that the metabolic activity of the cells was 
reduced. In contrast, another gi'oup demonstrated that transfection efficiency was 
significantly affected by the growth rate of cells (Kjer & Fallon, 1991).
Transfection by this method leads to transient gene expression of low efficiency 
and has a high degree of variability between experiments (Werner et al, 1990).
Injection of naked plasmid DNA directly into skeletal muscle, liver, tumours and 
epidermis results in efficient gene expression (Wolff et al, 1990, Hickman et al,
1994). However, this expression is transient and there are areas of the body that 
cannot be reached directly and as such are untreatable by this method. With this 
in mind a non-viral vector that could be administered either orally or 
intravenously may be considered an improvement for the treatment of diseases 
with distant target sites. Coupling DNA with cationic lipids was hoped to 
provide a method for achieving this. Cationic lipids have a polar head group 
which binds DNA, and a lipid portion that both protects the DNA from 
degiadation in plasma and binds to the cell membrane (Feigner et al, 1987,
Monck et al, 2000). Although DNA delivery via cationic lipids can be achieved, 
expression is transient and proteins have been shown to clear as quickly as a 
week after administration (Song et al, 1997). It has also been reported that
cationic liposomes are toxic to certain cells when administered orally (Filion & 
Phillips, 1997). Alternatives to cationic lipids are polymers such as poly-L- 
iysine (Wu & Wu, 1987) and monoclonal antibodies (Schachtschabel et al, 
1996). Like cationic lipids, these polymers prevent the degradation of DNA but 
they too are rapidly cleared from serum by plasma proteins (Dash et al, 1999).
Electroporation in situ provides another means of transducing tissues with DNA. 
When DNA is injected into target tissue and electric fields are applied, the cell 
membranes become permeable (Neumann & Rosenheck, 1972) and DNA gains 
access to the cells. This technique is very sensitive; varying the pulse strength 
and duration slightly, and changing the number of repetitions can cause large 
variations in the levels and duration of expression and therefore must be 
optimised for each individual application (Rols & Teissie, 1990, Rols & Teissie, 
1998). Gene therapy provided by electroporation has proven to be successful in 
experimental rats and mice in a variety of dividing and non-dividing tissues, 
including tumour masses (Suzuki et al, 1998, Heller et al, 2000, Nishi et al, 
1996, Wells et al, 2000, Yoshizato et al, 2000, Goto et al, 2000). Transgene 
expression can be maintained for periods of over 9 months and readministration 
is possible due to the lack of an immune response to the vector (Mir et al, 1999, 
Rizzuto et al, 1999).
Low intensity ultiasound co-administered with echo contrast microbubble 
(Optison) also increases the transfection of DNA to target cells when applied 
after the injection of DNA (Lawrie et al, 2000, Taniyama et al, 2002 (a), 
Taniyama et al, 2002 (h)). Optison causes permeability of the cell membrane 
and is usually used as an ultrasound contrast agent as it enhances the image 
produced by ultrasound equipment. It consists of gas-filled microspheres 
surrounded by a shell of denatured human albumin. Spreading of these 
microbubbles over tissues is thought to induce transient holes in the cell 
membrane. Injection of this complexed with DNA, followed by ultrasound 
treatment leads to transduction of cells. This method showed a 300-fold increase 
in transgene activity in vascular smooth muscle cells in vitro compared with 
injection of plasmid DNA alone (Lawrie et al, 2000). In vivo transfection of 
rabbit muscles with the human angiogenic gi'owth factor, hepatocyte growth
factor (HGF), in rabbit ischaemic models was demonstrated by this method 
(Taniyama et ah, 2002 (a)). When compared with HGF delivered by plasmid 
alone, transfection resulted in angiogenesis characterised by increased capillary 
density and blood flow to these tissues. Ultrasound can be applied to almost any 
tissue of the body and this technique shows gieat promise for the treatment of 
genetic disease. It was also found that reduced levels of DNA could be used if 
coupled with Optison and low intensity ultrasound, in such cases, and no toxicity 
could be detected.
The gene gun is a helium propellant that delivers DNA-coated gold or tungsten 
particles to target cells. There have been recent reports of transduction of heart, 
liver and corneal tissues in situ (Kuriyama et al, 2000, Tanelian et al, 1997). 
When Kuriyama et al, demonstrated the delivery of a plasmid carrying the lacZ 
gene with the gene gun, they found that there was a broad distribution of 
transgene expression with expression evident at sites relatively distant from the 
site of administration. Two days after administration, Kuriyama compared the 
efficiency of gene gun delivery with that of injected plasmid DNA and 
electioporated DNA and found that expression was significantly higher in mice 
that had been treated by gene gun. However, by 28 days expression had fallen 
approximately 5-fold and readministration would be required for longer periods 
of expression.
The lack of immunogenicity and toxicity induced by non-viral vectors is a major 
benefit to their use in gene therapy. Although the expression of transgenes is 
transient, short-term expression has applications in the treatment of certain 
diseases such as ischaemia.
1.3 VIRAL GENE THERAPY VECTORS
Viruses make efficient use of cellular processes to express genes and replicate. 
We can exploit viral vectors for the delivery of therapeutic genes to cells. Each 
family of viral vectors in development offers different potential benefits. Each 
varies in its potential insert capacity, target cell tropism and duration of 
expression within the host cell. Stable, long-term, gene expression is achieved 
with vectors that are capable of maintaining genome expression in the host cell 
i.e. by integiation into the host chromosome or autonomous replication as 
episomes. Otherwise, expression is transient, the vector DNA being eventually 
degraded by cellular factors or lost through cell division. However, each virus 
also carries a degree of risk with it, for example oncogenicity or pathogenicity. 
Viral vector research aims to enhance the benefits offered and eradicate the risks 
confeiTed by these viruses to optimise them for the therapy of genetic disease.
The treatment of most genetic diseases requires the use of replication deficient 
viral vectors, for safety purposes. This can be achieved by deleting essential 
genes, which has the potential benefit of creating space for the insertion of 
transgenes. For the treatment of cancer, the use of viral vectors that can 
specifically infect and replicate in tumours (conditionally replicative viruses) has 
been shown to lead to the regression of tumours. In some cases, the induction of 
immune responses against these vectors has aided this regression (see sections 
1.3.1, 1.3.3, 1.4.3.5).
Humoral and cellular immune responses induced by viral infections, inactivate 
viruses and are cytotoxic to infected host cells. Although these responses can be 
utilised for the tieatment of cancer, they must be diminished in the development 
of viral vectors for replacement therapies. It is therefore vital that the immune 
responses against candidate viruses are understood when developing a gene 
therapy vector.
The endocytotic uptake of virions by cells with antigen presenting potential, such 
as macrophages, dendritic cells or B cells, leads to the induction of the specific 
immune response. Virus containing endosomes fuse with lysosomes and are 
proteolysed. These vesicles then interact with major histocompatibility complex 
type II molecule (MHC-II) containing vesicles, which leads to the presentation of 
degraded viral antigens by MHC-II molecules at the cell surface. Antigen 
presenting MHC-II molecules are recognised by ‘helper’ CD4 T lymphocytes.
1.3.1 The Immune Response to Viruses
The following information is reviewed in greater depth by Whitton & Oldstone, ;
2001, and Roitt, 1997. The immune system can be functionally divided into non-
Specific (innate) and antigen-specific (adaptive) immune responses. Antigen-
specific immune responses involve the action of B and T lymphocytes that both X
destroy microbes and provide memory in order to prevent future attack. Non- |
specific responses kill pathogens and also direct the specific immune effectors to %the area of infection. Although these are classified separately, they work 
together closely in order to strengthen the defence against infectious agents.
The innate immune response is the body’s first line of defence against microbes 
and it becomes active within minutes of infection. There are various branches of 
the innate immune system, including interferon (IFN), macrophages and natural 
killer cells (NK cells). IFN inhibits viral replication by inhibiting protein 
synthesis and degrading viral RNA. It upregulates cellular proteins that are 
involved in the immune response e.g. major histocompatibility complexes 
(MHC) (see later in this section) and activates other cytokines and cells of the 
immune system such as NK cells and macrophages. Macrophages can limit viral 
spread either by killing virus infected cells or by inducing molecules such as IFN 
or TNFa, which selectively lyses infected cells. NK cells either kill viruses by 
perforin induced cytolysis or by the induction of cytokines. Later in infection, 
and in conjunction with the adaptive immune response, NK cells recognise IgG 
antibody-coated cells surfaces and kill these target cells.
Clonal expansion of the interacting T cell follows and the helper T cells secrete 
cytokines which lead to the activation and differentiation of other immune cells 
such as CD8 T lymphocytes, NK cells, macrophages and B cells.
f
B cells, the main component of the humoral immune system, have 
immunoglobulins on their surface and act as receptors for antigens. The 
formation of antigen-immunoglobulin complexes leads to the clonal expansion of 
B cells and the formation of specific antibody producing memory cells. In 
addition, the binding of antibodies to the surface of viruses prevent virus-cell 
interactions and when complement proteins bind to antibody-antigen complexes 
the complement cascade is activated (see later in this section).
A proportion of the proteins within every cell are degraded into peptides of 
approximately 9 amino acids in length. These are transported across the 
endoplasmic reticulum where they encounter major histocompatibility complex 
type I molecules (MHC-I), which take them to the plasma membrane for immune 
surveillance. When a virus has infected the host cell, the viral proteins produced 
by translation are also degraded and presented in this way. CD8 T lymphocytes, 
otherwise known as ‘killer’ T cells or cytotoxic T lymphocytes (CTLs), 
recognise peptides presented by MHC-I molecules and either destroy the 
presenting cells by releasing perforin, a protein which forms pores in the target 
cell, inducing apoptosis, or through the release of cytokines such as IFN and 
TNF.
As mentioned previously in this section, antigen-antibody complexes may 
activate the complement system. Inactive complement proteins are found 
circulating the bloodstream at all times. There are over 25 complement proteins 
that work in conjunction with antibodies to destroy pathogens. The binding of 
the first complement molecule. C l, to antigen-antibody complexes triggers off a 
‘complement cascade’ that results in the attack of infected cell membranes, 
allowing the flow of molecules and fluids in and out of the cell, which as a result 
swells and bursts. There are other consequences of the complement system, for 
example, target cells are coated with component C3b, which is recognised by 
phagocytes and the cells are therefore engulfed and destroyed by phagocytosis.
These immune functions are beneficial to the host during wild-type viral 
infection, however, when they are induced against viral gene therapy vectors 
they may lead to destruction of the vector. Understanding of the immune 
response that patients mount against a vector backbone is therefore vital.
The immune responses to adenovirus vectors are discussed in Chapter 6.
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1.3.2 Retroviral Vectors
The retroviruses are a diverse family of viruses that have been isolated from most 
species of vertebrates and invertebrates (see review by Goff 2001). The first 
human retrovirus to be discovered was Human T cell leukaemia virus (HTLV). 
In general, the effects of retroviral disease are mild, with infection resulting in 
life-long low-level viraemia. However, there is a small subgroup of retroviruses 
that causes significant disease. This includes human immunodeficiency virus 
(HIV) (section 1.3.3), and the transforming retroviruses, which potentially induce 
oncogenesis in host cells and consequently the formation of tumours.
Retroviruses have a diploid RNA genome of between 8 and 1 Ikb that is encased, 
along with reverse transcriptase and other regulatory proteins, in a nucleocapsid 
suiTOunded by a lipid envelope impregnated with glycoproteins. They gain entry 
to host cells via interactions between the viral glycoproteins and cellular 
receptors. Within the cell cytoplasm the RNA genome disassociates from the 
capsid and envelope and is converted into double stranded DNA (provirus) by 
reverse transcriptase. The pro virus DNA then migiates to the nucleus and is 
integrated into the host genome. The integrated retroviral DNA is maintained for 
the lifetime of the cell and expressed along with the host genome. The major 
genes of the retrovirus genome are the gag, pol and env genes, which are flanked 
by long terminal repeats (LTRs) that contain regulatory transcriptional elements 
and a packaging sequence Q¥) at the 5’end. Gag and pol encode proteins 
essential for encapsidation and reverse transcription, respectively. The env 
protein encodes glycoproteins are present in the viral envelope. The LTRs are 
required for integration into the host genome and expression of the viral genes, 
acting as promoter-enhancer elements.
The most commonly researched virus for gene therapy is Moloney murine 
leukaemia virus (MoMLV), which has been used in almost 70% of gene therapy 
trials (Journal of Gene Medicine 2001). Replication defective retrovirus vectors 
are created by engineering plasmids which contain the desired therapeutic gene.
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along with LTRs and the Y. These plasmids are transfected into cell-lines that 
provide gag, pol and env genes, which are essential for packaging in trans 
(packaging cell-line) (Markowitz et al, 1988). The deletion of these genes from 
the genome allows a tiansgene capacity of approximately 7kb and since they 
have been separated from Y and the LTRs, only the chimeric genome can be 
packaged, reducing the risk of recombination events leading to replication 
competent viruses (Takahara et al, 1992). The newly assembled viral vector can 
now infect cells and integrate into the host genome. In theory, the vector DNA 
will be maintained for the lifetime of the host cell and will be expressed along 
with the host DNA to produce therapeutic proteins.
Although the chromosomal insertion of transgenes is the major benefit to the use 
of retroviruses for gene therapy, insertion is iiTeversible and as such the long­
term mutation of host genes is a consequence that must be considered. Also, 
integration of retroviral proviruses is random (Seiki et al, 1984) and creates a 4
different insertional mutation in every cell the viral vector infects, so it is 
possible that oncogenes will be activated and essential genes such as tumour 
suppressor genes will be inactivated (Hansen et al, 2000, reviewed by Gray 
1991). An area of retroviral research that must be expanded is the development 
of retroviral vectors that mediate site-specific integration into the host genome.
This is likely to be achieved by creating chimeric vectors that encode for 
sequences known to integrate into specific areas of the host chromosome.
Therapeutic genes targeted to and integrated at their natural sites are more likely 
to function normally. The integration site also determines the level of 
transcription of the tiansgene.
Most retroviruses can only infect cells that are dividing at the time of infection 
and as such cannot infect tissues such as muscle, brain, lung and liver (Miller et 
al, 1992). However, non-dividing cells can be transfected ex vivo and 
transplanted back into the animal (Dai et al, 1992). Although the ex vivo 
approach has been problematic, in that transplanted cells may not graft to tissues 
of the animal and the expression of therapeutic proteins is often shut off soon 
after tiansplantation (Palmer et al, 1991), there has been a degiee of success
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with this approach (Pruchnic et al, 2002). For example, Suzuki et al, 
demonstrated expression of a gieen fluorescent protein (GFP) transgene for at 
least 8 weeks from retrovirus transduced neuronal progenitor cells grafted onto 
the brains of mice (Suzuki et al, 2002).
The selective replication of reti'oviral vectors in dividing cells has been used to 
provide a treatment of tumours in non-proliferating tissues. A vector based on 
MoMLV was developed which delivered drug susceptibility genes (herpes 
simplex thymidine kinase [HS-TK]) to brain tumours in rats (Ram et al, 1993). 
Upon administration of ganciclovir (normally non-toxic) to the HS-TK 
expressing brain tumours, the thymidine kinase phosphorylated the ganciclovir. 
Phosphorylation of ganciclovir results in a deoxyguanosine triphosphate (dGTP) 
analogue which inhibits the incorporation of dGTP, terminating DNA elongation. 
In this study, HS-TK expressing cells died upon ganciclovir administration and 
the tumours regressed. Alternatively, treatments for cancer could include the use 
of retroviral vectors that are targeted specifically to tumour cells and either 
induce apoptosis or provide tumour suppressor genes (reviewed in Nielsen & 
Maneval, 1998).
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Retrovirus based gene therapy has great prospects for a range of genetic diseases, 
including cancer. Nevertheless, in 2002 retrovirus based gene therapy suffered a 
serious set back (Marshall, 2003, Kaiser, 2003). A research group in France had 
previously restored the immune systems of 9 out of 11 X-linked severe combined 
immunodeficiency (X-SCID) sufferers using a retroviral vector. However, 
within 4 months of each other, 2 patients were diagnosed as suffering from 
leukaemia. In both patients the vector had inserted within or close to a gene, 
LM02, which has been associated with leukaemia when abnormally expressed. 
Such events highlight the need for development of retroviral vectors with an 
improved safety profile, perhaps through targeting of integration site, and for 
appropriate risk-benefit analyses.
1.3.3 Lentiviral Vectors
Viruses from the lentivirus subclass of the retiovirus family have the potential to 
infect both dividing and non-dividing cells. The best known of these is the 
human immunodeficiency virus (HIV) (reviewed by Freed & Martin, 2001). 
HIV infects cells expressing the CD4 epitope, which is present on two cell types 
of the immune system: CD4 helper cells and monocytes. It replicates in these 
cells and kills them, compromising both aims of the immune system and leaving 
the host vulnerable to infection. This eventuality is preceded by an 
asymptomatic carrier state that can last for 10 years or longer before acute 
disease occurs, known as acquired immune deficiency syndrome (AIDS).
Like other retroviruses, lenti viruses have gag, pol and env genes, LTRs defining 
the ends of the genome, and a similar replication cycle. In addition, they have 
six accessory genes termed tat, rev, vpr, vpu, nef and vif, which augment viral 
infectivity through modulation of the host cell and the enhancement of viral 
expression, assembly and release. The full range of function for each of these 
accessory genes is yet to be elucidated (see Klimatcheva et al, 1999 for a 
review).
The development of lentiviral vectors is difficult as a result of the complexity of 
the lenti virus genome. For example, it is essential that the vpr gene is provided 
in trans for the propagation of vpr deleted vectors. However, vpr gene products 
are cytotoxic to cells and initial attempts to develop packaging cell-lines were 
therefore problematic (Flanelles et al, 1995). Nevertheless, the development of 
inducible cell-lines that expressed all HIV-1 proteins except the envelope 
polyprotein overcame this problem and modified HIV vectors were produced to 
relatively high titres (Kafri et al, 1999).
HIV has all the advantages of the other retroviruses, such as insert capacity, and 
long-term expression of genes through integiation, and additionally it can 
replicate in non-dividing cells. Although the natural tropism of HIV is limited to 
CD4 positive cells, it can be modified by replacing the env glycoprotein with that
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of another virus, providing the vector with an extended range of infectivity. This 
is generally perforaied in trans and is called pseudotyping. Expression of P-gal 
from an HIV-based vector pseudotyped with the neurottophic vesicular 
stomatitis virus (VSV) envelope glycoprotein was demonstiated in rat brains in 
vivo. This expression was maintained for over 3 months after a single 
administration (Naldini et al, 1996a, Naldini et al, 1996b), highlighting the 
retargeting of this vector, the transduction of non-dividing cells and maintenance 
of expression.
As with all viral vectors, a major concern with the use of lentiviruses for gene 
therapy is the risk of development of replication-competent recombinants or 
regeneration of wild-type virus. The LTRs are necessary for both the integration 
and transcription of lentiviruses and as such it is also necessary to provide the 
LTR for vector integration. Self-inactivating vectors have been developed which 
have a partial deletion in the LTR that prevents transcription from the LTR 
without affecting integration of the vector (Zufferey et al, 1998, Deglon et al, 
2000), therefore preventing the generation of recombinant replicative viruses.
Considering the highly pathogenic nature of wild-type lentiviruses, the safety of 
vectors based on these viruses must be ensured. When this safety is achieved 
with confidence, it is expected that lenti virus vectors will be powerful tools for 
long term therapeutic gene therapy.
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1.3.4 Herpesvirus Vectors
Herpesviruses are DNA viruses that primarily infect the nervous system but also 
have the ability to infect other cells such as muscle, liver, lung and tumour cells 
(reviewed by Roizman & Knipe, 2001, Roizman & Pellet, 2001). The 
herpesvirus family includes herpes simplex viruses (HSV), varicella-zoster virus 
(VSV), epstein-baiT virus (EBV) and cytomegalovirus (CMV). These viruses 
have complex genomes of 100 to 250kb, expressing approximately 80 genes that 
are wound around a protein core and are enclosed in an icosahedral capsid. The 
capsid is sunounded by a proteinaceous tegument, which is in turn encompassed 
by an envelope embedded with glycoprotein spikes.
The most intensively researched herpesvirus for gene therapy is HSV-1. Many of 
the herpesvirus genes are nonessential and can therefore be replaced with 
transgenes. As such herpesvirus vectors have potentially large insert capacities. 
HSV-1 has a capacity of approximately 150 kbp, which allows expression of 
multiple transgenes from the same vector (Krisky et al, 1998a, Krisky et al, 
1998b). The two main types of HSV-1-based vectors developed are recombinant 
virus vectors and amplicon vectors. Recombinant HSV-1 vectors can be either 
replication-conditional or replication-deficient. Replication-conditional HSV-1 
vectors, which replicate only in tumour cells and destroy them, have been 
designed and replication in brain tumours without associated toxicity was 
demonstrated (Rampling et al, 2000, Papanastassiou et al, 2002). On the other 
hand, replication-deficient vectors have had essential functions deleted with the 
puipose of stably expressing therapeutic trans genes in target cells in the absence 
of cytotoxicity (Krisky et al, 1998a, Samaniego et al, 1998), However, it has 
proven difficult to eliminate all viral cytotoxicity (Toda et al, 1999, Todryk et 
al, 1999) and this has led to the development of HSV-1 amplicon vectors. These 
are plasmids that carry the HSV-1 origin of replication and packaging signal 
along with a transgene. Propagation of amplicon vectors requires cotransfection 
of these plasmids with helper plasmids that lack the packaging signal but contain 
essential HSV-1 genes (Fraefel et al, 1996, Saeki et al, 1998, Stavrapoulos & 
SUathdee, 1998). However, cytopathic effects from the viral packaging proteins
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are still difficult to remove completely (Fraefel et al, 1996) and as such strong 
immune responses are developed against amplicon vectors (Wood et al, 1994).
HSV has two separate life cycles, latent and lytic. During the latent cycle only 
the latency (LAT) promoter is expressed. The LAT promoter is a useful site for 
insertion of a transgene to ensure its stable expression during latency. 
Expression of transgenes under the control of the LAT promoter in a herpes 
simplex virus type I (HSV-I) vector has been shown to last for up to 18 months 
(Carpenter & Stevens, 1996). The lytic life cycle produces many virus particles 
that leave the cell by budding, enveloping the particles with the cellular plasma 
membrane. This budding eventually leads to death of the cell. The lytic cycle 
may be utilised in gene therapy for the destruction of tumour tissue (Toda et al, 
1999, Todryk et al, 1999), although this requires the specific transduction of 
tumour cells.
Herpesviruses attach to host cells via glycoproteins embedded in their lipid 
envelope (Rajcani & Vojvoda, 1998). Like retroviruses, vectors based on 
herpesviruses can be targeted by replacing the cell surface glycoproteins with 
ligands attracted to different receptors or surface determinants from other viruses 
(LaqueiTe ef fl/., 1998).
The replication of herpesviruses within neurones makes them particularly 
suitable for the treatment of neurological diseases. Their very large insert 
capacity and the possibility of long-term gene expression are also advantages. 
However, these are hampered by the inherent cytotoxicity of herpesvirus proteins 
and the induction of powerful immune responses. Further development of these 
vectors is required in order to optimise them for use in gene therapy.
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1.3,5 Adeno-Associated Virus Vectors
V
Adeno-associated viruses (AAVs) are the sole members of the genus i
Dependovirus of the parvovirus family (reviewed by Muzyczka & Berns, 2001).
Those that infect humans have not yet been associated with disease, although 
other parvoviruses are able to cause significant infection in the human host. For 
example, parvovirus B19 causes the predominantly childhood illness commonly 
known as fifth disease that usually causes a mild rash and is often preceded by a 
fever and malaise. However, infections with B19 are more problematic in 
immunosupressed patients, pregnant women or people suffering with 
haematological diseases such as chronic anaemia or sickle cell disease (reviewed 
by Katta, 2002). Despite the lack of AAV pathogenesis in humans, 87% of the 
population have anti-AAV type 2 antibodies and the less common AAVs range 
from 20-60% in prevalence (unpublished data Li & Samulski [Walsh & Chao,
2002]). AAVs possess a single stranded DNA genome of approximately 4.7 kb, 
which has 2 open reading frames (ORFs) and is encapsidated by three structural 
proteins, VPl, VP2 and VP3. The left-hand ORF, rep, encodes for proteins 
involved in replication, gene expression and integration; the right-hand ORF, 
cap, encodes for the capsid proteins, all of which are essential for formation of 
virus particles (Hermonat et a l, 1984). These ORFs are flanked by ITRs 
containing a packaging sequence. AAVs are capable of replication in both 
dividing and non-dividing cells (Flotte et al, 1994). However, they are unable to 
replicate independently and require factors from a helper virus such as 
adenovirus or herpes simplex virus. In the presence of a helper virus, AAV 
infection results in a productive infection. The lack of a helper virus leads to 
integration of the AAV genome specifically into human chromosome 19 where a 
latent infection is established. If the cell is subsequently infected by a helper 
virus the integrated genome is recovered and AAV replication takes place. As 
such the host range of AAV is determined by that of the helper virus. .
AAV vectors can be produced by providing the ITRs and T  in cis and the cap 
and rep genes in trans (Samulski et al, 1989). The production of AAV vectors
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also requires a helper virus that is attenuated for safety purposes e.g. E l deleted 
adenovirus (Samulski et al, 1989) that must be removed before administration.
AAV genomes have packaging limitations of up to 108%, and therefore have a 
potential capacity of only 5 kb (Dong et al, 1996, Rolling & Samulski, 1995).
This 5 kb includes the ITR, packaging sequence and any chosen promoter and 
enhancer elements, limiting the possible applications of an AAV vector for gene 
therapy e.g. the coding sequence of the cystic fibrosis transmembrane 
conductance regulator (CFTR) approaches 4.5 kb, with additional essential 
sequences the limit of 5kb will be exceeded.
A feature of AAVs is their site-specific integration (Kotin et a l, 1990), which 
requires expression of the rep protein (Kearns et ah, 1996). Integration of gene 
therapy vectors at predetermined sites is highly desirable, however, inclusion of 
the rep gene significantly reduces the potential tiansgene capacity of AAVs.
The limitation of small transgene capacity was overcome when Yang et al, 
found that the ability of AAV genomes to form circular concatamers when 
transduced into some cells (Yang et al, 1999) could be utilised to express genes |
that exceed the noimal packaging limits (Yan et al, 2000). This was canied out 
by transduction of two AAV2 genomes expressing separate portions of the 
erythropoietin gene (which alone exceeds the packaging limit of AAV2). The 
two genomes formed concatamers in cells and underwent intramolecular 
splicing. This splicing lead to the expression of the erythropoietin gene both in 
vivo and in vitro in muscle cells. Duan et a l also exploited this feature of AAV 
by the cotransduction of one AAV vector containing enhancer elements with a 
second containing the tiansgene of interest (luciferase) with or without the SV40 
promoter (Duan et al, 2000). The dual-vector without a promoter increased 
expression of luciferase 200-fold compared with a single AAV vector, and the 
dual-vector with the SV40 promoter increased expression 600-fold.
Although high proportions of the population have anti-AAV antibodies, 
neutralising antibodies to different AAV serotypes are non-cross-reactive 
(unpublished data Li & Samulski as referenced by Walsh & Chao, 2002).
Therefore, immunological testing and the availability of a range of AAV 
serotype vectors are likely to limit the restrictions posed by pre-existing immune
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responses. The site-specific integration of AAV vectors could result in long-term 
transgene expression without the risk associated with random integration 
provided that modifications were made to prevent mobilisation of the vector 
upon natural helper virus infection.
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1.3.6 Other Viral Vectors
In recent years there has been increased interest in more diverse viruses.
Examples of these include Kunjin virus, poliovirus and Semliki Forest virus from 
the flavi virus, picornavirus and alphavirus families, respectively (see Hew son 
2000 for a review). As with the other viral vectors described in this chapter, each 
of these comes with its own advantages and disadvantages for gene therapy 
application. For example, Semliki Forest virus is an alphavirus with 
neurotropism. It has been found to express high levels of proteins in the host cell 
cytoplasm for relatively short periods of time and would therefore appear to be a 
suitable candidate for transient delivery of genes for the treatment of neural 
disorders. However, this virus induces a severe cytopathic effect that results in 
host cell death within days of infection and as such it is necessary that rigorous 
investigations and significant modifications to SFV are made in order to prevent 
unwananted replication in patients. Nevertheless, this cytotoxicity could be used 
in the treatment of tumours. Replication-deficient SFV vectors which have had %
their structural genes removed (packaged using helper viruses) have been shown 
to be efficient in causing the regression of tumours (Murphy et al, 2000).
As with other viral vectors, detailed characterisation of these viruses is necessary 
prior to their use as gene therapy vectors. It essential that the life-cycles of any 
new candidate viral vectors are well understood and that essential and pathogenic 
genes are identified in order to ensure safety before they can be used as gene 
therapy vectors.
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1.4 ADENOVIRUS VECTORS
There are over 100 different serotypes of adenovirus classified in either 
Aviadenoviridae or Mastadenoviridae genera of the Adenoviridae family. They 
have a broad range of hosts with new members being discovered continually. 
Natural adenovirus hosts include humans, dogs and farm animals such as sheep, 
pigs, goats, cattle, chickens and turkeys; they have also been found to have 
simian, murine and reptilian hosts (McFenan et al, 1971, Kawamura et al, 
1972, Lehmkuhl & Cutlip, 1999, Darbyshire et al, 1965, S arma et al, 1965, 
Simmons et al, 1976, Fong et a l, 1965, Missal et al, 1969, Clark et al, 1973). 
Of the adenoviruses isolated, 51 are human adenoviruses (HAds) that have low 
pathogenicity, causing primarily mild respiratory distress and occasionally 
ocular, gastrointestinal and urinary tract diseases. Of these the most intensively 
researched have been human adenoviruses types 2 and 5 (HAd2 and HAd5) and 
from this work there is now a wealth of information about the adenovirus 
structure and life cycle that is applicable to many other serotypes.
1.4.1 Structure of Adenoviruses
Adenoviruses are non-enveloped viruses that have a linear double stranded DNA 
genome, which ranges in size between serotypes. The frog adenovirus genome is 
the smallest known, approximately 26 kb (Davison et al, 2000), compared with 
chicken embryo lethal orphan virus (CELO), the largest known adenovirus with a 
genome of approximately 44 kb (Chiocca et al, 1996). HAd genomes are 
approximately 36 kb and are packaged in an icosahedral capsid approximately 
80nm in diameter. This capsid is made up of 252 protein capsomeres: 240 
hexons and 12 pentons that are found at the 12 vertices of the virion (see Figure 
1.1). A trimeric fibre protein extends from each penton base that consists of a 
tail domain at the N-terminus, a long shaft domain made up of repeating beta 
sheet structures (van Raiij et al, 1999) and ends in a globular head domain at the 
C-terminus. The role of the fibre in infection is the binding of the appropriate
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cellular receptor. There are also four minor cement proteins (VI, VIII, IX and Ilia) 
present in the capsid shell that stabilise the capsid through associations with the 
hexons, pentons and core proteins. Within the capsid the viral DNA is covalently 
attached to terminal proteins at its 5’ ends and is also associated with core proteins V 
and VII in a chromatin like structure. A protein that has unknown functions. Mu, and 
has a molecular weight of approximately 4000, is also found within the capsid 
(Hosokawa & Sung, 1976).
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Figure 1.1 Structure of adenovirus (derived from Russell, 2000). Within the 
virus core, the double stranded DNA genome forms a chromatin like structure with 
proteins V, VII and Mu. It also has a 55Kda terminal protein (TP) located at the 5’ 
end of each strand. The core is connected to the viral capsid via protein VI 
interactions with hexon proteins. The hexon, penton and fibre proteins are the major 
capsid proteins; they are stabilised through associations with minor capsid proteins 
llla, VIII and IX (not shown).
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1,4.2 Adenovirus Life Cycle
Unless otherwise stated, the information that follows regarding the adenovirus 
lifecycle relates to either HAd2 or HAd5 (the wild-type adenovirus lifecycle is 
reviewed by Shenk 2001).
1.4.2.1 Attachment & Internalisation
The fibre facilitates attachment to the host cell membrane through high-affinity 
interactions between its knob domain (Henry et al, 1994) and the appropriate 
host cell receptor. Internalisation is achieved via interactions between the penton 
base and a secondary receptor (Wickham et al, 1993). These receptors differ 
between adenoviruses of different species and serotypes. In 1997 a 46 kDa 
cellular protein, which associated with the fibre in the attachment of HAds 2 and 
5 to permissive HeLa cells was isolated and named the coxsackie and adenovirus 
receptor (CAR) as it is also the receptor for coxsackie B virus (Bergelson et al,
1997). CAR consists of a 222-amino acid extracellular domain made up of two 
immunoglobulin like domains, a helical domain that spans the cell membrane 
and a 107-amino acid intracellular domain. It has been mapped to human 
chromosome 21 (Mayr & Friemuth, 1997, Bergelson et al, 1997). Homologues 
of CAR have been identified in avian, bovine, canine, porcine, murine and rat 
samples, and in humans it is known to be a receptor for all HAds other than those 
of serotype B (Bergelson et al, 1997, Roelvink et al, 1998, Thoelen et al,
2001). However, some of these serotypes also appear to recognise different 
receptors, for example, HAd41 has two different length fibres, of which only one 
binds CAR (Stevenson et al, 1995).
In wild-type infection, after initial receptor attachment, many adenoviruses have 
been found to bind to cell surface integiins av(33 and av(35 via an Arg-Gly-Asp 
(RGD) sequence found in the penton base (Mattias et al, 1994). This leads to 
the internalisation of the virus through clathrin-coated pits that form endocytic 
vacuoles (Wickliam et al, 1993). RGD integrin binding has been hypothesised as
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a common pathway for internalisation of adenoviruses since the RGD motif is 
conserved in most adenoviruses. Enteric adenoviruses of group F, which is 
comprised of FlAd40 and HAd41, do not have an RGD motif, however, 
adsorption and internalisation of HAd41 is inefficient compared with HAds 2 
and 5 (Davison et al, 1993, Albinsson et a l, 1999). Following endocytosis the 
pH of the vacuole falls below 6 causing the endosome to rupture, releasing the 
virus into the cell cytoplasm. As adenoviruses enter host cells, their fibres are 
released and the virus capsid is destabilised by L3 viral protease mediated 
degiadation of the structural protein VI, which connects the viral genome to the 
capsid (see Figure 1.1) (Greber et a l, 1993, Greber et al, 1996). After entering 
the cytoplasm the virus particle is transported along microtubules (Suomalainen 
et al, 1999, Leopold et al, 1998) and binds to cellular receptors (fibril protein 
CAN/Nup214) on the nuclear pore complex (Trotman et al, 2001). This induces 
the recruitment of nuclear histone HI, which attaches to the hexon and mediates 
further capsid disassembly (Trotman et al, 2001). In addition, HI is recognised 
by import factors that transport the viral DNA into the nucleus via the nuclear 
pores.
1.4.2.2 Early Transcription
Transcription of the adenovirus genome occurs in two main stages, and most of 
the adenovirus genome can therefore be divided into early and late transcription 
units i.e. E l-4 and Ll-5 (Figure 1.2). There are also proteins expressed at 
intermediate times, between early and late transcription.
Earlv Region 1 CEP
Within an hour of infection transcripts from early region 1 (El) can be detected. 
The E l transcription unit is divided into two functional regions, E la  and Elb. 
E la  and E lb  proteins interact with a number of host cell factors to ensure a 
suitable environment for viral replication and the progiession of the adenovirus 
life cycle.
The E la  gene products stimulate cell division and growth by several different 
methods, for example, they bind to cyclin dependent kinase inhibitors that
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ordinarily inhibit cell growth (Keblusek et al,  1999). The two major Ela mRNAs 
encode proteins of 289 (289R) and 243 (243R) amino acids in length, respectively. 
Although 243R, a 48kDa protein, has been found to be dispensable for viral 
replication in standard cell culture, it is necessary, together with 289R for 
adenovirus replication in growth arrested cells (Montell et al,  1984). The Ela 
proteins also alter cellular transcription patterns through interactions with host 
proteins. For example, 289R binds cellular p i05 (Retinoblastoma gene product) 
and inactivates it. p i05 normally interacts with the cellular transcription factor E2F 
in suppressing growth of cells unless they are damaged, and activation of this 
transcription factor predisposes cells to transformation.
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Figure 1.2 Transcription map of the human adenovirus genome (derived from 
Russell, 2000).
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Another important function of 289R is the activation of transcription from Elb, 
E3 and E4 genes approximately two hours post infection (p.i,), which is closely 
followed by transcription of E2a and E2b and some cellular genes vital for 
adenovirus replication. The E la  region is also involved in the activation of late 
gene transcription, although it is not the sole determinant.
The E lb  proteins facilitate the movement of viral mRNAs into the cell cytoplasm 
where translation of E2a and E2b transcripts on polyribosomes provides essential 
proteins for replication: the DNA binding protein (DBF), DNA polymerase and 
the DNA terminal protein (see 1.4.2.3). The E lb region codes for polypeptides of 
19kDa and 55kDa. The 55kDa protein binds and inactivates the cellular p53 
tumour suppressor protein and interacts with a 25kDa protein encoded in the E4 
region to shutoff gene expression in the host cell (Babiss & Ginsberg, 1984). 
The 19kDa protein promotes cell survival by disabling the death-promoting Bax 
protein (Han et al, 1996, Chinnadurai 1983). Bax normally induces both 
programmed cell death and necrosis in p53 defective cells, inactivation of this 
therefore induces cell transformation. The E lb  proteins form a complex with the 
E4 34kDa protein in order to selectively export adenovirus mRNAs and inhibit 
the movement of cellular mRNAs out of the nucleus, which reduces host cell 
DNA transcription by more than 90% during viral infection (Pilder et al, 1986, 
Bridge & Ketner, 1990). This is achieved by processes that are as yet unknown.
All HAds are able to transform cells in culture and human adenoviruses of 
serotypes A and B have oncogenic potential. The E la  region alone contains the 
genes responsible for immortalising host cells but the expression of both E la and 
E lb  is necessary for full transfoimation and, in certain serotypes, the formation 
of tumours in new-born hamsters (HAd transformation is reviewed by Akusjarvi 
1986 and Graham 1984).
Earlv Region 2 1E21
Transcription unit E2 is also divided into 2 regions, E2a and E2b. The E2a 
region encodes for the 72kDa DNA binding protein (DBF), a phosphoprotein 
with two domains. It has a nuclear localisation signal in the N-terminus domain 
(Cleghon et al, 1989) and this domain has been found to play a role in the
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determination of host range of different adenoviral serotypes (Anderson et al, 
1983, Brough et al, 1985). The N-terminus of the DBF is also involved in late 
gene expression (Rruijer et al, 1983). Both domains, although predominantly 
the C-terminal domain, are important for binding to both single stranded and 
double stranded DNA and RNA (Brough et al, 1993). The C-terminal domain 
interacts with neighbouring DBF molecules to form a flexible chain that is 
required for DNA unwinding and as such DBF is essential in viral DNA 
replication (Dekker et a l, 1997, van Breuklen et al, 2000). Viral DNA 
replication also requires the 80kDa precursor terminal protein (pTF) and 140 kDa 
DNA polymerase which are encoded by the E2B region. The pTF and DNA 
polymerase form a complex that is found covalently attached, via the pTF, to the 
5’ends of the viral DNA (Challberg et al, 1980, Lichy et al, 1981). DNA 
polymerase has both 5’ to 3’ polymerase and 3’ to 5’ exonuclease activity (Field 
et al, 1984). The action of these proteins in DNA replication is discussed in 
section 1.4.2.3. During virion assembly the pTP is processed, by an adenoviral 
protease, to the mature 55kDa terminal protein (TF), which remains attached at 
the 5’ end of each DNA strand (Challberg & Kelly, 1981).
Earlv region 3 (E3)
In HAds 2 and 5, the E3 region has been found to be nonessential in tissue 
culture, although it encodes a number of proteins with functions that are 
important in immune modulation. These include a 19kDa tiansmembrane 
glycoprotein localised in the ER membrane (Cox et al, 1991) that blocks the 
transport of major histocompatibility complex type 1 (MHC-I) to the host cell 
plasma membrane by binding both MHC-I and the transporter associated with 
antigen presenting (TAP) (Bennet et al, 1999). Ordinarily, TAP is involved in 
the transfer of peptides to the MHC-I molecule; the binding of TAP and MHC-I 
prevents MHC-I migiation from the ER to the cell surface, protecting the 
infected cell from CTL-mediated lysis. The receptor internalisation and 
dégradation proteins (RID), RIDa (10.4kDa) and RID(3 (10.4kDa) proteins, 
together form a complex, which, in addition to the E lb 19KDa, E3 14.7kDa and 
E3 6.7kDa proteins, protect the infected cell from apoptosis and lysis by cellular 
antiviral defence proteins. For example, the E3 6.7KD and 14.7KDa proteins
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and RID complex protect the cell from Fas induced apoptosis (Chen et al, 1998, 
Shisler et al, 1997, Elsing & Burgert, 1998, McNees et al, 2002, Moise et al, 
2002). These E3 proteins and the ElB  19K protein also protect infected cells 
from the lytic activity of TNF (Gooding et al, 1988, Gooding et al, 1991a, 
Gooding et al, 1991b, Moise et al, 2002). The RID complex also stimulates 
endosome-mediated internalisation and degradation of the epidermal giowth 
factor (EGF) receptor by the host cell (Tollefson et al, 1991).
Another E3 protein, the 11.6kDa adenovirus death protein (ADP) (Wold et al, 
1984), is synthesised at both early and late stages of tianscription (Tollefson et 
al, 1992). Although ADP is transcribed from an early region of the genome it is 
synthesised most abundantly at late stages of infection (approximately 400-fold 
higher synthesis at 25 hours p.i. compared with that of early stages) (Tollefson et 
al, 1992). Cells infected with ADP-mutants showed efficient viral replication; 
however, cell lysis was delayed by approximately 3 days compared with wild 
type HAds. ADP is clearly important for release of progeny virus particles via 
cell lysis (Tollefson et al, 1996).
Earlv region 4
The E4 region is complex; it has 6 ORFs, which encode a range of proteins with 
a variety of function. ORFs 3 and 6 encode proteins of llkD a and 34kDa, 
respectively. Both of these proteins bind cellular DNA-dependent protein kinase, 
preventing the activation of p53 and leading to the foimation of viral DNA 
concatamers (Boyer et al, 1999, Wei den & Ginsberg, 1994). The 34 kDa 
protein forms a complex with the E lb  55 kDa polypeptide that results in both the 
transportation of viral mRNAs to the cytoplasm (Weigel & Dobbelstein, 2000) 
and the binding of p53 leading to it’s destabilisation and subsequent degiadation 
(Boyer & Ketner, 2000). The E4 ORF 4 encodes a 14 kDa protein that has 
anticytolytic activity in conjunction with E3 proteins (Kaplan et al, 1999). It has 
also been suggested that E4 may be involved in DNA replication and shut off of 
host macromolecular synthesis (Medghalchi et al, 1997, Shenk 2001).
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1.4.2.3 DNA Replication
Adenoviruses undergo two types of replication that begin within 6 to 8 hours of 
infection (Lechner & Kelly, 1977), Type I replication occurs on one strand of the 
parental DNA and type II replication takes place on the strand displaced during 
type I replication. It is hypothesised that the displaced strand is circularised 
through annealing of the ITRs at either end of the DNA (Leegwater et al, 1988). 
For both types of replication the pTP and the DNA polymerase form a complex 
that binds, via the pTP, to the origin of replication in the ITR at the 5’ end of the 
adenoviral DNA (Challberg et al, 1980, Lichy et al, 1981, Challberg & 
Rawlins, 1984, Temperley & Hay, 1992). Following this, the DNA polymerase 
recruits deoxycytidine monophosphate (dCMP), which binds to the hydroxy 
group of a serine residue with the pTP (Challberg et al, 1982). This complex 
then ‘jumps back’ to the beginning of the template DNA strand and acts as a 
primer for DNA synthesis via strand displacement (King et al, 1994). The DNA 
polymerase dissociates from pTP and elongates the strand and the pTP is later- 
cleaved to the 55 kDa TP (King et al, 1994, Challberg & Kelly, 1981). DBPs 
binds in a sequence independent fashion to ssDNA and form a chain that 
separates the annealed DNA templates during chain elongation (see section 
1.4.2.2, Dekker et al, 1997). DBPs also protect the displaced single stranded 
parent DNA from nuclease digestion during type I replication. In addition, DNA 
replication requires the involvement of cellular nuclear factors (NF) I and III; 
NFI binds to the pTP-polymerase complex, perhaps stabilising it, whereas NFIII 
makes contact with the pTP causing a conformational change (Mul et al, 1990, 
Sotting & Hay, 1999).
1.4.2.4 Intermediate transcription units
As well as early and late transcription units, the HAd genome has a range of 
inter-mediate transcription units, which encode virus associated (VA) RNAs I and 
II, and proteins IVa2 and IX. The VA genes are transcribed by RNA polymerase 
III and do not encode proteins (Weinmann et al, 1976). VA RNA I binds to and 
inhibits protein kinase (PKR), which provides an important host defence against 
viral infections through the inhibition of translation by phosphorylation of eIR-2,
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thereby preventing the shut down of protein synthesis (Pe’ery et al, 1993, Ma & 
Mathews, 1996). The VA RNAs are also hypothesised to be involved in the 
regulation of splicing of cellular and viral mRNAs (Mathews, 1980, Naora & 
Deacon, 1981).
The IVa2 protein has a nuclear localisation signal and is found almost 
exclusively in the host cell nucleus (Lutz & Kedinger, 1996). It binds 
specifically to nucleotide motifs found in both the MLP and the Y  (Lutz & 
Kedinger, 1996, Zhang & Impériale, 2000). IVa2 is one of the adenovirus 
proteins involved in the activation of the major late promoter (MLP), which is 
responsible for late gene transcription (see section 1.4.2.5) (Lutz & Kedinger, 
1996, Tribouley et al, 1994). In addition IVa2 has been found to be essential for 
adenoviral packaging (Zhang & Impériale, 2003) and interacts with Y  in a 
serotype specific manner (Zhang et al, 2001)
Expression of the IX protein (pIX) begins shortly after the onset of viral DNA 
replication, earlier than other capsid components (reviewed by Flint 1982). The 
N-terminal domain of the pIX protein is essential for its localisation in the capsid 
(Furcinitti et al, 1989, Rosa-Calatrava et al, 2001). The C-terminal domain 
activates tianscription from both cellular and viral TATA-containing promoters 
(Lutz et al, 1997, Rosa-Calatiava et al, 2001). In addition, the pIX protein is 
involved in the nuclear reorganisation of adenovirus infected cells (Rosa- 
Calatrava et al, 2001). It concentrates in nuclear inclusion bodies, however, the 
physiological roles of these inclusions are unknown.
1.4.2.5 Late transcription
Late transcription begins shortly after the initiation of DNA replication and is 
activated by a cascade of events that include protein IVa2 binding and E la  
activation of the MLP. Only one RNA is transcribed, which encodes the 
products of the 5 late tianscription units. This is subsequently spliced into at 
least 11 mRNAs, each encoding a single protein. All mRNAs issued from the 
MLP possess a 5’ bipartite leader sequence, which gives them priority for 
translation over cellular mRNAs (Logan & Shenk, 1984) by eliminating the
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requirement for the cap-binding complexes that provide binding sites for 
translation initiation factors (Dolph et al, 1988). The late genes encode mostly 
viral structural proteins that self-assemble into empty capsids.
Once there is an excess of DNA molecules, interactions between viral proteins 
and the packaging sequence, ig, found at the left end of the genome have been 
shown to initiate encapsidation of the viral genome (Grable & Hearing, 1992, 
Schmid & Hearing, 1998). This occurs within the host cell nucleus, on the 
nuclear matrix (Zhai et al, 1987, Khittoo et al, 1986). Progeny virions are then 
released by host cell lysis induced by the ADP (see section 1.4.2.2) (Tollefson et 
al, 1996).
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1.4,3 Adenovirus Vectors
HAds have been investigated as gene therapy vectors since the early 1990s 
(Boucher et al., 1994, Bout et al, 1994, Chen et al, 1994, reviewed by Kozarsky 
& Wilson 1993). This research has provided a wealth of information regarding 
the host immune response towards adenovirus vectors and a wide range of 
transgenes. It is clear from this that there are several factors that influence 
transgene expression from adenovirus vectors and the immune response elicited 
against them. These factors include the nature of the transgene itself, choice of 
promoters and enhancing elements, dose of vector, delivery site and route of 
administi'ation, strain/species of experimental animal used, genotype of the 
recipient (heterozygote or homozygote for genetic deficiency), age of recipient, 
immune status of the recipient and so on.
A major benefit to the use of adenoviruses for gene therapy is their large insert 
capacity. Human adenoviruses (HAds) have an insert capacity of approximately 
+5% (Bett et al, 1993) and as such 1.8 kbp can be inserted into the HAd5 
genome without making any deletions. In order to prevent replication of 
adenovirus based vectors the E l region is usually deleted. The potential 
oncogenicity, if only in rodents, of the E l region is another good reason for 
making this deletion.
The main obstacle to using the ubiquitous HAds 2 and 5 as gene therapy vectors 
is the immune response that the human body elicits against HAd based vectors 
(see section 5.1) (Harvey et a l, 1999, Yang et al, 1995, Dai et al, 1995). As 
well as increasing the insert capacity, multiply deleted adenovirus vectors have 
been developed that have had a degree of success in avoiding deleterious 
immune responses. However, suitable adenovirus gene therapy vectors that can 
completely evade the human immune system, provide optimal transgene 
expression and allow readministration are still in developmental stages.
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1,4.3.1 First Generation Vectors
First generation vectors were mainly based on HAds 2 and 5, as these are the 
most prevalent human adenoviruses and their genomes and lifecycles have been 
thoroughly researched. The E l region is deleted to render the virus replication 
deficient. As such, these vectors must be propagated in complementing cell-lines 
that express E l gene product. The most common of these is the 293 cell-line, 
which was derived from human embryonic kidney cells ti’ansformed with the left 
12% of the HAd5 genome and therefore contains the ITR, Y, and E l regions 
(Graham et al, 1977). Many first generation vectors also have deletions in the 
non-essential E3 region. Deletion of the both of these regions allows up to 8.5 
kbp of insertion (Bett et al, 1993).
Transgene expression from first generation HAd vectors has been demonstiated 
in a wide range of cell and tissue types including epithelial, renal, cardiac, and 
brain cells in vivo and in vitro (Rosenfeld et al, 1994, Bout et al, 1994, Herz & 
Gerard, 1993, Barr et al, 1994, Ghadge et al, 1995). Nevertheless, their 
effectiveness has been limited by short-term expression in vivo. In animal 
models, transient trans gene expression has been shown to be due to strong 
immune responses that are elicited against the vector, which often result in liver 
toxicity (Herz & Gerard, 1993). Both arms of the immune system are activated 
in response to adenovirus vectors and administration to knockout mice lacking 
specific functions of the immune system has shown extended periods of 
transgene expression (Dai et al, 1995, Yang et al, 1994). The treatment of 
immunocompetent mice with first generation adenoviruses in conjunction with 
immunosuppressive drugs lengthens the period of transgene expression 
considerably (Dai et al, 1995).
Although deletion of the E l region was intended to block the expression of viral 
genes, it was demonstrated that both early and late viral genes were still 
expressed (Yang et al, 1994) as the E2a gene can be activated by cellular E2F
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proteins (Reichel et al, 1988). Expression of late genes is one of the main 
reasons for immune induction against these vectors.
Several gioups have shown that immune responses against transgenes are also a 
limitation in the administration of these vectors. Immune responses against 
certain transgenes, for example P-galactosidase, have resulted in increased 
toxicity and reduced persistence of transgenes (Juillard et al, 1995, Michou et 
al, 1997). In contrast, the administration of vectors expressing tiansgenes that 
were recognised as native by the host immune system resulted in longer periods 
of transgene expression (Michou et al, 1997, Yang e ta l,  1996).
It became apparent from this research that E l and E3 deletions alone were 
insufficient for the complete prevention of viral gene expression and therefore 
evasion of the immune system.
1,4.3.2 Second Generation Vectors
It was generally accepted that the immunogenicity of first generation vectors was 
due to cellular complementation and expression of adenovirus late genes. To 
overcome this, further deletions in essential early regions were proposed. The 
majority of strategies deleted the E2a (DNA polymerase) and E4 regions. 
Deletions in these regions have the additional benefit of increasing the packaging 
capacity.
E2a-deleted second generation vectors have been investigated in both tissue 
culture and in vivo (Zhou et al, 1996, Andrews et al, 2002). Vector replication 
is not observed (Lusky et al, 1998) and transgene expression has been 
demonstrated in a variety of tissues of experimental animals such as mice, rabbits 
and monkeys (Bristol et al, 2001, O’Neal et al., 1998, Andrews et al, 2002). 
However, when compared with first generation vectors transgene expression is 
not extended (Morral et al, 1997, Wen et al, 2000) and immune responses 
elicited to the vectors are not reduced (Lusky et al., 1998). Furthermore, vector
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induced hepatotoxicity is comparable to that induced by first generation vectors 
(O’Neal a/., 1998).
The situation with E4-deleted second generation vectors is far more complicated. 
E4 products have multiple roles in the HAd life cycle (section 1.4.2.2). Although 
low level expression of viral genes has been detected from E4-deleted vectors 
(Lusky et al, 1998), they generally have lower cytotoxicity in animals (Wang et 
al, 1997, Christ et al, 2000). However, several groups have reported lower 
transgene expression from such vectors (Brough et al, 1997, Wang et al, 1997, 
Christ et al, 2000). Christ et al. examined the specific roles of E4 proteins in 
determining transgene expression and found that vectors retaining either ORFs 3 
and 4 or ORFs 3, 6 and 7 prolonged tiansgene expression. In addition, retention 
of ORFs 3 and 4 is associated with reduced hepatotoxicity (Christ et al, 2000). 
Investigations into the induction of immune responses by E4 defective 
adenoviruses have produced varied reports (Gao et al, 1996, Wang et al, 1996, 
Dedieu et al, 1997); however, when Lusky et al, compared an E4-deleted vector 
with a first generation vector the immune responses were similar (Lusky et al,
1998).
It is clear from work on first and second generation vectors that there are many 
variables to consider in the delivery of HAd vectors. Transgene expression and 
immune responses will not only be affected by the nature of HAd backbone but 
also the route and titie of inoculation, the transgene and even strain of animal 
used.
1.4.3.3 Third Generation/Gutless Vectors
Third generation adenoviral vectors only possess the packaging sequences, ITR 
and Y, which flank the transgene, and as such require the assistance of helper 
viruses for their propagation. Helper viruses are usually El-deleted and the 
gutless vector is propagated in their presence on E l expressing 293 cells (Fisher 
et al, 1996). These vectors are otherwise known as gutless, gutted, or helper- 
dependent (HD) adenovirus vectors. The elimination of almost the entire viral
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genome enables the insertion of up to 37 kbp of heterologous DNA (Morsy et al, 
1998, Morsy & Caskey, 1999), allowing the expression of large transgenes or 
multiple transgenes. The removal of all viral coding regions ensures that no viral 
replication or tianscription can take place and, it was hoped that this would 
minimise immune responses to the vector, leading to longer term transgene 
expression. Although transgene expression was extended with such vectors 
compared to first and second generation vectors (Morral et al, 1999, Roth et al, 
2002) initial investigations demonstrated an eventual loss of transgene 
expression associated with immune responses to the vector (Chen et al, 1997). 
When this was expanded further and immune responses against transgenes 
investigated, several groups demonstrated that by eliminating immune induction 
to the transgene, expression could be maintained (Chen et al, 1997, Maione et 
al, 2001, Kochaneck e? nZ., 1996).
The successful use of HAds for gene delivery in primates has been demonstiated 
(Morral et al, 1999). A HAd5 based HD vector expressed the human a- 
antitrypsin gene (hAAT) transgene for over a year in the livers of 2 out of 3 
young baboon models after a single intravenous injection (MoiTal et al, 1999). 
Transgene expression from equivalent first generation vectors lasted only 3-5 
months, and as no hAAT antibodies were detected, this suggested that tiansgene 
loss was due to anti-HAd immune responses.
It is important to note that pre-existing antibodies to capsid proteins are likely to 
limit the effectiveness of HD adenovirus vectors (Parks et al, 1999). Vectors 
derived from less common adenovirus serotypes are likely to avoid these pre­
existing immune responses in the majority of patients.
1.4.3.4 Chimeric Vectors
Chimeric adenovirus vectors have capsid proteins originating from different 
adenovirus serotypes. The rationale behind this is that anti-adenovirus 
neutralising antibodies specifically recognise capsid proteins (see Chapter 5) and 
therefore immune responses to common adenovirus serotypes might be evaded
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by developing vectors that possess capsid proteins from less prevalent adenovirus 
serotypes. This was demonstrated by Roy et al, who in 1998 developed a vector 
that had a chimeric HAd5/HAdl2 hexon with 99.2% identity with the HAdl2 
hexon. Mice that had been immunised with HAd5 were unable to neutralise the 
HAd5/HAdl2 chimera and the vector successfully transduced the livers of all 
mice tested. Chimeric adenoviruses have also been produced with a view to 
targeting adenoviruses; this is discussed further in Chapter 4.
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1.4.3.5 Conditionally Replicative Adenovirus Vectors
An alternative field of adenovirus vector research is the development of 
conditionally replicative adenoviruses (CRADs) (reviewed by Curiel 2000). 
CRADs are developed to preferentially replicate within and lyse tumour cells. 
This is achieved by mutating or deleting adenovirus genes whose function can be 
complemented by the tumour cell but not normal cells. For example, the 
adenovirus mutant ONYX-015 has a 827 kb deletion in the E lb  gene that 
prevents E lb  inactivation of cellular p53. As such, ONYX-015 replication is 
limited in normal cells due to a p53 response (see section 1.4.2.2) however in 
tumour cells, which often lack a p53 gene, ONYX-015 is able to undergo lytic 
replication, destroying infected cells (Bischoff et al, 1996). Human trials have 
proven promising with this vector, with its administration leading to the 
significant regression of tumours when administered with and without 
chemotherapeutic drugs (Nemunaitis et al, 2000, reviewed by Ries & Korn,
2002). However, it was found that replication of these vectors was not strictly 
restricted to p53 mutated cells and replication was noted in non-tumour cells 
(Vollmer et al, 1999). Another method of directing cytolysis is to replace the 
E l a promoter with that of a tumour specific promoter, so that E l a expression 
will only occur in tumour cells resulting in selective lysis (Rodriguez et al, 
1997). This technology could be used in combination with an E lb  deleted vector 
such as ONYX-015. The main limitation with CRADs at present is that they 
require local administration because of the wide h'opism of adenoviruses. The 
systemic delivery of CRADs will rely on the development of specifically 
targeted adenovirus vectors.
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1 .4 3 .6  Adenovirus Vaccine Vectors
Recombinant vaccines are attenuated viruses that have genes from other 
pathogens inserted into their genome. These viruses enter cells and express the 
chosen antigens, which are then processed and presented to the immune system. 
Adenoviruses are well characterised and the immune response to them has been 
studied in depth, which has aided their development for use as vaccine vectors in 
replication-competent or replication-deficient form. Although these vaccines are 
effective at eliciting immune protection against heterologous immunogens, 
immunity is also elicited to the adenovirus (Ye et al, 1991, Buge et al, 1997).
The choice of vaccine vector is dependent on the pathogen being vaccinated 
against and the immune response required to protect against infection. The 
method of administration often dictates the type of immune response induced 
and, where possible, administration via the same route as wild-type antigen 
presentation is favourable, as it is more likely to induce immunity similar to that 
against the wild type pathogen. Natural adenovirus infection occurs via the 
airways. As such, adenovirus based vaccines are likely to offer efficient 
protection against other pathogens that infect mucosal surfaces. Examples of 
such viruses are hepatitis B, herpes simplex viruses types 1 and 2 and HIV, all of 
which have proven difficult to vaccinate against.
As with other forms of gene therapy, the existence of a pre-existing immune 
response is likely to reduce the efficiency of a recombinant vaccine vector. 
Many adenoviruses are capable of abortive infection in cells from hosts of 
heterologous species, and therefore have the potential to express transgenes in 
these cells (discussed in Chapter 3). The reduced possibility of patients having 
pre-existing immunity to an adenovirus of a heterologous species opens up the 
possibility of using a range of adenovirus serotypes. The examples that follow 
describe vaccination using adenoviruses of heterologous host species as vectors.
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Vaccination of monkeys with either a replication incompetent HAd5 vector, 
plasmid DNA or a modified vaccinia Ankara virus vector, each expressing the 
simian immunodeficiency (SIV) gag protein, was compared (Shiver et al, 2002). 
The most effective was found to be based on HAd5. Furthermore, a replication- 
deficient adenovirus vector induced anti-measles IgG antibodies in 100% of 
mice, compared with 30% in those treated with the equivalent DNA vaccine 
(Fooks et al, 2000).
An E l and E3 deleted HAd5 vector backbone was used to deliver glycoproteins 
of bovine herpesvirus type 1 (BHV-1) to calves intranasally (Gogev et al, 2002). 
Administration induced neutralising antibodies that were still evident 3 weeks 
later and protected these calves from intranasal wild-type BElV-1 challenge.
Buge et al, used an animal model to demonstrate that vaccination against HIV in 
humans using a heterologous adenoviral backbone is feasible. SIV genes 
delivered by a HAd5 vaccine vector induced humoral, cellular and mucosal 
immune responses specific to SIV in rhesus macaques (Buge et al, 1997). These 
responses provided a degree of protection against vaginal challenge with SIV. 
Although full protection was not conferred, in some of the subjects the infection 
was transient and where the infection was persistent, viral burden was decreased 
compared to infected control macaques.
Large deletions from the adenovirus genome can be made that render the virus 
replication-deficient and also permit the expression of large tiansgenes. HAds 
have an upper packaging limit of 105% (Bett et al, 1993) and large deletions 
allow the presentation of epitopes from multiple pathogens, producing 
multivalent vaccines. A vaccine that expressed 3 different hepatitis B antigens 
from different loci of a HAd7 vector induced significant antibody responses to 
each of the 3 antigens in inoculated dogs. (Ye et al, 1991). Multiple deletions 
within the vector genome reduces the risk of reversion of vector virus.
Often vaccination that results in a rapid immune response is particularly 
desirable. For example, Moraes et al, recently demonstrated that a single dose 
of a replication defective HAd 5 vaccine vector expressing foot-and-mouth
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disease virus (FMDV) capsid proteins was sufficient to protect against challenge 
by wild-type FMDV as early as 7 days after vaccination in pigs (Moraes et al.,
2002).
Intranasal vaccination proved more effective than intraperitoneal administration 
with a HAd 5 based vector carrying the glycoprotein B gene of HSV-1 (HSVl- 
gB) (Gallichan et al, 1993). After intranasal administration, HSVl-gB specific 
antibodies were produced on mucosal tissues and specific CTLs were found on 
the spleen and lymph nodes; intranasal challenge was protected against.
However, intiaperitoneal administration induced less antibodies in the nasal (-mucosa and none in the lung mucosa, no CTLs were found in the lymph nodes.
The above examples demonstrate that adenoviruses are suitable as vaccine 
vectors for many diseases, by a number of different 
administration routes. The broad range of adenovirus serotypes will allow 
their use in several host species.
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1.4.4 Animal Adenovirus Vectors
Most other adenoviruses in vector development belong to the genus 
Mastadenovirus, with the exception of ovine adenoviruses (OAV), which are 
Atadenoviruses (Universal virus database of the International Committee for 
Taxonomy of Viruses). In addition some avian adenoviruses (Aviadenovirus) 
are being developed.
Several animal adenoviruses have been found to infect human cell-lines 
abortively in culture, examples of these are bovine adenovirus type 3 (BAV-3), 
canine adenovirus types 1 and 2 (CAV-I and CAV-2), ovine adenovirus (OAV) 
and porcine adenovirus type 3 (PAV-3) (Gehle & Smith 1969, Thoelen et al, 
2001, Klonjkowski et al, 1997, Xu et al, 1997, Reddy et al, 1999). CAV-1, 
CAV-2, BAV-3 and PAV-3 have been shown to have colinear genetic 
organisations to HAds and the functions of many animal adenovirus genes are 
comparable with those of HAds (Moiiison et al, 1997, Klonjkowski et al, 1997, 
Reddy et al, 1998b, Reddy et al, 1998a). Moffatt et a l immunised mice with 
HAd5, BAV-3 or PAV-3, then challenged them with a different adenovirus 
recombinant. The mice developed virus specific antibodies that could prevent 
transgene expression when challenged with the same vector, however there was 
no cross-neutralisation between human and non-human adenoviruses (Moffatt et 
al, 2000). These results provide support for the development of animal 
adenoviruses as gene therapy vectors in humans. Animal adenoviruses are 
discussed further in section 3.1.
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1.4.4,1 Bovine Adenoviruses
There are 10 known bovine adenovirus (BAV) serotypes, which are divided into 
2 subgroups classified by cell culture characteristics and the presence or absence 
of complement-fixing antigens (Bartha 1969), Of these, BAV-3 has been studied 
in the most depth. It is similar in diameter (75nm) (Niiyama et al., 1975) and 
genetic organisation to the HAds (Reddy et al, 1998b). Many of the BAV-3 
genes have similar functions to the equivalent genes in HAds. The E l a region is 
essential for activating transcription of other BAV-3 early genes (Zhou et al, 
2001). As with HAds, the BAV-3 E3 region is non-essential for virus gi'owth in 
culture. At 1.5 kbp, it is approximately half the size of the E3 regions of HAd2 
and HAd5 (Evans et al, 1998, Mittal et al, 1995). One of the four E3 ORFs 
shows significant homology and has functions similar to the 14.7 kDa protein of 
HAd5 (Mittal et al, 1993, Zakhartchouk et al, 2001). However, the E4 region 
of BAV-3 differs from HAds significantly. It has only 5 ORFs, each of which 
can be deleted individually from the BAV-3 genome with no loss of viability and 
therefore each separate E4 ORE is nonessential (Baxi et al, 2001). In addition, 
ORFs 1-3 and 3-5 are nonessential in complex. However, Baxi et a l were 
unable to isolate a BAV-3 vector with the whole E4 region deleted and suggested 
that the deletion of the E4 region may have been destabilising for adjacent 
regions of the genome. In contrast to other adenovirus fibres, the BAV-3 fibre 
was found to be both bent and significantly longer. It has been suggested that 
with the added length of this fibre, bending is necessary for secondary penton 
interactions and therefore internalisation of the virus (Ruigrok et al, 1994).
BAV-3 is capable of abortive infection in cultured human cells (Mittal et al,
1995). A BAV-3 vector with a firefly luciferase gene expressed from E3 region, 
which had a 696 bp deletion, was produced. Although vector replication in 
Madin-Darby bovine kidney (MDBK) cells was 10-fold less than with wild type 
BAV-3, luciferase expression was detected. In addition, the BAV-3 vector was 
able to express the luciferase gene in human 293 cells for at least 6 days. With 
this potential realised, the production of replication defective BAV-3 vectors 
may result in a useful alternative to the HAds for human gene therapy.
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1.4.4.2 Murine Adenoviruses
There are 2 murine adenoviruses (MAV) serotypes (Hamelin et al, 1988). 
Murine adenovirus type 1 (MAV-1) was discovered in 1960 by Hartley and 
Rowe and is the most extensively studied of the two serotypes. It naturally 
infects heart, kidney and brain cells of mice and has low sequence homology 
with HAds 2 and 5 (Meissner et al., 1997). This adenovirus appears to be a 
potential candidate for human gene therapy as it has been shown by RT-PCR that 
MAV-1 is able to enter mouse, monkey and human epithelial cells and express 
E l genes (Nguyen et al., 1999). Like the HAd E3 region, the MAV-1 E3 region 
functions in the modulation of the host immune system and is dispensable for 
viral gi'owth in culture (Beard & Spindler 1996).
As well as providing another possible human gene therapy vector, research with 
MAV-1 may be able to provide an animal model for gene therapy since it can be 
studied with relative ease in its natural host, which would parallel the use of 
HAds in humans to a certain extent.
1.4.4.3 Ovine Adenovirus
There have been 7 OAVs described to date (Both, 1999). With a genome size of 
approximately 29 kbp these are considerably smaller than the HAds (Vrati et al.,
1996), and have significant structural and genomic differences to other 
adenoviruses. The shaft region of the fibre is only 120 residues in length in 
comparison to approximately 200 residues of other adenoviruses (Khatii et at.,
1997) and the E la/E lb, E3 and E4 regions show little homology to those of other 
adenovirus. A 4.3 kbp insert in OAV can be tolerated without any deletion in the 
viral genome, and it was found that a 2 kbp deletion could be made, which does 
not affect virus viability and increases the maximum potential insert capacity to 
approximately 6.3 kbp (Xu et al, 1997). These differences may offer OAVs 
advantages over other adenoviruses for human gene therapy since the immune 
response to them may be expected to be significantly different. There were no 
antibodies against OAV detected in human sera collected from 15 healthy 
individuals, all of which had significant anti-HAd titre. Cross-administration
45
studies with HAd5 and OAV vectors showed that antibodies to HAd5 did not 
block OAV vector transduction and vice versa (Hofmann et al, 1999).
Several OAV vectors have been investigated in human cells in vitro and in mice 
in vivo. One OAV vector was shown to transduce a broad range of human cell 
types (lung and foreskin fibroblasts, liver, prostate, heart, colon and retinal) and 
also bovine and rabbit cells in vitro (Khatri et al, 1997). In vivo, expression 
from replication competent OAVs was found to be comparable with replication- 
deficient HAd vectors (Hofmann et al, 1999, Voeks et al, 2002). However, 
whereas expression from a HAd vector was found predominantly in the livers of 
mice, OAV vector expression was found in mice spleens, kidneys, hearts and 
livers at similar levels. Retargeting of an OAV to non-permissive human 293 
cells has been demonstrated by swapping the fibre knob domain with that of 
HAd5 (Xu & Both, 1998). In addition, the infectivity of this vector in other 
human cell-lines was enhanced.
Despite being quite distinct from HAds, OAV shows great promise in the 
development of a human gene therapy vector. Further investigation of the 
genome is required in order to identify other genes that can be deleted, either 
because they are non-essential for transcription or can be provided in trans, 
allowing the insertion of larger transgenes.
1.4.4.4 Porcine Adenoviruses
Five porcine adenoviruses (PAV) have been isolated which generally do not 
cause disease in the pig population (reviewed in Tuboly & Nagy, 2000). Of 
these PAV-3 has been studied most for gene therapy pmposes. It has a genome 
of approximately 34 kbp, similar in size to HAd serotypes, and the E3 region is 
non-essential in culture. A recombinant PAV-3, with E la  and partial E3 
deletions, expressing a GFP gene, was propagated in a porcine cell-line 
transformed with HAd5 E l proteins (Reddy et al, 1999). The resultant 
recombinant virus was able to tiansduce canine, ovine, bovine and human cells 
(Reddy et al, 1999).
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The E3 region of another porcine adenovirus type 5 (PAV-5), which is more 
closely related, genetically, to certain BA Vs than other PA Vs, was also found to 
be non-essential for virus replication, which would allow an additional vector 
capacity of at least 2.9 kbp (Tuboly & Nagy, 2000, Nagy et al., 2001, Tuboly & 
Nagy, 2001).
As the widespread exposure of humans to PAVs is unlikely, they may provide 
yet another alternative to HAds in the development of gene therapy vectors for 
humans.
1.4.4.5 Avian Adenoviruses
An Aviadenovirus developed with a view to application in human gene therapy is 
chicken embryo lethal orphan virus (CELO), otherwise known as fowl 
adenovirus type 1, which was first identified in 1957 (Yates et al., 1957). It has 
the largest known adenovirus genome of approximately 44 kbp in length 
(Chiocca et al., 1996). The virus is structurally similar to the mammalian 
adenoviruses except that it has two fibres of different lengths at each capsid 
vertex (Hess et al, 1995). The short fibre, fibre 2, is essential for normal viral 
infection (Tan et al, 2001). Mutation of the fibre gene 1, which encodes the long 
fibre, allows the production of infectious virus, although the virus loses the 
ability to transduce human cells -  suggesting that CELO fibre 2 binds a receptor 
on chicken cells that is not present on human cells. However, the replication of 
this recombinant CELO in chicken embryos was impaired demonstrating that 
both fibre genes are necessary for efficient viral infection. CELO was also found 
to be able to use human CAR as a receptor; a CELO vector transduced Chinese 
hamster ovary (CHO) cells that express CAR with 100-fold higher efficiency 
compared with naturally CAR-deficient CHO cells (Tan et al, 2001).
CELO is significantly different from the Mastadeno virus es in that it has no 
regions that correspond to early regions E l , E3 or E4 of HAd5 (Chiocca et al,
1996). Michou et a l identified a set of ORFs of CELO that could be deleted and 
complemented in trans, and also another region that was completely dispensable 
for viral replication (Michou et al, 1999). This group found that CELO vectors
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expressing a luciferase or (enhanced green fluorescent protein (EGFP) gene 
under the influence of CMV promoter were able to express transgenes in 
mammalian cell-lines, including human cells, to levels comparable with HAd5 
vectors expressing the same transgenes from the same promoter.
The large genome of CELO suggests that it may be able to accommodate larger 
transgenes. Humans are unlikely to have a pre-existing immune response to 
CELO. CELO can therefore be added to the group of non-human adenoviruses 
with potential for human gene therapy. However, further investigations into the 
molecular biology of this virus and the human immune response against it are 
required.
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1.5 CANINE ADENOVIRUSES TYPES 1 AND 2
CAV-1 was first isolated in 1954 by Cabasso et al, from a dog with acute 
hepatitis and was originally known as infectious canine hepatitis virus (ICH 
virus). In 1962, Ditchfield et a l isolated a virus similar to CAV-1 from dogs 
suffering from laryngotracheitis that was found to be antigenically 
distinguishable from CAV-1. This virus was originally known as canine 
laryngotracheitis virus and was later renamed canine adenovirus type 2 (CAV-2). 
These viruses both have genomes of approximately 30 kbp, which is smaller than 
HAds, but their structures are typical of adenoviruses. They are both 
approximately 80nm in diameter and are made up of 252 capsomeres. 
Haemagglutination inhibition tests and restriction digest analysis of viral DNA 
confirmed the distinct genomic differences between the two canine adenoviruses 
(Daria et al, 1985, Ditchfield et al, 1962, Hamelin 1984, MacCartney et al, 
1988).
1.5.1 Pathogènes is o f CA V~ 1 and CA V-2
CAV-1 has a wide tissue tropism, replicates in endothelial cells of the vascular 
system (Greene, 1998) and can cause chronic diseases of the nervous system, 
respiratory tract, gastrointestinal tract, liver, kidneys and eyes (Koptopoulos & 
Cornwell 1981). CAV-2 is normally restricted to replication in respiratory 
epithelial cells, though CAV-2 variants have been isolated from the intestine of a 
7-week-old puppy that had died from haemonhagic diarrhoea and from the 
faeces of kennelled dogs with diarrhoeal disease (Hamelin et al, 1986, 
MacCartney et al, 1988),
Like some HAds, CAV-1 is able to transform cells in culture, which, when 
injected into newborn hamsters, cause tumours (Kinjo et al, 1968). CAV-2 also 
contains genes that transform cells and are tumourigenic in newborn rats 
(Yamashita et al, 1985, Tsukiyama et al, 1988). However, there is no evidence 
of canine adenovirus associated tumour formation in the natural host.
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1.5.2 Genomic comparisons between CAV-1 and CAV-2
There are notable biological differences between CAV-1 and CAV-L Early 
DNA hybridisation experiments demonstrated that there is less that 70% overall 
homology between their genomes (Jouvenne & Hamelin, 1986).
The E3 regions of CAV-1 and CAV-2 are approximately 1300 nucleotides and 
1800 nucleotides, respectively, (Linne 1992) compared with the 4300 nucleotides 
of HAd3 E3 region and 3300 nucleotides of HAd2. Most HAds have 10 E3 
ORFs (reviewed by Shenk 2001) whereas both canine adenoviruses have only 
two ORFs in this region. The E3 regions of CAV-1 and CAV-2 both encode 13.3 
kDa polypeptides, which have 78% amino acid identity. However, the major 
ORF of region E3 of CAV-1 encodes a 22kDa and the corresponding region of 
CAV-2 encodes a 40.7 kDa polypeptide. The amino- and carboxy- termini of 
these polypeptides are similar but the CAV-2 genome has 500 nucleotides that 
are not present in CAY-1. This variance between hosts and serotypes of 
adenoviruses in the E3 region may contribute to the biological differences in host 
and cell tropism, and pathogenesis of adenoviruses.
The differences in CAV-1 and CAV-2 tropism may be attributable, in part, to 
differences in their fibre genes. They have approximately 80% amino acid 
sequence identity although the CAV-2 has been found to be about lOnm longer 
than that of CAV-1 (Rasmussen et al, 1995, Yamamoto & Marusyk, 1968, 
Marusyk er u/., 1970).
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1.5.3 Canine Adenoviruses type 2 as a Gene Therapy Vector
A research group in France is currently developing CAV-2 as a gene therapy 
vector for use in humans and most of their work has been published concunently 
with the investigation presented here. The genetic organisation of CAV-2 early 
and late genes, and the growth kinetics of CAV-2 are comparable to those of 
HAd5 in culture (Chillon & Kremer, 2001). Although CAV-2 is able to use CAR 
to enter cells, it can also transduce cells lacking CAR, albeit at a low efficiency 
(Soudais et al, 2000). It also lacks the RGD motif that, in HAds, interacts with 
integrins for internalisation of the virus. CAV-2 attachment and internalisation is 
clearly different from HAds implying that the tropism of this virus might differ 
significantly from HAds (Soudais et al, 2000), Nevertheless, CAV-2 DNA 
replication and gene expression has been demonstrated in human cells (293, 
A549 and HeLa) to varying degrees, although the formation of infectious 
particles was not detected (Rasmussen et al, 1999). A CAV-2 vector expressing 
GFP has also been found to preferentially transduce neurons both in vitro in 
rodents and ex vivo in human brain tissue (Soudais et al, 2001). E l deleted 
CAV-2 vectors have been produced which express the lacZ transgene, under the 
control of an RSV promoter, in human, mouse, rat and monkey cell-lines in vitro 
and also in a variety of cells in 2 day old chick embryos in vivo (Kremer et al, 
2000, Klonjkowski et a l, 1997).
Neutralisation studies from a lung cancer clinical trial showed that sera from 
patients containing HAd5 neutralising antibodies had little effect on CAV-2 
infectivity (Klonjkowski et al, 1997). Although sera from 3 out of 7 of these 
patients contained CAV-2 neutralising antibodies, another study showed that 
49/50 samples from healthy individuals did not contain detectable levels of 
CAV-2 neutialising antibodies (Kremer et al, 2000).
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1.5.4 Canine Adenoviruses type 1 as a Gene Therapy Vector
CAV-1 possesses the positive attributes that are true of HAds for gene therapy. 
These include a broad range of host cells (Koptopoulos & Cornwell, 1981), a 
large insert capacity (between -f6 and +9%, compared with +5% of HAds) 
(Monison et al., 1997, Bett et al., 1993) and relative ease with which the viral 
genome can be manipulated (Monison et al, 2002).
Like many adenoviruses, CAV-1 binds human CAR (unpublished data Monison 
et al. 2002) and may thus have a common primary receptor with the HAds, 
however, little is known regarding the secondary routes by which CAV-1 can 
enter cells. In nature CAV-1 has a wider range of host tissues than CAV-2 and as 
such may be able to express recombinant genes in tissues of the human body that 
CAV-2 is unable to transduce. It is hoped that with the natural ability of CAV-1 
to infect a broad range of cell types, combined with targeting technology (see 
Chapter 4), that the use of CAV-1 based vectors in humans would show efficient 
and specific transduction of a wide range of tissue types.
Although there have been no reports of CAV-1 infection in humans, in 1969 
Gehle and Smith demonstrated that a CAV-1 sLain could infect and replicate in 
human cells in vitro, albeit at low levels, which indicated that CAV-1 had 
potential for development as a human gene therapy vector. As CAV-1 and CAV- 
2 cross-neuti'alise, it would be expected that CAV-1 would have the same 
neutralisation profile in human sera as CAV-L In 1970, a study in the Bexar 
County, Texas, USA, reported that a high proportion of normal adults had 
antibodies that neutralised CAV-1 (Smith et al 1970). It is not known if these 
antibodies were specific to CAV-1 or were cross-reactive antibodies elicited in 
response to prior infection by human adenoviruses. These results differ greatly 
to the CAV-2 study by Kremer et a l in France, 2000, however, there are 
geographical differences, the Smith study is over 30 years old and the 
methodology is different. Theoretically, it is possible that anti-CAV-1 immune 
responses could be elicited in the UK population through exposure to human 
adenoviruses [Smith et al, found that anti-HAdS neutralising antibodies cross 
react with CAV-1 (Smith et al, 1970)], CAV-1 or CAV-2. However, there is no
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reservoir for either CAV-1 or CAV-2 in the domestic canine community as 
vaccination is common practice in the UK; vaccination against the canine 
adenoviruses is mediated by administration of live-attenuated CAV-2 (Appel et 
al, 1975, Tribe & Wolff, 1973). Nevertheless, canine adenoviruses are found in 
the wild, with the fox as an example of a host and the cross-neutralisation of 
CAV-1 by other HAds may be relevant (Davidson et al, 1992, Truyen et al, 
1998).
The full sequence of CAV-1 is available and the genome has a similar genetic 
organisation to that of published HAds (Figure 1.3) (Morrison et al, 1997). In 
addition, recombinant CAV-1 vectors have been developed that are deleted 
singly or multiply in the E l, E3, and E4 regions , and E l and E4 
complementing cell-lines have been produced for the propagation of E l and E4 
deleted vectors (Monison et al, 2002, unpublished data Monison et al). 
Towards the end of the PhD project presented herein, a first generation, E3 
deleted, vector with a GFP reporter gene also became available.
1.5.5 Objectives o f this project
The aim of this project was to investigate the potential application of CAV-1 as a 
vaccine or gene therapy vector in non-canine species. Specifically the following 
questions were posed -
1) could wild type CAV-1 transduce, and express transgenes, within feline 
and human cells?
2) could a system be developed whereby CAV-1 fibre modified viruses could 
be generated (that could later be exploited to improve vector delivery to 
target tissues)?
3) would pre-existing antibodies in feline and human recipients limit 
efficacy of vectors?
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Figure 1.3 Schematic of CAV-1 genome. Open reading frames are indicated 
by arrows and numbered (in brackets), polyA sites are shown as? for upper 
strand or  ^ for lower strand. The location of the major late promoter (MLP) is 
indicated. A scale (marked in 1 kb increments) is given underneath (Morrison et 
ai, 1997).
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CHAPTER 2
Materials & Methods
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2.1 MATERIALS
2.1.1 General
2.1.1.1 Major Equipment
• ABI Prism 3100 genetic analyser (Applied Biosystems, UK).
• ABI Prism 770 sequence detector system (Applied Biosystems, UK).
• Automated Sequencing Apparatus and appliances; Lie or 4000 (Lie or Inc., 
USA).
• Benchtop orbital shaker (New Brunswick Scientific, USA).
• C25 incubator shaker (New Brunswick Scientific, USA).
• Centrifuges
Microcentrifuge 5415 (Eppendorf GMBH, Germany).
- Benchtop centrifuge GS-6R (Beckman Instruments Inc., USA).
- Ultracentiifuge 12-21 (Beckman Instruments Inc., USA).
• CÜ2 incubator for tissue culture (Leec Ltd., UK).
• Gel Documentation System (Ultra Violet Products Inc., USA).
• High Performance Ultraviolet Transilluminator (Ultra Violet Products Inc., 
USA).
• Pipetteman (P20, PlOO, P200, P I000) (Gilson Medical Electionics, France).
• Spectrophotometer: WPA U V llO l Biotech Photometer (Jencons-Pls, UK).
• Thermal Cyclers: GeneAmp 9600 (The Perkin Elmer Corporation, USA), 
PGR Express (Hybaid Ltd., Middlesex, UK).
• Vacuum Dessicator (Jencons-Pls, UK).
• Water baths (Grant Instruments Ltd., UK).
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2.1 .L 2 Consumables
0.2 ml PCR tubes (The Perkin Elmer Corporation, USA).
15 ml and 50 ml falcon tubes (Becton Dickinson lab ware, UK).
2 ml Cryogenic vials (Corning Incorporated, USA).
200 jul and lOOfil pipette tips (Sarsteds, Germany).
Cell scrapers (Greiner Labortechnik Ltd, UK).
Disposable sterile scalpels (Swann-Morton, UK).
Falcon tubes: 15 and 50 ml (Coming Incorporated, USA).
Filter pipette tips (Costar, Corning Inc., USA; Greiner Labortechnik Ltd, 
UK).
Flat ended gel loading tips (Sorenson Bioscience Ltd., Denmark).
PCR tubes (The Perkin Elmer Corporation, USA).
Bijoux and universals (Greiner Labortechnik Ltd, UK).
Screw top and flip top 1.5ml microfuge tube (Treff AG, Switzerland)
Single use syringe filter, 0.2 and 0.45 jam (Sartorius, Germany).
Syringes of 1, 2, 5, 10, 20 and 50 ml (Becton Dickinson Labware, UK). 
Tissue culture disposables: flasks (TRP, Switzerland), multi well plates and 
pipettes (Corning Incorporated, USA).
2.1.1.3 Complete kits
• ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kits
(Applied Biosystems, UK).
• Access RT-PCR System (Promega, UK) for reverse transcription and PCR
amplification of specific target RNA from total RNA.
• DNeasy® Tissue Kit (Qiagen, UK) for purification of DNA from cultured 
cells,
• Purescript® RNA isolation kit (Flowgen, UK) for the isolation of RNA from
cultured cells.
• LipofectAMINE Reagent (Invitiogen Life Technologies, UK).
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• Generation® Capture Column Kit (Flowgen, UK) for the isolation of DNA 
from cultured cells.
• Qiagen Plasmid Mega Kit supplied by Qiagen (Qiagen, UK) was used to 
isolate up to 2.5mg of high-purity plasmid DNA from 500 ml bacterial 
culture.
• Qiaprep Miniprep Kit (Qiagen, UK) was used to isolate up to 20pg of high- 
purity plasmid DNA from 3 ml bacterial culture.
• QIAquick Gel Extinction Kit (Qiagen, UK) for purification of DNA and 
extraction of DNA from agarose gel.
• TOPO TA Cloning Kit (Invitrogen Life Technologies, UK) for the cloning of 
PCR products with A overhangs generated by Taq polymerase.
2.1.1.4 DNA plasmid vectors
• pCI-neo Mammalian Expression Vector (Promega, USA).
• pCR®2.1-TOPO TA cloning vector (Invitrogen Life Technologies, UK) as 
part of the TOPO TA cloning kit, supplied as linearised DNA with 3' T 
overhangs.
2.1.1.5 Enzymes
• Calf Intestinal Alkaline Phosphatase (CIAP) (Invitrogen Life Technologies, 
UK).
• DNasel (Invitrogen Life Technologies, UK).
• Restriction enzymes and appropriate buffers (New England Biolabs, UK, or 
Invitrogen Life Technologies, UK).
• RNaseA (Invitrogen Life Technologies, UK)
• T4 DNA Ligase and buffer (New England Biolabs, UK, or Invitrogen Life 
Technologies, UK).
• Taq DNA polymerase (Qiagen, UK).
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2.1.1.6 Molecular size standard
Ikb DNA Ladder (size range 100 bp to 12 kb) (Invitrogen Life Technologies ,
UK).
2.1.1.7 Reagents and solutions
The following list represents commonly used solutions. Other reagents are listed
in the appropriate methods section of each chapter.
• Water for the preparation of media and general solutions was purified using a 
Millipore ROIO system (Millipore, UK). Ultrapure water (milli-Q H2O) for 
work using recombinant DNA and protein was purified by a Millipore Q50 
water purification system (Millipore, UK).
• All general chemicals used were of analytical (Analar) or ultra pure grade, 
supplied by Sigma Chemical Company, UK, or BDH Ltd., UK, unless 
otherwise specified.
• 1 M Tris-HCl: 121 g Tris base, 800 ml dH20 adjusted to desired pH with 
concentrated HCi and made up to 1 litre.
• 10 X DNA loading buffer: 50% (v/v) glycerol, 0.5% (w/v) bromophenol blue, 
0.5% (w/v) xylene cyanol, 100 mM EDTA (pH 8) in milli-Q H2O.
• 10 X TBE: 0.9 M Tris-HCl, 0.9 M Boric acid, 25 mM EDTA (pH 8.3). Dilute 
to 1 X  with milli-Q H2O.
• Ethidium bromide: 10 mg/ml stock in milli-Q H2O, working solution at 3 
mg/ml with milli-Q H2O; stored at room temperature.
• Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HP0 4 , 1.8 mM KH2PO4 (pH 7.3).
• STET: 8% (w/v) sucrose, 50 mM Tris-HCl (pH 8), 50 mM EDTA pH8, 5% 
triton XlOO made up in dH20, filtered (0.22 mm).
59
2.1.1.8 Oligonucleotides
All oligonucleotides were synthesised and supplied freeze dried by the 
manufacturer MWG-Biotech and were then suspended in milli-Q H2O for use. 
Sequencing primers for Licor model 4000 were modified by IRD 800 labelling. 
Sequencing primers for ABI Prism 7700 system were unmodified. Specific 
primers are detailed in the appropriate chapters.
2,1.2 Bacteria
2.1.2.1 Bacterial strains
• BJ5183 electrocompetent E.coli cells were a kind gift from M. Mehtali 
(Transgene S.A., Strasbourg).
• TOP 10 cells comprising One Shot chemically competent E. coli (Invitrogen 
Life Technologies, UK).
• MAX Efficiency STBL2 competent cells (Invitrogen Life Technologies, 
UK).
2.1.2.2 Bacterial media and supplements
• Ampicillin: 100 mg/ml in dH20, filtered through a 0.22 mm filter, aliquoted 
and stored at -20°C. Used at a final concentiation of 100 fig/ml.
• Chloramphenicol: 34 mg/ml in ethanol. Stored at -20°C. Used at a final 
concentiation of 100 ftg/ml.
• Luria-Bertani (LB) medium: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% 
(w/v) sodium chloride in dH2 0 , autoclaved and stored at room temperature.
• LB-agar: LB medium containing 1.5% (w/v) agar.
• SOC Medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl,
2.5 mM KCl, 10 mM MgCH, 10 mM MgS0 4 , 20 mM glucose.
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2.1,3 Cell culture
2.1.3.1 Cell-lines
• 293 cells (American Tissue Culture Collection, Manassas, USA) are primary 
human embryonal kidney transformed by human adenovirus type 5 (Ad 5) 
DNA.
• A549 cells (American Tissue Culture Collection, Manassas, USA) were 
derived from human lung carcinomatous tissue.
• CrFK cells were isolated from feline kidney cortex and FEA cells are feline 
embryonic fibroblast cells. Both cell-lines were kind donations from Mathew 
Golder (Feline Virus Unit, University of Glasgow).
• Canine cell-lines A l l ,  D17 and CMLIO were supplied by Lizzie Gault 
(Division of Small Animal Clinical Studies, Faculty of Veterinary Medicine, 
University of Glasgow). A l l ,  D17 and CMLIO cells are skin fibroma, 
osteosarcoma and melanoma cells, respectively.
• MDCK cells (kindly provided by Anne Weir of the Feline Virus Unit, 
University of Glasgow) are normal canine kidney cells.
2.1.3.2 Media
All media and supplements were purchased from Invitrogen Life Technologies,
UK, unless otherwise stated.
Dulbeccos’s Modified Eagle’s Medium (DMEM) with lOOOmg/L D-glucose, 
sodium pyruvate and pyridoxine
Foetal Calf Serum (FCS), virus screened and mycoplasma screened. 
Heat-Inactivated Foetal Calf Serum (HI-FCS), virus screened and 
mycoplasma screened-glutamine, supplied as a 200mM (100 x) stock 
solution.
Minimum Essential Medium (MEM), containing Earle's Salts and L- 
glutamine.
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• MEM Non Essential Amino Acids (NEAA), Supplied as a lOOx solution 
containing L-alanine (890 mg/L), L-asparagine (1320 mg/L), L-glutamic acid 
(1470 mg/L), glycine (750 mg/L), L-proline (1150 mg/L) and L-serine (1050 
mg/L)
• Penicillin/streptomycin (Pen/Stiep), supplied as a 100 x stock solution of 
10,000 units penicillin and 10 g streptomycin per ml.
• 1 X Trypsin-EDTA solution: 0.05% Trypsin (w/v), 0.53 mM EDTA 4Na.
2.1,4 Viruses, Viral DNA, Cosmids and Plasmids
CAV-1 isolate RI261 was used throughout. RI261 was obtained from the 
lungs of a naturally infected dog, and as such was more likely to represent 
wild-type CAV-1 than strains that had been passaged extensively in tissue 
culture (Morrison e? <3?, 1997).
Human Adenovirus type 5 was a kind gift from Dr Andrew Baker 
(Department of Medicine and Therapeutics, University of Glasgow).
Canine Adenovirus type 2 DNA was donated by Anne Weir (Feline Virus 
Unit, Department of Veterinary Pathology, University of Glasgow).
Human Adenovirus type 5 DNA was supplied by Laura Blackwood (Division 
of Small Animal Clinical Studies, Faculty of Veterinary Medicine, University 
of Glasgow).
The CAV-1 vector AE3-GFP-CAV-1, which has a 844 bp section of the E3 
region replaced by a GFP reporter gene under the control of the CMV 
immediate early promotor (see section 3.2.5), plasmids pSwapmeCm^, 
KXCm^ and cosmid FLR-CAV were donated by Dr Mark Monison (Vaccine 
Research Group, Department of Veterinary Pathology, University of 
Glasgow).
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2.2 METHODS
2.2.1 General Molecular biology
2.2.1.1 Quantitation o f DNA
The concentration of DNA in a solution was determined by specti'ophotometry 
with a WPA U VllO l Biotech spectrophotometer (Jencons-Pls, UK). The 
spectrophotometer was initially calibrated using dH^O as a blank. DNA was 
diluted in dH20 at a ratio of 1:100 and transferred to a quartz cuvette. The 
optical density readings were obtained at 260 nm and 280 nm. The ratio between 
readings at 260 nm and 280 nm (A26o:A28o) provided an estimate of the sample 
purity; a ratio approximately 1.8 indicated that preparations contained essentially 
no protein contamination. As 1 OD260 is equivalent to 50 flg/jil DNA, the 
concentration of nucleic acid in samples was deduced by 5 x OD260-
2.2.1.2 Restriction Enzyme Digests
Restriction digests were performed using the appropriate enzymes and reaction 
buffers according to the manufacturer’s instructions. Typically, plasmid DNA 
was incubated with 2 units of restriction enzyme/pg DNA in a buffered solution 
at the temperature recommended by the manufacturer. Restriction digestion of 
small quantities of plasmid or cosmid DNA (0.2-1 pg) was canied out in a 20pl 
reaction volume for 1-3 hours. Restriction digestion of larger quantities of DNA 
(1-5 pg) for gel extraction (section 2.2.1.6) was carried out in a volume of 50- 
100 pi for 3 hours, or overnight.
2.2.1.3 Dephosphorylation o f Vector DNA
Vector DNA was dephosphorylated at its termini to prevent re-ligation. After 
vector DNA had been linearised by digestion, the reaction mixture was adjusted
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by adding milli-Q H2O, dephosphorylation buffer (Invitrogen Life Technologies, 
UK) to make a 1 x solution, and 5 units of CIAP. The reaction mixture was 
incubated at 37°C for an hour. Enzyme activity was terminated by heating to 
72*^0 for 10 minutes.
2.2.1 A  Blunting o f Restriction Endonuclease Termini
T4 DNA Polymerase was used to fill termini created by restriction enzyme 
digestion of DNA as follows. For each reaction, G.5-2.5 pg of DNA was mixed 
with 20 pi 5 X T4 DNA polymerase buffer, 20 pi 0.5 mM dNTP mixture, 1 pi 50 
mM dithiothreitol (DTT) and 10 units of T4 DNA polymerase, and milli-Q H2O 
added to bring the volume to 100 pi. The reaction was incubated at 11°C for 15 
minutes, followed by incubation of ice.
2.2.1.5 Agarose Gel Electrophoresis
A  perspex horizontal gel cast apparatus was used. Agarose gel mix to 0.7% 
(w/v) agarose, unless otherwise stated, was dissolved in 1 x TBE buffer by 
heating the solution in a glass conical flask in a microwave. 5 pi of ethidium 
bromide working solution was added per 100 ml of gel to allow visualisation of 
bands under UV after running. The gel was poured when the agarose was hand 
hot and a comb with the required number and size of teeth was placed 
immediately into the gel to form the sample wells. Once the gel had set it was 
submerged in 1 x TBE buffer. The samples containing 1 x loading buffer were 
loaded in each well alongside 1Kb DNA ladder and electrophoresed at a constant 
voltage of 10 V/cm gel length. DNA fragments were visualised by illumination 
with short wave (312 nm) UV light and photographed using the Gel 
Documentation System (Ultra Violet Products Inc., USA),
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2.2.L6 Isolation and Purification o f DNA Restriction Fragment from
Agarose Gel
Restriction enzyme digested DNA (section 2.2.1.2) was visualised by agarose gel 
electrophoresis as described in section 2.2.1.5. Desired fragments were cut out 
of the gel with a clean scalpel blade and individual gel slices placed in microfuge 
tubes. Extraction of DNA fragments was achieved using the QlAquick gel 
extraction kit following the manufacturer's inshuctions. DNA was eluted in 30 
pi of dH2 0 .
2.2.1.7 Ligation o f DNA Fragments
DNA was analysed by agarose gel electrophoresis in order to estimate quantity 
(section 2.2.1.5). DNA fragments were ligated to dephosphorylated vectors (100 
ng) at a ratio of 3:1. The vector and inserted DNA were incubated together in a 
reaction containing 1 x iigase buffer and 1 unit of T4 ligase at 16°C overnight.
2.2.1.8 Preparation o f LB plates
LB plates were prepared by melting 200 ml of LB agar in a microwave at the 
lowest temperature setting for 8 minutes. The melted agar was cooled until hand 
hot, 100 pg/ml ampicillin was added (unless otherwise stated) and approximately 
20 ml of agar was poured into each 10 cm^ petri dish.
2.2.1.9 Transformation o f Bacterial Hosts
Transformation of TOP 10 and Max Efficiency STBL2 bacteria was performed 
using commercial kits according to the manufacturer's instructions. 
Electrocompetent BJ5183 cells were prepared and transformed as follows.
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Preparation of electrocompetent BJ5183 cells
A BJ5183 glycerol was streaked out on antibiotic free LB agar plates and 
incubated at 37°C overnight. 20 ml of antibiotic free L broth was inoculated 
with a single BJ5183 colony and shaken at 200 rpm for approximately 5 hours, 
until the OD^oo = 0.5 -  0.7. The bacteria were then chilled on ice for 20 minutes 
followed by centrifugation for 20 minutes at 3 K at 2°C in a benchtop centrifuge. 
The supernatant was removed and the pellet resuspended in 20 ml of ice cold 
dH20 and centrifuged for 20 minutes at 3K, 2°C. The procedure was repeated 
and the pellet resuspended in an equal volume of ice cold dH2 0  and stored on ice 
until electroporation.
Electi'oporation of electrocompetent BJ5183 cells
50pl aliquots of electrocompetent cells were added to cold electrocuvettes on ice. 
DNA samples for cotransformation were added to the electrocuvettes 
immediately prior to electi'oporation. The electrocuvette was placed in a 
prechilled cuvette holder and pulsed using a pulse contioller set to 200 ohms, 
gene puiser at 25 pFD and 2.5 V. 1 ml of SOC medium was added to the cells, 
which were then shaken at 37°C for 1 hour to allow expression of antibiotic 
resistance genes.
2.2.1.10 Small Scale Preparation o f Plasmid DNA (Miniprep)
A single bacterial colony or 50 pi from a 2.5 ml overnight bacterial culture was 
used to inoculate 2.5ml of L-Broth (section 2.1.2.2) containing antibiotic (100 
pg/ml ampicillin unless otherwise stated) and grown overnight at 37°C with 
shaking. 1.5ml of bacterial culture was pelleted by centrifugation in a 
microcentrifuge (14000 ipm) for 15 seconds. Supernatant was removed and 
plasmid DNA was prepared from the pellet using either Qiagen’s QlAprep Spin 
plasmid miniprep kit according to the manufacturer’s instructions or the 
Stet/Lysosyme minipreparation method as follows.
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Stet/Lvsosvme Miniprep
After centrifugation the supernatant was removed and the bacterial pellet 
resuspended in lOOpl STET containing 3mg/ml of iysosyme (Sigma Chemical 
Company, UK). The sample was then boiled for 45 seconds and centrifuged at 
14 K for 15 minutes. The pellet containing cell debris was picked out with a 
toothpick and discarded. lOOpl of isopropanol was added and the sample 
incubated at -20°C for 30 minutes to precipitate DNA, followed by centrifugation 
at 14 K for 6 minutes. The supernatant was removed and the pellet air dried. 
DNA was resuspended in 20pl or 30pl of milli-Q H2O.
2.2.1.11 Large Scale Prepai'ation o f Plasmid DNA (Maxiprep)
A  single bacterial colony or 1 ml of a 2.5ml overnight bacterial culture was used 
to inoculate 400 ml of L-broth containing the appropriate antibiotic (100 pg/ml 
ampicillin unless otherwise stated) in a 2 litre conical flask. The culture was 
incubated overnight at 37°C with shaking. Bacterial cells were pelleted by 
centrifugation (7 K, 15 min, 4°C). DNA was prepared from the pellet using the 
Qiagen Megaprep kit according to the manufacturer’s instructions.
2.2.1.12 Glycerol Stocks
Bacterial cultures were preserved for further use by making glycerols from 
overnight cultures. 800 pi of an overnight culture was mixed with 200 pi of 80% 
glycerol in a 1.5 ml microcentrifuge tube and stored at -70°C. To recover the 
bacteria from glycerol stocks, the glycerols were thawed, stieaked out onto an 
LB-agar plate with appropriate antibiotics using a sterilised platinum wire and 
incubated overnight at 37°C.
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2.2.2 Polymerase Chain Reaction (PCR)
2.2.2.1 PCR Primer Design
Primers used were between 18 and 25 nucleotides in length, with a G/C 
concentration of 50-60% where possible. Melting temperatures were determined 
for the binding sequences of each primer using the formula:
Tm = 4(G + C) + 2(A + T)
Where Tm = melting temperature in °C, and G, C, A and T represent the number 
of guanine, cytosine, adenine and thymine residues in the primer, respectively 
(Itakura et al 1984). Wherever possible, primer pairs with similar melting 
temperatures were used to ensure similar annealing temperatures for both 
primers.
2.22.2 Taq PCR
Qiagen master mixes were prepared in bulk in a designated PCR clean area. 
PCR master mixes contained 200 pM each dNTP, 2.5 units of Taq polymerase in 
a total volume of 25 pi containing 2 x Qiagen PCR buffer, in 0.2ml sterile 
reaction tubes. Approximately 30 ng of DNA template, 100 pmol of each primer 
and PCR giade H2O were added to a total volume of 50 pi. PCR amplification 
was earned out using a Perkin Elmer 9600 Thermal Cycler. Unless otherwise 
stated, an initial dénaturation step at 94°C for 3 minutes was followed by 30 
cycles of dénaturation, annealing and extension as follows. The samples were 
denatured by heating at 95°C for 45 seconds, followed by annealing at 
approximately 5°C below the melting temperature (Tm) of the primers for 45 
seconds. The extension step was earned out at 72°C for approximately 1 minute 
per Kb of DNA. 5pi of each PCR reaction was analysed by agarose gel 
electrophoresis (section 2.2.1.5).
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2.22.3 RT-PCR
RNA was incubated with 1 unit of DNasel in a solution buffered with React I at 
37°C for 30 minutes. The reaction was terminated by incubation at 65°C for 10 
minutes. RNA was then reverse transcribed, and the resultant cDNA amplified 
in a single tube using Promega's "Access" kit according to the manufacturer's 
instructions. For each reaction of 50pl total volume, 5pi of RNA was mixed 
with lOpl AMN/Tfl 5x Reaction Buffer, Ipl dNTP Mixture (lOmM each of 
dATP, dCTP, dGTP and dTTP), 2pl 25mM MgS0 4 , Ipl AMV Reverse 
Transcriptase (5U/pl), Ipl Tfl DNA Polymerase (5U/pl), lOpl primer mix 
(50pmol of each per reaction) (see Table 3.2), 20pl PCR giade H2O. Reverse 
transcriptase free controls were earned out on selected samples to ensure there 
was no DNA contamination. Cycling conditions were as follows: 45 minutes at 
48°C for reverse transcription; followed by 5 minutes at 94‘^ C to denature the 
reverse transcriptase and 45 cycles of 30 seconds at 94°C (dénaturation), 30 
seconds at 52°C (annealing) and 1 minute at 68°C (extension), followed by a 
final extension step of 72°C for 10 minutes.
2pl of lOx loading buffer was added to 20pl aliquots of the RT-PCR reactions, 
which were analysed by electrophoresis of 2% agarose TBE gels stained with 
0.5pg/ml ethidium bromide.
2.2.2.4 TaqMan
The development of TaqMan PCR has enabled quantitative PCR, which was in 
the past laborious and time consuming, to be earned out effortlessly and quickly. 
TaqMan is made possible by the use of a hybridisation probe that is labelled with 
fluorogenic dyes. This probe is designed to specifically anneal between 5’ and 3’ 
primers on the target DNA strand (see Figure 2.1). At the 5' end the probe is 
labelled with a reporter dye (e.g. 6-carboxy fluorescein [FAM]) and at the 3' end 
it is labelled with a quencher dye (e.g. 6-carboxy-tetramethyl-rhodamine 
[TAMRA]), which fluoresce at different wavelengths. Whilst the probe is intact
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the quencher dye absorbs the fluorescent emission of the reporter dye. However, 
during target amplification the exonuclease activity of Taq polymerase degiades 
the hybridised probe from the 5' end, releasing the reporter dye from the vicinity 
of the quencher dye (Heid et a l, 1996). This results in an increase of reporter 
fluorescence, which is measured, along with the fluorescence of the quencher, by 
an ABI prism sequence detector in real-time. From these measurements the 
software calculates a value termed ARn, which is the difference between the 
reporter fluorescence in the sample and that in the no template control. The ARn 
reflects the amount of probe that has been degraded, allowing fluorescence from 
the reporter dye. The amount of fluorescence generated during each 
amplification cycle is directly proportional to the degree of amplification of the 
target sequence. The ARn value is plotted on the y-axis of an 'amplification plot' 
against the cycle number on the x-axis (see Figure 2.2).
A threshold value is assigned to the plot either by the user or by the computer at 
a level where there is a significant increase in reporter fluorescence above 
baseline. The cycle at which the amplification plot for a given sample intersects 
the threshold is defined as the threshold cycle ( C t ) ,  which is indicative of the 
initial target quantity, with C t values decreasing linearly with increasing target 
quantity.
The requirements for three hybridisation events results in a sensitive and precise 
technique. In addition, the buffer used for most TaqMan contains uracil-N- 
glycosylase (UNG). This prevents the amplification of dUTP-containing PCR 
products as it hydrolyses uracil containing amplicons. The use of dUTP instead 
of dTTP in the PCR reaction means that only the amplification of template DNA 
is detected during TaqMan PCR.
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Figure 2.1 TaqMan PCR
A Forward and reverse primers, and fluorogenie probe anneal to the template 
DNA strand. Primers are extended by Taq polymerase.
B The DNA produeed by elongation of the primer displaces the fluorogenie 
probe at the 5’ end.
C and D The exonuclease activity of Taq polymerase cleaves the reporter from 
the probe and releases it from the quencher generating a fluorescent signal 
which is detected by the ABI Prism sequence detection system.
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Figure 2.2 TaqMan Amplification Plot
An example of an amplification plot as produced by Applied Biosystems 
Sequence Detection Software. The ARn value is plotted against the cycle 
number. The cycle that the amplification plot crosses the threshold is referred to 
as the threshold cycle (Ct).
TaqMan Analvsis of DNA
Sample DNA was assayed in triplicate for both El a and rDNA by an ABI Prism 
7700 Sequence Detection system (PE Applied Biosystems). Ela was used as 
target for viral DNA. Cellular rDNA levels were analysed to provide an 
endogenous control, the levels of rDNA present in each sample provided a 
reference with which the relative amount of viral DNA detected could be 
quantitated. A master mix was prepared which contained dNTPs with dUTP 
(200pM dCTP, dGTP and dATP), and 400 pM dUTP, Ix PE buffer, 5.5 pM 
MgClz, Amplitaq (1.5U/50pl), 300nM of each forward and reverse primers 
(Table 2.1) and 200nM TaqMan probe (reporter dye- FAM; quencher dye-
72
TAMRA) (Table 2.1) (rDNA primer and probe sequences from Dr S Dunham, 
Retrovirus Research Laboratory, University of Glasgow), and PCR grade water 
to a final volume of 45pi. 5pi of DNA was added to each reaction. The cycling 
conditions were as follows: initial 5 minute 95°C denaturing step followed by 45 
cycles of 15 seconds at 95 °C and 1 minute at 60°C (combined 
annealing/extension step). Fluorescence was measured at the end of each cycle. 
All PCR data was captured using Sequence Detector Software (SDS version 1.6, 
PE Applied Biosystems). The threshold value must be set at the same value for 
separate TaqMan experiments to be comparable. The threshold was set at 0.43 
for E la  samples and 0.14 for rDNA samples. The Sequence Detector Software 
calculated the threshold cycle (C t ) value for each sample, this value was used for 
calculations that were later performed in Microsoft Excel.
Gene
Represented
Nucleotide Sequence Location on 
CAV-1
Amplicon
Length
(bp)
CAV-1 E la Primer 1 
Primer 2 
Probe
5' GAG GCT GAC AGT GAA TC 3’
5' CCG GCG GAG TGT TCA AAG T 3’ 
5' AAG CCA ACA ACA TCA GTC TCC 
GTG GAA ATT GT 3'
649-665
715-697
695-667
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Cellular
rDNA
Primer 1 
Primer 2 
Probe
5' CCA TCG AAC GTC TGC CCT 3'
5' TCA CCC GTG GTC ACC ATG 3’
5' CGA TGG TGG TCG CCG TGC CTA 3' N/A
67
Table 2.1 Primers and probes for Real-Time PCR
Standards
DNA isolated from wild-type CAV-1 infected MDCK cells, consisting of a 
mixed population of viral and cellular DNA, was used for standards in TaqMan. 
These were serially diluted and stored at -20°C in 50pl aliquots. As the actual 
amount of cellular and viral DNA was unknown in these standards, relative 
standard curves were produced. Relative standards allow quantification and 
comparison of individual samples using arbitiary units. 5pi of standards
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containing 0.64pg, 3.2pg, 16pg, 80pg, 400pg, 2000pg or lOOOOpg of total DNA 
underwent TaqMan analysis in duplicate using both E la  and rDNA probe and 
primer sets. Standard curves were produced for both cellular and viral DNA for 
each TaqMan experiment. This allowed the quantitation of CAV-1 DNA relative 
to cellular rDNA in each sample. The C j values of the standards were plotted 
against log DNA values on giaphs to give standard curves for both E la  and 
rDNA.
Excel Calculations
The log DNA value of each sample was obtained by extrapolation of the Cj 
values from the standard curve. At each time point the average E la  and average 
rDNA values, and the standard deviations of the averages were calculated from 
the triplicates. The average E la  value was noraialised (to account for differences 
in cell number) by dividing with the average rDNA value. As both values were 
means with associated standard deviations, the coefficient of variance was 
calculated to determine the standard deviation of the normalised mean:
CV =  V  (C V i^  +  CV2^)
where the cv = standard deviation 
mean value
and standard deviation of the normalised mean = (cv)(mean).
The -fold increase in E la  was calculated for each time point by dividing each 
normalised E la  value by that of the 0 hour time point.
The results for each time point from different experiments were averaged and the 
standard eiTor of the mean (SEM) calculated as follows:
SEM = Standard Deviation of mean
V(number of samples)
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Where the Standard Deviation = (cv)(mean)
with cv = to the coefficient of variance and the mean = normalised E la  value.
Analysis of variance (ANOVA) tests the hypothesis that means from two or more 
samples are equal. A confidence level is set for the ANOVA test and if the p- 
value of the test is less than the confidence level specified the hypothesis being 
tested is rejected. For each TaqMan time course ANOYAs were performed 
between the replicates of samples, with a confidence level of 0.05, to test 
whether the means of the samples could be considered equal at each time point. 
All had p-values greater than 0.05.
The pooled results were plotted on a logarithmic scale giaph with error bars 
showing the SEM.
2.2.3 Sequencing
2.2.3.1 LiCor Sequencing
LiCor sequencing reactions were prepared using the ThermoSequenase 
Fluorescent Labelled Primer Cycle Sequencing Kit with 7-deaza-dGTP 
(Amersham Pharmacia, UK). Cycle sequencing is based on the chain 
termination method described by Sanger et al 1977.
A reaction mix of 500 ng DNA, 1 pmol of IRD800 labelled primer and 2 pi of 
reaction mix containing 45 mM of dGTP, dATP, dTTP and dCTP, reaction 
buffer and thermostable DNA polymerase was prepared in a 0.2 ml reaction tube 
and dHzO was added to a volume of 8 pi. Cycle sequencing was as follows: 5 
min 95°C denaturing step, 30 cycles of 30 second denaturing step (95°C), 30 
second annealing step (5°C below the Tm of the primer) and 30 second extension 
step (72°C). 4pl of loading buffer provided with the kit was added to each 
reaction.
75
66 cm glass plates were thoroughly cleaned and polished with isopropanol. 330 
pi of 0.05% (v/v) bind saline in 100% ethanol was mixed with 10 pi of 10% 
(v/v) acetic acid and applied to the top and bottom of the plates, allowed to dry 
and then buffed with paper towel. The glass plates were then assembled in the 
casting stand with spacers. The gel was prepared using 7.2 ml 10 x TBE (216 g 
Tris, 1110 g Boric acid, 80 ml 10.5 M EDTA pH 8, made up to 2 litres with 
milli-Q H2O), 25.2 g urea and 4.8ml Long Ranger™ solution (National 
Diagnostics, USA) and H2O to a final volume of 60ml. A volume of 400 pi of 
10% ammonium persulphate (APS) was added and 3ml was removed and placed 
in a bijou. 40pl of 10% (w/v)APS and 4pl N'-tetramethyl-ethylenediamine 
(TEMED) were added to the 3ml of solution and applied to the channels at the 
bottom of glass plates. Once this plug had polymerised 40pl of TEMED was 
added to the remaining solution and poured into the electi’ophoresis gel plates 
using a 50 ml syringe. A comb was placed in the top of the gel and the gel was 
allowed to polymerise for approximately 2 hours. The gel was placed in a LiCor 
4000 system with 1 x TBE added to the buffer tanks. The comb was removed, 
the wells flushed with buffer and a pre-electrophoresis step performed which 
focussed the microscope, adjusted the gain contiols and warmed the gel. 1.5 pi 
of each sample was loaded into separate wells. The gel was electrophoresed and 
sequence data was recorded. The data was analysed using the GCG package 
(Wisconsin Package Version 9.1, Genetics Computer Group (GCG), Madison, 
Wisconsin, USA).
2.2.3.2 ABI Prism Sequencing
Cycle sequencing reactions were prepared in 0.2 ml PCR tubes using a ready 
made BigDye Terminator RR master mix (Applied Biosystems, UK). This 
consisted of 3.2 pmol of the appropriate primers, dNTPs, dye terminators, 
magnesium chloride, buffer, AmpliTbg DNA polymerase and FS, which is a 
variant of Thermus aquaticus DNA polymerase. In general, around 500 ng of 
high-quality double stranded DNA template was included in the cycling reaction. 
The reactions were made up to a total volume of 20pl with dH20.
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The cycle sequencing reaction was carried out under the following conditions: 25 
cycles of the following: rapid thermal ramp to 96°C, 96°C for 10 seconds, 50°C 
for 5 seconds, 60°C for 4 minutes.
Reactions were either purified by ethanol precipitation or by using the Performa 
DTR gel filti'ation cartridge kit (Edge Biosystems, USA) - see below. DNA 
pellets were resuspended in 20 pi Hi Di Formamide (Applied Biosystems, UK). 
The samples were loaded onto a 96 well plate and electrophoresed on an ABI 
prism 3100 Genetic Analyser. The chromatogiam was studied by eye and 
sequences were analysed using the GCG package (Wisconsin Package Version 
9.1, Genetics Computer Group (GCG), Madison, Wisconsin, USA).
Ethanol precipitation
Cycle sequencing reactions were diluted with 80 pi of dH^O. 1 pi of 3 M 
sodium acetate and 200 pi of 100 % ethanol and the mixture was incubated at - 
20°C for 30 minutes to precipitate DNA. DNA was pelleted by centrifugation at 
12 K for 10 minutes in a microcentiifuge. The supernatant was removed and the 
pellet was washed with 150 pi 70% ethanol and centrifugation at 12 K for 5 
minutes. The supernatant was removed and the pellet was air dried.
Performa DTR gel filtiation cartridge kit
A fresh spin column was centrifuged at 750 g for 2 minutes to remove interstitial 
fluid. The column was removed from the wash tube and placed in a new 
collection tube and the cycle sequencing reaction was applied to the centre of the 
binding column and centrifuged for 2 minutes at 750 g. The binding column was 
then removed and the DNA pellet dried for 15 minutes using a vacuum pump.
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2.2.4 Cell Culture and Transfection
All cell culture was performed using strict aseptic techniques inside a BioMAT 
laminar flow hood (Medical Air Technology Ltd., UK).
2.2.4.1 Maintenance o f Cells
All cell-lines were maintained in plastic tissue culture flasks and incubated at 
37°C in a wet atmosphere containing 5% (v/v) CO2. 5 ml of medium was used in 
25 cm^ flasks, 15 ml of medium was used in 75 cm^ flasks and 30 ml of medium 
was used in 175 cm^ flasks.
MDCK cells were maintained in MEM, 5% (v/v) ECS, 1% (v/v) L-glutamine, 
1% (v/v) NEAA and 1% (v/v) Pen/Stiep.
293 cells were maintained in MEM, 10% (v/v) HI-FCS, 1% (v/v) L-glutamine, 
1% (v/v) NEAA and 1% (v/v) Pen/Strep.
A549, A72, CMLIO, CrFK, D17 and FEA cells were maintained in DMEM, 10% 
(v/v) HI-FCS, 1% (v/v) L-glutamine and 1% (v/v) Pen/Strep.
2.2.4.2 Seeding o f Cell-lines
Cells were subcultured twice a week at a density determined by the rate of cell 
gi'owth. The subculture routine was performed by removing the culture medium, 
washing the cells once with 2 ml (25cm^ flasks), 3 ml (75cm^ flasks) or 5 ml 
(175cm^ flasks) of PBS, followed by the addition of 1ml (25cm^ flasks), 2ml 
(75cm^ flasks) or 4ml (175cm^ flasks) of trypsin and incubation at 37°C (20 min 
for MDCK, 5 min for A549, A72, CMLIO, CrFK, D17 and FEA cells). Trypsin 
is neutralised by serum, therefore, 2 ml (25cm^ flasks), 4 ml (75cm^ flasks) or 6 
ml (175cm^ flasks) of the appropriate growth medium was added to the 
trypsinised cells. The cells were then split according to the gi'owth rate of each 
cell-line. Cells were resuspended in 5mi of medium in 25cm^, 15ml of medium
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in 75cm^ and 30ml of medium in 175cm^ flasks, and incubated as described 
above.
2.2.4.3 Counting cells
Cells were counted by tiypan exclusion of dead cells. 50 pi of cell suspension 
was diluted with 50 pi tiypan blue (Invitrogen Life Technologies, UK) and lOpl 
was loaded onto a haemocytometer with cover slip. Cells in 5 of the 9 open 
squares were counted under the 10 x objective of an inverted microscope. The 
sum of the counted cells was divided by 5 (the number of open squares counted), 
multiplied by 2 (dilution factor) and multiplied by 10"^  to determine the number 
of cells per ml.
2.2.4.4 Storage and Revival o f Cells
To freeze cell stocks for storage, confluent cell cultures were trypsinised and 
pelleted by centiifugation at 1000 ipm for 5 minutes. The cells were then 
resuspended at a concentration of approximately lO*" cells/ml in FCS containing 
10% (v/v) DMSO. The DMSO in the medium acts as a cryoprotectant. 
Suspensions were divided into 1 ml aliquots in 1-2 ml cryogenic vials and placed 
at -70"^C overnight. The following day the tubes were placed in liquid nitrogen.
Frozen stocks were recovered by removing the vials from liquid nitrogen and 
placed into water at 37°C. Once thawed, the cells were added to 15 ml of growth 
medium in 75 cm^ flasks and maintained as described above
2.2.4.5 Ti'ansfection o f Cells
Cells were subcultured at 5 x 10  ^ cells in 25cm^ tissue culture flasks. The 
following day transfections were caiiied out using LipfectAMINE Reagent 
(Invitrogen Life Technologies, UK) as follows. The required amount of DNA 
was added to 250pl OptiMEM (mixture A) and 25pi of lipofectamine was added 
to 250pl OptiMEM (mixture B). Mixture A and mixture B were combined and
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incubated at room temperature for 30 minutes to allow interaction of DNA and 
lipofectamine. The mixture was diluted with 2ml of OptiMEM and added to 
MDCK cells that had been washed twice with PBS. Cells were incubated at 37°C 
for 4-6 hours, OptiMEM removed and cells washed once with 5% medium 
before incubating overnight in 5ml of fresh medium at 37®C.
2.2.4.6 TCIDso method
Whole log dilutions were made by diluting 200pl of samples, or previous 
dilution, with 1.8ml of the appropriate medium. Half log dilutions were made by 
diluting 1ml of whole log dilutions with 2 .2 ml of the appropriate medium. 1 0 0  
pi of each virus dilution was added to multiple wells of a 96-well plate 
containing 1.5 x 10"^  cells. Plates were scored for c.p.e. every day over a period 
of 7-10 days. TCID50 values were calculated using the Karber fonnula:
log TCID50 = D - A(S - 0.5)
where TCID50 = tissue culture dose where 50% of cells die, D = log of lowest 
dilution showing 100% c.p.e., A = difference between successive log dilutions, S 
= sum of the proportional mortalities (Karber 1931).
2.2.4.7 Adenovirus Neutralisation Assay
Complement in serum samples was inactivated by incubation at 56°C for 30 
minutes. 4-fold dilutions of the serum samples were made by adding 30 pi to 90 
pi of the appropriate medium (1:4 dilution). Growth medium containing 2 % 
serum (v/v) was used throughout. 25 pi of this dilution was added to each of 4 
wells of a 96 well plate, each containing 75 pi of growth medium (1:16 dilution). 
25 pi of each 1:16 dilution was diluted by adding it to 75 pi of gi'owth medium 
(1:64 dilution). This step was repeated 4 times to make 1:256, 1:1024, 1:4096 
and 1:16384 dilutions. 100 TCID50 units of the appropriate virus were added to 
each well in 50 pi of medium. Serum/virus mixtures were incubated at 37°C for 
1 hour, followed by further incubation at room temperature for 1 hour to allow
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virus antibody interactions to form. 50 pi of growth medium containing 1 x 10 
of the appropriate cells was added to each well. Plates were incubated at 37°C 
for 6 days. The plates were then read for cytopathic effect and neutralising 
antibody titres were determined using Table 2.2 as follows. The number of wells 
showing c.p.e. in the first dilution demonstrating c.p.e. determines the 
neutralising antibody titre of the appropriate sample. For example, a sample 
which had no cytotoxicity in the 1/16 and 1/64 dilutions and one well of c.p.e. in 
the 1/256 dilution would have a neutralising antibody titre of 362 (the 
appropriate cell on the table is highlighted in grey).
No. of wells
showing
c.p.e./dilution
1/16
dilution
column
1/64
dilution
column
1/256
dilution
column
1/1024
dilution
column
1/4096
dilution
column
1/16384
dilution
column
4 0 32 128 512 2048 8192
3 11 45 181 724 2896 11584
2 16 64 256 1024 4096 16384
1 23 91 362 1448 5792 23168
Table 2.2 Adenovirus Neutralisation Assay Table
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CHAPTER 3
Canine Adenovirus type I (CAV-1):
Potential as a Gene Therapy and Vaccine Vector in Heterologous Species
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3.1 INTRODUCTION
Immunological responses pose a challenge to the development of safe and 
efficacious adenovirus-based vaccine and gene therapy regimes. The existence 
of a pre-existing immune response is likely to reduce the efficiency of adenovirus 
based vectors in either therapeutic gene therapy or vaccination. This is a 
particular problem for the use of vectors based on ubiquitous serotypes HAd2 
and HAd5 in humans as a high proportion of the population have pre-existing 
immunity (see Chapter 5). In addition, development of immunity to administered 
Ad vectors can compromise efficacy of subsequent administrations of vector 
necessary for sustained transgene expression. Adenovirus vectors of less 
common human serotypes or from heterologous species are less likely to 
encounter pre-existing immune responses to either natural infections or previous 
vector administration and therefore offer an alternative to common HAds for 
vector development.. There is therefore a need to develop vectors from less 
prevalent adenovirus serotype, or from Ads of different host species. Before an 
adenovirus can be developed as a vector in a host other than its natural host it is 
necessary to investigate the life cycle of the wild type virus in the target cell type. 
This research has been earned out for a range of animal adenoviruses in human 
cells, as discussed below.
3.1.1 Animal Adenovirus Infection of Human Cells
Animal adenoviruses CAV-2, BAV-3 and PAV-3 are similar in size to HAds 2 
and 5, have similar genetic organisations (Campbell, 1996, Babiuk et al, 2002, 
Reddy et ai, 1998a) and the functions of many of their genes are comparable 
(see section 1.4.4). All of these viruses are capable of expressing their genes in 
human cells (Rasmussen et ai, 1999, Reddy et al, 1999).
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Infection of human A549 and HeLa cells by wild-type CAV-2 is semi-productive 
and viral proteins are expressed (Rasmussen et al, 1999). Rasmussen et al, 
detected an increase in viral particles and observed cytotoxicity during CAV-2 
infection of these cells. Although the infection was only semi-productive, in that 
limited numbers of infectious viius particles were produced, CAV-2 transduced 
91% of the HeLa cells. As with the common C group HAds, deletion of the E l 
region rendered this virus replication defective and such a first generation vector 
was efficient in the transduction of human cells to levels comparable with a 
HAd5 vector (Ki*emer et al, 2000). Soudais et al, also demonstrated that a GFP 
expressing CAV-2 vector was able to transduce neurons in human brain tissue 
biopsies (Soudais et al, 2001).
Wild-type BAV-3 infection of human cells was found to be abortive (Rasmussen 
et al, 1999). E la  and late gene expression were detected by RT-PCR, however 
no viral protein synthesis was evident and no cytotoxicity was observed in any of 
the 3 human cell-lines tested when infected at a m.o.i. of 10 p.f.u./cell. A BAV-3 
vector partially deleted in the E3 region was the first non-human adenovirus 
vector reported (Mittal et al, 1995). It was capable of expressing a firefly 
luciferase transgene in non-permissive human 293 cells as early as 12 hours after 
infection and for up to 6 days. The peak expression of the luciferase gene was 
only 10% less than in its native Madin Darby bovine kidney cells (MDBK). 
Rasmussen et a l, also demonstrated that an El-deleted BAV-3 was able to 
transduce 6 human cell-lines investigated and express a lacZ transgene 
(Rasmussen ef fl/., 1999).
A first generation replication defective PAV-3 vector (Ela and E3 deleted) was 
able to express a GFP transgene gene in human cells (Reddy et al, 1999).
MAV-1, CELO and OAV have lower homology to HAds 2 and 5 (Spindler, 
1990, Chiocca et al, 1996, Both, 1999) but these too are able to transduce human 
cells. MAV-1 infected human endothelial cells and gene expression from the E la 
region was detected by RT-PCR (Nguyen et al, 1999). Wild-type CELO was 
found to be replication defective in human cells, but was capable of expressing a 
GFP transgene in human hepatoma, lung epithelial and dermal fibroblast cells
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(Michou et al, 1999). Similarly, OAV infection of human cells is non­
productive, however, DNA replication, both early and late viral transcription and 
protein synthesis were demonstrated (Kiimin et al, 2002). A replication- 
competent OAV vector was also able to express transgenes in several human 
cell-lines (Kliatri et al, 1997).
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3,1.2 Adenovirus infection in domestic cats
Adenovirus infections are prevalent in humans and, before the development of an 
effective vaccine, were also widespread in dogs (see section 1.5.4). However, 
there have been few reports of adenoviral infection in the cat. In 1993 Kennedy 
and Mullaney reported disseminated adenovirus infection in the intestinal 
contents of a domestic cat that presented with a swollen liver and kidneys, and 
high volumes of fluid in the abdominal cavity. Election microscopy revealed the 
presence of ‘roughly icosahedral’ particles of approximately 65 nm in diameter, 
which formed crystalline arrays and this group concluded that this was an 
adenovirus. However no other biological techniques were used to confirm the 
identity of this virus. Another cat, which presented with transient liver failure, 
was seropositive for purified HAdl hexon antigen over 18 months (Lakatos et 
al, 1999). Pharyngeal and rectal swab samples were examined for adenoviral 
hexon sequences by PCR. The rectal sample was positive and pharyngeal 
sample was negative. 12 months later both rectal and pharyngeal samples were 
found to be positive. The PCR primers used were modified versions of those 
used for the general detection of HAds (Allard et al, 1990) that amplify a portion 
of the hexon region of most mammalian adenoviruses (Kiss et al, 1996). All 3 
PCR amplicons were sequenced, found to be identical, and to have 95% 
similarity to both the HAd2 and HAd5 hexon sequences. This indicates a 
persistent adenovirus infection which resulted in the shedding of virus from this 
animal, however, it us unclear what the source of this adenovirus was. This 
domestic cat was a single pet kept in isolation. The close homology to HAd 
sequences suggest that it may be possible that the adenovirus was originally 
acquired from an infected human and had mutated for survival in a heterologous 
host or that it was an alternative HAd serotype.
PCR of DNA from infected Hungarian cats, with primers for human adenovirus 
hexon, yielded bands at the expected size. After serial passages c.p.e. was 
observed in HeLa cells inoculated with rectal swabs taken from these cats 
(Ongi’âdi 1999). Immunofluorescent labelling of the isolated virus confirmed the
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presence of adenovirus hexons in the cytoplasm of infected cells. Icosahedral 
capsids of approximately 88nm in diameter were observed under eleetron 
microscopy, although these appeared to be fibreless.
Lakatos et al, investigated field serum samples obtained from 622 cats in 
Scotland, Hungary, the Netherlands and the USA (Lakatos et al, 2000). Overall, 
17.4% of these samples were seropositive for adenovirus when tested by indirect 
ELISA earned out with purified HAdl hexon antigens (see Table 3.1). 
Experiments were carried out using HAdl hexon antigens on the theoretical basis 
of the hexon containing a common determinant of immunity to adenoviruses. 
The lowest percentage was 9.8% in Scotland and the highest was 26% in the 
USA.
Site Number of samples Number and percentage (%) of 
positive samples
Hungary 294 43 (14.6)
Scotland 102 10(9.8)
The Netherlands 64 13 (20.3)
USA 162 42 (26.0)
Total 622 108 (17.4)
Table 3.1 Prevalence of anti-HAdl hexon antibodies in the serum of cats 
from Hungary, Scotland, The Netherlands and the USA (Lakatos et al, 
2000).
Whether these adenoviral infections are from a novel adenovirus of cats or have 
HAd origins is unknown as all of these results were carried out using detection 
methods for HAds. The infrequent isolation of adenoviruses from cats and the 
low seropositivity makes the use of adenoviruses as a vaccine vector in this
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species a possibility as there is less chance of pre-existing immunity preventing 
effective vaccination (see section 1.4.3.6 for an overview of vaccination using 
adenovirus vectors).
3,1.3 Objective
CAV-1 possesses many positive biological attributes with respect to vector 
development. These include its wide tropism (Koptopoulos & Cornwell, 1981), 
a large insert capacity (between 106 and 109%, compared with 105% of HAds) 
(Monison et al, 1997, Bett et al, 1993) and relative ease with which the viral 
gene can be manipulated (Monison et al, 2002).
With a view to developing CAV-1 as a gene therapy vector for humans and a 
vaccine vector for cats, it was important to investigate the lifecycle of CAV-1 in 
both human and feline cells in detail. CAV-1 infection of 2 human cell-lines, 
A549 and 293 (lung carcinoma and adenovirus transformed embryonic cells, 
respectively) and 2 feline cell-lines, CrFK and FEA, (kidney and fibroblast cells, 
respectively) was investigated by isolation of infectious virus, determination of 
levels of viral DNA, detection of tianscription of viral genes and expression of a 
transgene from a replication competent vector.
3.2 MATERIALS AND METHODS
3.2.1 D e Novo Production of CAV-1 in Human and Feline Cells
3.2.1.1 De Novo Production o f  CAV-1 in Human Cells
MDCK, A549 and 293 cells were subcultured at 5 x 10  ^ cells, in 5 ml of 
medium, per 25cm^ flask and incubated at 37°C overnight. Individual flasks 
were prepared for each time-point. The cells were infected the following day 
with CAV-1 at a m.o.i. of 10 p.f.u./cell in 2 ml of medium at 31°C  for 1 hour. 
The medium containing virus was removed and 1 ml aliquots were stored at -  
70°C. The cells were washed twice with PBS and 5 ml of fresh medium was 
added to each flask. This was considered the 0 hour time point. At each time 
point until, and including, 48 hours the medium was removed and 1 ml aliquots 
were retained. The cells were scraped into 1 ml of fresh medium and stored at - 
70°C. The flasks assigned for harvest on day 5 were subcultured into a 75cm^ 
flask on day 2 to maintain the cells at subconfluency. The culture medium was 
also transferred to this flask and supplemented with 10 ml of fresh medium. At 5 
days the medium was removed and 1 ml aliquots were retained, the cells were 
scraped into 2 ml fresh medium and 1 ml aliquots were stored.
Infectious virus was isolated and titred using the TCID50 method detailed in 
section 2.2.4.6.
3.2.1.2 De Novo Production o f CAV-1 in Feline Cells
MDCK, CrFK and FEA cells were subcultured and infected as described in 
section 3.2.2.1. At each time point up until, and including, 48 hours the medium 
was removed and the cells were scraped into 1 ml of fresh medium and stored at
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-70°C. The flasks assigned for harvest on day 5 were subcultured into a 75 cm^ 
flask on day 2 ; the suiTounding medium was also transfeired to this flask and 
supplemented with 10 ml of fresh medium. At day 5 the cells were scraped into 
2 ml of fresh medium and 1 ml aliquots were stored at -70°C.
Virus was isolated from cell samples and titred using the TCID50 method detailed 
in section 2.2.4.6 .
3.2.2 CAV-1 DNA Replication in Human and Feline Cells
3.2.2.1 DNA replication over a 14 day time course in human cells
infected with CAV-1 at a m.o.i. o f 1 0 p .fu ./ce ll
MDCK, A549 and 293 cells were subcultured at 2 x 10  ^ cells, in 2 ml of 
medium, per well of a six-well tissue culture plate. These were incubated at 
31°C  overnight. The following day each well was infected with CAV-1 at a 
m.o.i. of 10 p.f.u./cell in 0.5 ml of the appropriate medium and incubated at 37°C 
for 1 hour. The medium containing virus was then removed, the cells were 
washed twice with PBS and 2 ml of the appropriate medium was added to each 
well. This was taken as the 0 hour time point. For MDCK cells a separate 6 - 
well plate was used for each time point (0, 6 , 12, 24, 48, 72 and 96 hours), 
MDCK cells exhibited 100% c.p.e. by 48 hours. Separate 6 -well plates were 
used for each time point up until 4 days and 8  days for the A549 and 293 cells, 
respectively. By these time points the cells were confluent and 2 wells were 
pooled and subcultured into 75cm^ flasks with 15 ml of the appropriate medium 
for each triplicate. At subsequent time-points, 20% of the cell population was 
retained for DNA isolation with 20% of the remainder returned to the tissue- 
culture flask. This maintained the cell population at subconfluency. Cells in 6 - 
well plates were washed twice with PBS and trypsinised with 0.5 ml of trypsin, 2 
wells were pooled for each sample, at the appropriate time points. DNA was 
harvested using Centra’s Generation® capture column kit according to the
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manufacturer’s protocol (Flowgen) (section 2.1.1.3). TaqMan analysis was 
carried out on samples as described in section 2.2.2.4.
3 2 .2 2  DNA replication over a 4 day time course in human cells infected
with CAV-1 a t a m.o.i. o f  0.1 p.f.u./cell
MDCK, A549 and 293 cells were subcultured at 2 x 10  ^ cells, in 2 ml of 
medium, per well of a six-well tissue culture plate. These were incubated at 
37°C overnight. The following day each well was infected with CAV-1 at m.o.i. 
of 0.1 p.f.u./cell in 0.5 ml of the appropriate medium and incubated at 37°C for 1 
hour. The medium containing virus was then removed, the cells were washed 
twice with PBS and 2 ml of the appropriate medium was added to each well, this 
was considered to be the 0 hour time point. At each time point the cells were 
washed twice with PBS and trypsinised with 0.5 ml of trypsin. For each sample 
2 wells were pooled and DNA was harvested using Centra’s Génération® 
capture column kit according to the manufacturer’s protocol (Flowgen) (section 
2.1.1.3) and stored at -20°C. The time points were: 0, 6, 12, 24, 48, 72 and 96 
hours. TaqMan analysis was canied out as described in section 2.2.2.4.
3.2,2.3 DNA replication over a 15 day time course in feline cells
infected with CAV-1 at a m.o.i. o f  10 p .fu ./cell
CrFK and FEA cells were subcultured at 2 x 10^  cells, in 2 ml of medium, per 
well of a six-well tissue culture plate and incubated at 37°C overnight. The 
following day each well was infected with CAV-1 at a m.o.i. of 10 p.f.u./cell in 
0.5 ml of medium for 1 hour. The medium containing virus was then removed, 
the cells were washed twice with PBS and 2 ml of the appropriate medium was 
added to each well. This was taken as the 0 hour time point. By 72 hours the 
cells were confluent and cells from 2 wells were pooled and transfeixed to 75 cm^ 
tissue culture flasks. The cells of 75 cm^ flasks were transferred to 850 cm^ 
roller bottles at the 10 day time point. DNA was harvested from 2 pooled wells 
in triplicate at the following time points: 0, 8, 24, 48 and 72 hours and from the
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appropriate vessels at 4, 7, 10 and 15 days. Cells in 6-well plates were washed 
twice with PBS and trypsinised with 0.5 ml of trypsin. Cells in 75 cm^ flasks 
were washed twice with PBS and trypsinised with 1.5 ml of hypsin. Cells in 
roller bottles were washed twice with PBS and trypsinised with 20 ml of trypsin. 
DNA was harvested using Centra’s “Génération” DNA isolation kit according to 
the manufacturer’s protocol (section 2.1.1.3). TaqMan analysis was carried out 
on samples as described in section 2.2.2.4.
3.2.3 Transcription of CAV-1 DNA in Human and Feline Cells
MDCK, A549, 293, CrFK and FEA cells were subcultured at 5 x 10  ^ cells per 
25cm^ flask and incubated overnight at 37°C. Individual flasks were prepared 
for each time point. The following day the cells were infected with CAV-1 at a 
m.o.i. of 10 p.f.u./cell in 2 ml of medium and incubated at 37°C for 1 hour. The 
cells were washed twice with PBS and 5 ml of the appropriate medium was 
added to the flasks. Cells were harvested from flasks at the following time 
points: 0, 4, 8, 24, 48 and 72 hours (except for the MDCK cells which had shown 
100% c.p.e. by 48 hours and therefore no 72 hour time point was taken). RNA 
was harvested from cells Centra's Purescript® RNA isolation kit according to the 
manufacturer's protocol (section 2.1.1.3). RNA was DNase treated, reverse 
transcribed, and the resultant cDNA amplified in a single tube using the primers 
detailed in Table 3.2 and Promega's "Access" kit as described in section 2.2.2.3. 
Reverse transcriptase free PCR was earned out on the 48 hours samples to check 
for DNA contamination.
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Gene Represented Primers Amplicon Length 
(bp)
Ela 5' TGT GAG TAG TGG ATG GTG G 3' 
5' CCT GOT AAT AGO GAG AAG GG 3'
369
E4 - 34kDa homologue 5' TGG GGT GCT GTA TGG AG A TG 3' 
5’ GGA GGG TGG AAG ATT TAG AG 3’
450
Polymerase 5' AGO AGT GTT GGA AGA AGG AG 3' 
5' GAG ATA GTG TGT GGG AAG AG 3'
417
Fibre 5' TGG AAA TGG AGT GTG AGT GG 3' 
5' ATG AGG TGG AGT GGA TAG AG 3'
357
Table 3.2 Primers for RT-PCR of CAV-1 Ela, E4 34 kDa homologue, 
polymerase and fibre transcripts.
2jil of lOx loading buffer was added to 20pl aliquots of the RT-PCR reactions, 
which were analysed by electrophoresis of 2% (w/v) agarose TBE gels stained 
with 0.5jig/ ml ethidium bromide.
3.2.4 CAV-1 Maintenance in A549 Cells Over a 28 Day Time 
Course
A549 cells were subcultured at 1.5 x 10  ^ cells per 75cm^ flask and incubated 
overnight at 37°C. The following day the cells were infected with CAV-1 at a 
m.o.i. of 10 p.f.u./cell in 5 ml of medium for 1 hour at 37'^C, after which the 
medium containing virus was removed and 1 ml aliquots were retained. The 
cells were washed twice with PBS and 15 ml of the gi'owth medium was added to 
each flask. Cells were maintained at subconfluency for 28 days by routine 
subculture at 0 ,1 , 2, 4, 6, 8, 10, 12, 14, 17, 21, 24 and 28 days. At 0, 1, 2, 4, 6, 8, 
10, 12, 14, 21 and 28 days p.i. the culture medium was retained and 1 ml samples 
containing 1/6 of the cells were retained for isolation of cell-associated CAV-1, 
DNA and RNA.
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3.2.4.1 De Novo Production o f Infectious CAV-1 in A549 Cells
Cell-associated virus was isolated from cell samples by subjecting cell pellets to 
three freeze thaw cycles, then both these and the samples of medium were 
centrifuged at 14K in a benchtop centrifuge for 10 minutes to pellet the cell 
debris. The supernatant was removed and infectious virus was titred using the 
TCID50 method detailed in section 2.2.4.6.
3.2.4.2 CAV-1 DNA Replication in A549 Cells
DNA was isolated from the cells samples using Centra’s “Generation” DNA 
isolation kit according to the manufacturer's protocol (section 2.1.1.3). TaqMan 
analysis was carried out on the DNA samples, as described in section 2.2.2.4.
3.2.4.3 CAV-1 DNA Transcription inA549 Cells
RNA was isolated from the cell samples using Gentia's Purescript® RNA 
isolation kit according to manufacturer's protocol (section 2.1.1.3). RNA was 
DNase treated, reverse transcribed, and the resultant cDNA amplified in a single 
tube using the primers in Table 3.2 and Promega's "Access" kit as described in 
section 2.2.2.3. Reverse transcriptase free PCR was earned out on the 48 hours 
samples to check for DNA contamination.
3.2.5 Infection of Human and Feline Cells with a CAV-1 Vector
carrying a GFP Transgene
AE3-GFP-CAV-1 was constructed as follows. GFP driven by the CMV 
immediate early promoter was cloned as an Ase I and Mlu I fragment of pEGFP- 
C2 (Clonetech) into the Eco RY site of pSwapme (Monison et al, unpublished
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data). It was subsequently cloned as a Pme I fragment into the Pme I site of 
cosmid AE3CAV-1. The resultant cosmid was digested with Fse I to release the 
virus genome. Transfection into MDCK cells led to the recovery of infectious 
AE3-GFP-CAV-1 (Morrison et al, 2002, and unpublished data). MDCK, A549, 
293, CrFK and FEA cells were subcultured at 5 x 10^  cells, in 5 ml of medium in 
25 cm^ tissue culture flasks and incubated at 3TC  overnight. The following day 
the cells were infected at a m.o.i. of 0.1 or 10 p.f.u./cell with AE3-GFP-CAV-1. 
No manipulation of the cells or medium in these flasks took place at later time 
points. The cells were visualised at 8, 24, 48 and 120 hours using an Axiovert 25 
inverted microscope (Zeiss, Germany) and photographed using a Digital CCD 
Camera (Hamamatsu Photonics K.K., Japan) and Simple PCI Version 5 (Compic 
Inc., USA) software for the Apple Macintosh. At each time point the infected 
cells were compared with uninfected controls.
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33  RESULTS
In each of the experiments CAV-1 infected MDCK cells were used as positive 
conh'ols.
33.1 CAV-1 Replication in Human and Feline Cells
To investigate whether CAV-1 infection of human and feline cells resulted in de 
novo virus production, canine and human cell-lines were infected at a high m.o.i. 
with CAV-1 and investigated over a 5 day time course. Virus was isolated from 
the cells and also from the culture medium suiTounding the human cells. The 
virus titres were determined by the TCID50 method. Figures 3.1 and 3.2 show 
the total log TCID50 values at each time point.
3.3. L I  Productive CAV-1 Infection o f Human Cells
At 0 hours the cell-associated and extracellular levels of CAV-1 were similar in 
each cell-line (Figure 3.1).
The levels of cell-associated MDCK cells initially dropped (6  hour time point), 
however by 24 hours there was approximately 2 logs more CAV-1 than input and 
this increased by another 2 logs by 48 hours, at which point 100% c.p.e. was 
evident and MDCK harvests were discontinued. The amount of CAV-1 in the 
medium surrounding the MDCK cells had increased slightly by 6  hours and 
continued to do so. By 48 hours post infection there was over 3 logs more CAV- 
1 in the extracellular medium than there was at 0  hours.
Cell-associated CAV-1 in A549 cells also decreased at 6  hours, however, in 
contrast to CAV-1 infected MDCK cells, the levels had dropped even further by 
24 hours. Nevertheless, by 48 hours cell-associated CAV-1 had increased to 
levels higher than input in A549 cells and this increased further by 5 days post 
infection. At this point there was approximately 1 log more infectious CAV-1
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than at 0 hours. Although there was an initial increase in extracellular CAV-1 
at 6 hours post infection, the levels fell to below input at 24 hours. The levels 
then increased gradually and by 5 days p.i. the titre of extracellular virus was also 
approximately 1 log higher than at the beginning of the time course. This 
increase in extracellular virus in A549 cells indicates that new virus has been 
produced, however, this is over 1000-fold less than that produced in infected 
canine cells.
There was an overall decrease in the amount of both cell-associated and 
extracellular virus isolated from infected 293 cells over the 5 day time course. A 
slight increase in extracellular CAV-1 was detected 24 hours p.i., however, by 5 
days p.i. there were undetectable amounts of cell-associated virus and the amount 
of extracellular virus had decreased by 3 logs.
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Infectious CAV-1 Production in MDCK, A549 and 293 Cell-line
DC
Time (hours)
— - cell-associated MDCK- cell-associated A 549cell-associated 293
- - A- - - extracellular MDCK-  -  a -  -  -  extracellular A549- - O—  extracellular 293
Figure 3.1 Infectious CAV-1 production in human ccll-lincs. MDCK, A549 
and 293 cells were infected with CAV-1 at a m.o.i. of 10 p.f.u./cell. Cells and 
supernatant were harvested at 0, 1,2 and 5 day time points and virus titre was 
determined by TCID50.
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3.3.1.2 Productive CAV-1 Infection o f  Feline Cells
One-step growth curves were earned out with CAV-1 at a m.o.i. of 10 p.f.u./cell 
in MDCK and feline cells in order to investigate the production of de novo virus 
particles. Cell-associated virus was isolated and the titi'e was determined by the 
TCIDso method. Log TCID50 values are presented, indicating the total amount of 
virus at each time point (see Figure 3.2).
An overall increase in CAV-1 particles was observed in all three cell-lines. 48 
hours p.i. CAV-1 levels had increased more than 100-fold in MDCK cells, 10- 
fold in CrFK cells and 3-fold in FEA cells. By 5 days p.i. the overall increase in 
CAV-1 titre in CrFK cells was almost 500-fold greater than input. There was 
only a 35-fold increase in titre of CAV-1 in FEA cells over the 5 days of the time 
course. However, it should be noted that the starting titre in these cells was 
more than 5-fold less than for both MDCK and CrFK cells and that there was an 
initial 2-fold decrease in the titre of CAV-1 at 24 hours p.i. in this cell-line.
It should also be noted that the gi'owth curved of the MDCK cells is quite distinct 
from that of Figure 3.1 and of published results (Morrison et al., 2002). The 
reasons for this are unknown.
99
De novo Cell Associated infectious Viral Particles Isolated from 
CAV-1 Infected MDCK, CrFK and FEA Cells
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Figure 3.2 Infectious CAV-1 production in feline ccll-lincs. MDCK, CrFK 
and FEA cells were infected with CAV-1 at a m.o.i. of 10 p.f.u./cell. Cells were 
harvested at 0, 1 ,2  and 5 day time points and virus titre was determined by 
TCID50.
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3.3.2 CAV-1 DNA Replication in Human and Feline Cells
To determine whether viral DNA is replicated in infected human and feline cell- 
lines, TaqMan PCR was perfoiTned on DNA samples isolated from CAV-1 
infected cells at different times post infection. The amount of viral DNA was 
determined relative to the endogenous control, rDNA, and the E la  DNA values 
at each time point were established in relation to those at day 0. These values 
were plotted on logarithmic graphs.
5.5.2.7 Infection o f Human Cells with CAV-1 at High M.o.i, 14 Day Time
Course
All 3 cell-lines showed an initial decrease in CAV-1 DNA 6 hours post infection, 
which was more pronounced in the human cell-lines (see Figure 3.3). The 
amount of CAV-1 DNA detected in MDCK cells had increased by approximately 
1000-fold by 24 hours. The levels of CAV-1 DNA in human cells remained 
lower than input until 48 hours p.i. By 48 hours the amount of viral DNA had 
increased in A549 and 293 cells by 27-fold and 2-fold, respectively. By 14 days 
viral DNA levels detected in 293 cells fell to lower than that input initially, 
however, in A549 cells DNA was 6-fold higher than input.
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3.3.2.2 Infection o f Human Cells at Low M.o.i., 4 Day Time Course
To investigate whether the high virus to cell ratio increased the levels of viral 
DNA replication, infection of both cell-lines with CAV-1 was performed at a low 
m.o.i., 0.1 p.f.u./cell.
There was an initial decrease in CAV-1 DNA levels in each cell-line by 6 hours 
p.i. A gain in viral DNA was detected by 12 hours in the infected MDCK cells 
that continued throughout the time course to approximately 24000-fold by 4 days 
(Figure 3.4). The levels decreased further by 12 hours p.i. in the human cell- 
lines, however, by 24 and 48 hours p.i. there was a boost in CAV-1 DNA in the 
A549 ceils and 293 cells, respectively. The levels of DNA continued to rise in 
both cell-lines over the remainder of the time course with an overall increase of 
approximately 100-fold in the A549 cells and approximately 70-fold in the 293 
cells. This is considerably less than that of the MDCK cells, however it 
demonstiates that DNA replication does take place, even at low m.o.i.
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3.3.2.3 Infection o f  Feline Cells a t High M .o.i, 15 Day Time Course
There was an initial decrease of approximately 3-fold in the detected amount of 
CAV-1 DNA in both CrFK and FEA cells by 8 hours p.i. (Figure 3.5). However, 
24 hours p.i the amount of CAV-1 DNA had increased by 7- and 471-fold in 
FEA and CrFK cells, respectively, demonstiating that CAV-1 DNA replication 
takes place in both cell-lines. Between day 3 and day 10 the levels of CAV-1 
DNA in the CrFK cells were consistently more than 1000 fold higher than input 
(Figure 3.5). However, by day 15 a decrease of approximately 1 log was 
observed; at this point most of the CrFK cells were rounded and detached from 
the flask. The increase in CAV-1 DNA detected in FEA cells was slower, 
nevertheless, by day 10 the amount of E la  detected in the FEA cells had also 
increased by more than 1000-fold from input.
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3.3.3 CAV-1 DNA Transcription in Human and Feline Cells
Four genes were selected for analysis by RT-PCR based on the following rationale. 
Each of these genes is found in a different transcription unit, demonstrating 
b'anscription from the essential early regions, E l, E2, and E4, and the late region. The 
E la  gene should be the first to be transcribed and is intimately involved in 
transcription of other adenoviral genes. The 34 kDa ORE in HAd5 is an essential E4 
protein. The polymerase gene must be expressed if the viral DNA is replicating, and 
therefore acts as an internal control. The late region encodes structural proteins of 
which the fibre, penton and hexon are the major immunogens.
Figure 3.6 shows the transcripts obtained from MDCK, 293, A549, CrFK and FEA 
cells infected with CAV-1 at a m.o.i. of 10 p.f.u./cell over a 3 day period. Within 8 
hours, E la  and 34 kDa transcripts were detected in the infected MDCK cells, and by 
24 hours the polymerase and fibre transcripts were also evident. The presence of all 
four ti'anscripts was demonstiated at the 48 hour time point. Transcripts were not 
found in either of the human cell lines until the 24 hour time point, when all four 
could be detected. The four transcripts were present for the remainder of the time 
course in A549 cells but there were no transcripts detected by 72 hours in the 293 
cells. E la  and fibre transcripts were evident by 24 hours p.i. in samples isolated from 
infected CrFK cells and the samples taken 48 and 72 hour p.i. contained all 4 
transcripts. No transcripts were apparent until 48 hours p.i. in the FEA cell samples. 
At both this time point and 72 hours p.i. all 4 transcripts could be detected. In all 
cells the sample taken 48 hours p.i. was analysed for DNA contamination as this 
proved to be the time point when target was most abundant. These samples were 
negative indicating the absence of CAV-1 DNA in the RNA samples.
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Figure 3.6 RT-PCR of RNA isolated from CAV-1 infected (i) MDCK, (ii) 293, 
(iii) A549, (iv) CrFK and (v) FEA cells at 0, 4, 8, 24, 48, 72 hour time points. M = 
1Kb molecular weight marker, 1 = ela, 4 = E4 34 kDa homologue, P = DNA 
polymerase, F = fibre, -RTase = no RTase control for the 48 hours samples.
3.3.4 Maintenance of CAV-1 in Human Cells
A549 cells were infected with CAV-1 at a m.o.i. of 10 in order to investigate 
maintenance of CAV-1 over an extended time period. Samples were taken over a 28 
day period for determination of de novo virus production. DNA was harvested for 
TaqMan analysis and RNA was isolated and subjected to RT-PCR. Following an 
initial decrease in cell-associated and extracellular CAV-1 titres, 2 days p.i. cell- 
associated CAV-1 virus particles were detected at levels approximately 0.6 logs 
higher than input and by 4 days the amount of extracellular virus detected in the 
culture medium was also slightly higher than input level (Figure 3.7(i)). Thereafter, 
the amount of CAV-1 infectious virus particles decreased until, by 14 days, no cell- 
associated or extracellular CAV-1 could be detected. When compared with Figure 3.1, 
although both growth curves show a decrease in titres in both the cell-associated and 
extracellular samples, this is more pronounced in Figure 3.7(i). Nevertheless, cell- 
associated virus increased by approximately the same amount in both experiments. It 
is noteworthy that the experimental protocol in this section was canied out quite 
differently from previous experiments: cells were subcultured more frequently with 
cell culture medium being discarded and replaced with fresh medium.
TaqMan analysis revealed that CAV-1 levels increased to approximately 38-fold 
higher than input by 2 days, but declined throughout the remainder of the time course 
and by 14 days the amount of E la  DNA was 100-fold less than that at the beginning 
of the time course (Figure 3.7(ii)). In Figure 3.3, where less aggi'essive subculture 
took place, the maximum fold increase was approximately 100-fold and the levels of 
DNA were still higher than input 14 days p.i.
Transcripts were detected at 1 and 2 days but not at any other time point (Figure 3.8). 
In Figure 3.6 there were transcripts for all 4 CAV-1 genes detected 1, 2 and 3 days p.i. 
and, although only carried out for 3 days and not quantitative PCR, there is no 
evidence of the levels of ti'anscripts detected dropping at the 3 day time point. As 
mentioned above, the experimental conditions were quite distinct from those of Figure
3.6 where cells were untouched over the 3 days of the experiment.
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Figure 3.7 Maintenance of CAV-1 infection in A549 cells. A549 cells were 
infected with CAV-1 at a m.o.i. of 10 p.f.u./cell. Cell and supernatant samples 
were taken at 0, 1, 2, 4, 6 ,8 , 10, 12, 14,21 and 28 day time points, (i) Cell- 
associated and extracellular virus particles were isolated at the appropriate time 
points. TCIDso values are presented (n=2). (ii) DNA was isolated at the 
appropriate time points and subjected to TaqMan analysis as described in the 
text.
I l l
10 days 12 days
28 days -RTase21 days
Figure 3.8 RT-PCR of RNA isolated from CAV-1 infected A549 cells over a 
28 day time course. M = 1Kb molecular weight marker, 1 = Ela, 4 = E4 34 kDa 
homologue, P = DNA polymerase, F = fibre. Time points are shown below, 
-RTase = no RTase control for the 48 hour samples.
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3.3.5 Transgene Expression from a CAV-1 Vector in Human and Feline
Cells
MDCK, A549, 293, CrFK and FEA cells were infected with AE3-GFP-CAV-1 at a 
m.o.i. of 0.1 or 10 p.f.u./cell. Individual flasks were set up for each time point and no 
subculture took place. The cells were photogmphed at 8, 24, 48 and 120 hours post 
infection using light and fluorescent microscopy (see Figures 3.9 -  3.28), the same 
field was photographed for both light and fluorescent microscopy.
MDCK cells infected at a m.o.i. of 0.1 p.f.u./cell expressed the GFP transgene by 8 
hours p.i., albeit at a very low intensity and in only very few of the cells (Figure 3.9). 
Nevertheless by 24 hours p.i. (Figure 3.10), GFP was evident in a higher proportion of 
the cells and the intensity of fluorescence had clearly increased. These features had 
become even more pronounced by 48 hours p.i. (Figure 3.11). At this time almost all 
the cells displayed high intensity fluorescence, although under a light microscope 
there was no evidence of c.p.e.. Productive adenovirus infection is characterised by 
the formation of ‘gmpe-like’ clusters of rounded cells and by 120 hours p.i., c.p.e. had 
reached 100% and all cells showed high intensity fluorescence (Figure 3.12). By 8 
hours p.i. more than half the MDCK cells infected at a m.o.i. of 10 p.f.u./cell showed 
a degiee of fluorescence (Figure 3.9) and at 24 hours p.i. there was almost 100% 
c.p.e. (Figure 3.10) and all the cells present fluoresced intensely. 100% c.p.e. was 
evident by 48 hours p.i. (Figure 3.11).
By 8 hours p.i. there was no fluorescence observed in the 293 cells infected at a m.o.i. 
of 0.1 and those infected at a m.o.i. of 10 showed minimal fluorescence (Figure3.13). 
There was also no fluorescence evident in the A549 cells infected at a m.o.i. of 0.1, 
although a few of those infected at a m.o.i. of 10 showed very low levels of 
fluorescence (Figure3.17). The expression of GFP was similar throughout the time 
course in A549 and 293 cells at later time points. There was evidence of GFP 
expression observed in the either human cell-line infected at both a m.o.i. of 0.1 and 
10 by 24 hours p.i. (Figures 3.14 and 3.18), although this was sporadic and none of 
the fluorescing cells appeared to be excessively rounded. By 48 hours p.i. more 
human cells infected at a m.o.i. of 10 were fluorescing, and of these a proportion were
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rounded (Figures 3.15 and 3.19). However, human cells infected at a m.o.i. of 10 
showed less GFP expression at 120 hours than at 48 hours p.i. (Figures 3.16 and 
3.20). There was no change in fluorescence in the human cells infected at a m.o.i. of 
0.1 after the 24 hour time point.
GFP expression was evident 8 hours p.i. in CrFK cells infected at both 0.1 and 10 
m.o.i. (Figure 3.21). This expression was very scattered in those infected at a m.o.i. 
of 0.1 p.f.u./cell., however, at a m.o.i. of 10 p.f.u./cell, a substantial number of cells 
fluoresced weakly. By 24 hours p.i. there was fluorescence to a high intensity evident 
in the CrFK cells infected at a m.o.i. of 10 p.f.u./cell and most of these cells were 
significantly rounded (Figure 3.22). There was also rounding and GFP expression in 
CrFK cells infected at a m.o.i. of 0.1 p.f.u./cell at the 24 hour time point, however, the 
fluorescence was weaker and the rounding was less distinct and GFP expression was 
evident in a smaller proportion of the cells. From 48 hours p.i. onwards, the CrFK 
cells infected at a m.o.i. of 10 p.f.u./cell showed high levels of GFP expression and 
c.p.e. (Figure 3.23), however this c.p.e. had not reached completion by the end of the 
time course. 5 days p.i. CrFK cells infected at a m.o.i. of 0.1 p.f.u./cell showed no 
evidence of c.p.e. but more than 50% of the cells demonstrated expression of GFP 
(Figure 3.24).
There was no evidence of transgene expression in FEA cells infected at a m.o.i. of 0.1 
p.f.u./cell until 24 hours p.i. (Figure 3.26). At this time-point there were only very 
few cells fluorescing, however this fluorescence was intense. The number of GFP 
expressing cells increased slightly by 48 hours p.i. (Figure 3.27) and even more so by 
120 hours p.i. (Figure 3.28). The fluorescent cells were rounded, although classical 
adenoviral c.p.e. was not observed. However, infection of FEA cells at a m.o.i. of 10 
p.f.u./cell did result in a significant level of cell death. Although by 120 hours p.i. 
there was distinct rounding and clumping of many of the cells present there was also a 
proportion that of cells that did not demonstrate c.p.e..
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Figure 3.9 GFP expression in MDCK cells 8 hours post infection
MDCK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). 
The same cells were viewed with both a light microscope (A, C and E) and with a 
microscope fitted with fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
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Figure 3.10 GFP Expression in MDCK cells 24 hours post infection
MDCK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 24 hours p.i. (see section 3.2.5).
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Figure 3.11 GFP expression in MDCK cells 48 hours post infection
MDCK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 48 hours p.i. (see section 3.2.5).
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Figure 3.12 GFP expression in MDCK cells 5 days post infection
MDCK cells were either uninfected (A and B), infected at a moi o f 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). 
The same cells were viewed with both a light microscope (A, C and E) and with a 
microscope fitted with fluorescence (B, D and F) 120 hours p.i. (see section 3.2.5).
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Figure 3.13 GFP expression in 293 cells 8 hours post infection
293 cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV-1 
(C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells were 
viewed with both a light microscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
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Figure 3.14 GFP expression in 293 cells 24 hours post infection
293 cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV-1 
(C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells were 
viewed with both a light mieroscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 24 hours p.i. (sec section 3.2.5).
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Figure 3.15 GFP expression in 293 cells 48 hours post infection
293 cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV-1 
(C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells were 
viewed with both a light mieroscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 48 hours p.i. (see section 3.2.5).
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Figure 3.16 GFP expression in 293 ceils 5 days post infection
293 cells were either uninfeeted (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 120 hours p.i. (see section 3.2.5).
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Figure 3.17 GFP expression in A549 cells 8 hours post infection
A549 cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV- 
1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells 
were viewed with both a light microscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
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Figure 3.18 GFP expression in A549 cells 24 hours post infection
A549 cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 24 hours p.i. (sec section 3.2.5).
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Figure 3.19 GFP expression in A549 cells 48 hours post infection
A549 cells were either uninfected (A and B), infected at a moi o f 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 48 hours p.i. (sec section 3.2.5).
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Figure 3.20 GFP expression in A549 cells 5 days post infection
A549 cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV- 
1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells 
were viewed with both a light microscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 120 hours p.i. (see section 3.2.5).
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Figure 3.21 GFP expression in CrFK cells 8 hours post infection
CrFK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
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Figure 3.22 Transgene Expression in CrFK cells 24 hours post infection.
CrFK cells were either uninfected (A and B), infected at a moi o f 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 24 hours p.i. (see section 3.2.5).
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Figure 3.23 GFP Expression in CrFK cells 48 hours post infection
CrFK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). 
The same cells were viewed with both a light microscope (A, C and E) and with a 
microscope fitted with fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
129
BF -
D
Figure 3.24 GFP expression in CrFK cells 5 days post infection
CrFK cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 120 hours p.i. (see section 3.2.5).
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Figure 3.25 GFP expression in FEA cells 8 hours post infection
FEA cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 8 hours p.i. (see section 3.2.5).
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Figure 3.26 GFP expression in FEA cells 24 hours post infection
FEA cells were cither uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 24 hours p.i. (see section 3.2.5).
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Figure 3.27 GFP expression in FEA cells 48 hours post infection
FEA cells were either uninfected (A and B), infected at a moi of 0.1 with 
AE3GFPCAV-1 (C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and 
F). The same cells were viewed with both a light microscope (A, C and E) and with 
a microscope fitted with fluorescence (B, D and F) 48 hours p.i. (see section 3.2.5).
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Figure 3.28 GFP expression in FEA cells 5 days post infection
FEA cells were either uninfected (A and B), infected at a moi of 0.1 with AE3GFPCAV-1 
(C and D) or infected at a moi of 10 with AE3GFPCAV-1 (E and F). The same cells were 
viewed with both a light microscope (A, C and E) and with a microscope fitted with 
fluorescence (B, D and F) 120 hours p.i. (see section 3.2.5).
134
135
3.4 DISCUSSION
In 1969 Gehle and Smith reported that CAV-1 infection of human amnion cells 
resulted in ‘progressive disappearance of the virus, or in a low-level production of 
infectious particles which never exceeded the input’. On the basis of this information 
the current study investigated the potential of CAV-1 as a vector for gene delivery in t
humans. In addition, as there is a lack of a widespread adenovirus in domestic cats,
CAV-1 may also be a candidate for use as a vector in cats. In order to investigate its 
suitability as a vector, the wild-type life-cycle of CAV-1 was assessed in two cell- 
lines from each of the proposed host species.
I
A549 cells are derived from a human alveolar cell carcinoma (Lieber et al, 1976), 
whereas 293 cells are human kidney cells that were transformed with the HAd5 El 
region (Graham et al, 1977). Both of these cell-lines are commonly used for the 
propagation of HAds. CrFK cells are a feline kidney derived cell-line (Crandell et al,
1973) and FEA cells are feline embryonic fibroblast cells (JaiTet et al, 1973). When 
infected with wild-type CAV-1 neither human cell-line developed classical adenoviral 
induced c.p.e., however, the rounded morphology of a proportion of the cells did 
suggest a degree of cytotoxicity. Although 100% c.p.e. was not observed in either 
feline cell-line, CAV-1 infection of both cell-lines was cytotoxic and in CrFK cells 
was characteristic of adenoviral c.p.e..
One step gi'owth curves were canied out with each cell-line. In 293 cells CAV-1 
titres decreased over a 5 day time course and by 5 days there was no detectable 
infectious CAV-1 in the cell-associated samples. However, infection of A549, FEA 
and CrFK cells resulted in an overall increase in the yield of infectious CAV-1 over a 
5 day period compared to input level (Figures 3.1, 3.2 and 3.7(i)). Replication was 
delayed in onset in A549 and FEA cells and the amount of cell-associated CAV-1 
detected was approximately 1 and 1.5 logs above that at 0 hours, respectively. On the 
other hand, CAV-1 replication in CrFK cells did not appear to be delayed (Figure 3.5) 
and a significant increase in titie, almost 3 logs, was detected by 48 hours p.i..
The adenoviral life cycle consists of many different stages, which include attachment, 
entiy, uncoating, tianscription, replication, tianslation, assembly and release. If any 
of these steps are sub optimal then the subsequent infection of the target cells may be 
inhibited. CAV-1 infection of 293, A549 and FEA cells is clearly impeded at one or 
more of these stages and, although there was no apparent delay in CAV-1 replication 
in CrFK cells, the level of cytotoxicity observed in these cells was lower than in 
MDCK cells; full c.p.e. was not observed until after 14 days p.i.. It was therefore 
necessary to investigate different stages of the CAV-1 life-cycle in all these cell-lines.
Based on the number of virus particles recovered at 0 hours p.i., the ability of CAV-1 
to bind MDCK, human and CrFK cells appeared to be comparable as the amount of 
cell-associated CAV-1 was similar in each of the cell-lines (Figures 3.1 and 3.2). 
However, the reduced CAV-1 titre in FEA cells at 0 hours suggests that CAV-1 may 
not be as efficient at binding these cells (Figure 3.2). Following entry to the host cell, 
adenovirus particles are uncoated in order for replication and tianscription of the 
genome to take place. The infection of MDCK cells with CAV-1 showed a decrease 
in the amount of cell-associated infectious virus at 6 hours p.i. (Figure 3.1) although 
the amount of DNA detected at this time was similar to that detected at 0 hours p.i. 
(Figure 3.3), indicating viral uncoating. However, in both human cell-lines the 
decrease in cell-associated CAV-1 titie at 6 hours p.i. was less than that in MDCK 
cells. In contrast there was a large decrease (approximately 2-fold) in viral DNA 
levels in human cell-lines compared to MDCK cells (Figure 3.3). This suggests that in 
these human cells CAV-1 entiy and uncoating is poor relative to canine cells, and that 
proportionally more of the CAV-1 DNA associated with human cells at 6 hours p.i. is 
encapsidated and infectious, and most likely still bound at the cell-surface.
Transcription was demonstrated in all of the cell-lines investigated (Figure 3.6). 
However, the only cell-line that had evidence of CAV-1 transcription at 8 hours was 
MDCK cells. Transcripts were not detected until the 24 hour time point in 293, A549 
and CrFK cells and the 48 hour time point in FEA cells. In addition, transcripts were 
detected for a shorter interval in 293 cells and, although the RT-PCR cairied out was 
not quantitative, it appeared that the amount of transcripts in the FEA cells at 72 hours 
p.i. had dropped considerably. Tiemessen et al. also found that optimal transcription
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was delayed in human conjunctiva cells (Chang), which are semi-productively 
infected with HAd41, compared with productive infection of 293 cells (De Jong et al, 
1983, Tiemessen et al. 1996). The same research group found that Chang cells 
required multiple HAd41 infecting genomes per cell (calculated at 4.32) in order to 
establish a productive cellular infection, whereas permissive 293 cells only required 
on infectious particles per cell (Tiemessen & Kidd, 1990). Although DNA replication 
was evident in human cells infected at a m.o.i. of 0.1 p.f.u. per cell with CAV-1 
(Figure 3.4), it may be interesting to investigate transcription and CAV-1 replication 
in A549, FEA and CrFK cells at a low m.o.i. to determine whether these processes 
require multiple copies of CAV-1 per cell for productive infection. It may be that the 
high CAV-1 to cell ratio compensates for deficiencies in transcription, as Tiemessen 
et al., observed with HAd41 infection of Chang cells (Tiemessen & Kidd, 1990). 
Silverman and Klessig found that HAd2 infection of African green monkey cells (CV- 
1) was abortive at least in part because of the under expression of late proteins, 
including the fibre gene (Silverman & Klessig, 1989, Ross & Ziff, 1992). The level 
of fibre transcripts detected in CAV-1 infected 293 cells appears to be lower than in 
the other cell-lines examined, however, quantitative RT-PCR would be necessary to 
confirm this. A qualitative RT-PCR screen of a wider range of genes may indicate 
other proteins that are inefficiently transcribed.
In 293 cells CAV-1 entered cells, DNA replication took place and levels remained 
constant for 12 days (and were comparable to those found in A549 cells). However, 
there was a reduction in CAV-1 tide in both the cell and extracellular fraction 
following infection. This indicates that the block to infection occurs at a stage after 
DNA replication but prior to viral release. These findings bear a resemblance to the 
infection of hamster cells (BHK) transformed with the left terminal 19.7% of HAd5 
(BHK297-C131) with HAdl2. Although BHK cells are non-permissive to HAdl2, 
BHK297-C131 cells allowed HAdl2 DNA replication and late gene expression 
(Klimkait & Doerfler, 1985, Schiedner et al., 1994). However, as has been 
demonstrated in 293 cells, the infection of these cell-lines was not then productive, 
late mRNAs were not translated and virions were not assembled. There are evidently 
defects at other stages of the HAdl2 life cycle in these cells and this is most likely the 
case for CAV-1 infection of 293 cells. It would be of interest to investigate the 
infection of untransformed human kidney cells with CAV-1 to determine whether
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complementation of CAV-1 infection is confened by the HAd5 sequences found in 
293 cells, allowing DNA replication and transcription.
Infection of MDCK cells at m.o.i.s of 0.1 and 10 p.f.u./cell resulted in a 24000- and 
2600-fold increase in CAV-1 DNA, respectively, relative to input (Figures 3.4 and 
3.3). This is to be expected as at a m.o.i. of 0.1 p.f.u./cell only 10% of cells can be 
infected initially, however virus produced within these cells will spread to the 
remaining 90% of the population generating further virus. In contrast at a m.o.i. of 10 
p.f.u./cell, the majority of cells will be initially infected and in these cells only one 
round of viral replication will take place. In CAV-1 infection of canine cells at low 
m.o.i. newly released virus particles infect uninfected cells, starting a new cycle that 
is repeated until all cells in the culture are lysed. In infected A549 cells , no classical 
adenoviral c.p.e. is observed and infection at either a m.o.i. of 0.1 or 10 p.f.u./cell 
leads to similar fold increases relative to input DNA, namely 100- and 50-fold, 
respectively. Although some virus is released initially, infectious CAV-1 is 
eventually lost from cells and medium during the long term culture of infected A549 
cells (Figure 3.7(1)). There are a number of possible reasons for this. The virus 
particles produced in A549 cells could be defective for reinfection of A549 cells but 
allow infection of MDCK cells, although this would be sub-optimal. Alternatively, 
particles may be inefficiently released to the medium (as evidenced by a lack of 
c.p.e.) and this combined with repeated subculture might eventually dilute out both 
extracellular virus and cells infected with virus. As previously mentioned, there may 
also be a requirement for multiple CAV-1 genomes for productive CAV-1 infection in 
A549 cells. The passaging of CAV-1 on human amnion cells was previously shown 
to result in an almost 3-fold reduction in infectious virus yield with each passage, 
whereas in MDCK cells the yield was either the same or increased (Gehle & Smith, 
1969). The integiity of the CAV-1 particles produced during infection of A549 cells 
could be analysed by election microscopy and particle counts would allow a 
comparison between the number of defective and infectious viruses in these cells.
Subsequent to this work a CAV-1 vector cairying a GFP transgene in place of the E3 
gene became available. This permitted direct investigation of transgene expression in 
human cells. This research supported the previous findings with wild-type CAV-1; 
transgene expression from the CAV-1 vector was delayed in the human and FEA cells
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and present in a smaller proportion, compared to canine cells (see Figures 3.9 -  3.28). 
In addition, classical c.p.e. was not observed. However, in CrFK cells GFP 
expression was evident from 8 hours p.i. and a higher proportions of the cells by 5 
days p.i. and the c.p.e. observed was typical of productive adenovirus infection.
The results presented demonstrate that CAV-1 can infect cells of human origin and 
that there is moderate replication and transcription of the viral genome. In addition, 
CAV-1 expressed a transgene in both of the human cell-lines investigated. 
Consequently, CAV-1 would appear to be a worthwhile candidate for development as 
a human gene therapy vector. 293 and A549 cells are normally permissive for HAd 
infection, and as A549 are tumour cells with a respiratory system origin and 293 cells 
contain part of the HAd5 genome, it would be prudent to investigate the CAV-1 life­
cycle of other human cells that would perhaps be less likely to support CAV-1 
infection, including primary cell-lines. The availability of a AE3-GFP-CAV-1 will 
facilitate such screening. In addition, investigations with an E l deleted vector with a 
GFP transgene will establish whether the expression of transgenes occurs with a 
replication defective vector.
The investigation into CAV-1 infection of feline cells was less in depth, however it 
did demonstrate that CAV-1 infects feline cells, DNA replication and transcription 
occurs, and a productive infection is established. In addition, it appears that the lack 
of full c.p.e. may allow a persistent CAV-1 infection in feline cells, however, more in 
depth investigations would be necessary to confirm this hypothesis. Nevertheless, 
significant levels of transgene expression was demonstrated in both CrFK and FEA 
cells using a GFP expressing CAV-1 based vector. These features of CAV-1 suggest 
that it is a worthwhile candidate for development as a vaccine vector for use in cats. 
An extension of this work would be an investigation of administering wild-type CAV- 
1 infection in domestic cats. This would provide information on, not only the in vivo 
tropism of CAV-1, but also the immune responses elicited against it in cats.
Possible candidates for the vaccination of cats using CAV-1 based vectors are feline 
leukaemia virus (FeLV) and feline immunodeficiency virus (FIV). FeLV and FIV 
cause major diseases in cats and both are transmitted via mucosal epithelium; FIV is 
shed in the saliva and is mainly spread through bites, FeLV is contracted through
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bodily fluids. They are both members of the reti'Ovirus family: FeLV is a
gammareti'ovirus and FIV is of the genus lenitiviridae. Like HIV, both these viruses 
infect cells of the immune system causing immune suppression. There is no cure or 
treatment for either disease, and as such the development of vaccines that prevent 
infection are cunently underway. There is no commercially available vaccine for FIV 
in the United Kingdom (for a review of FIV and vaccines see Uhl et al, 2002), There 
are 4 different FeLV vaccines available in the United Kingdom, one is a recombinant 
peptide vaccine based on the FeLV envelope glycoprotein, another consists of 
inactivated whole virus, and the third is made up of inactivated subunits prepared 
from FeLV infected tissue culture filtrate (reviewed by Sparkes, 1997, Harbour et a l, 
2002. All three of these vaccines are adjuvanted, however, to date none of these have 
been 100% effective, with readministration commonly necessary (Harbour et al, 
2002). In addition, FeLV vaccines have been implicated in the formation of tumours 
at the site of injection (Kass et al, 1993). The most recent FeLV vaccine available is 
a canarypox virus vector which expresses the FeLV env and gag genes; canarypox is 
replication deficient in mammalian cells and expression of these FeLV genes was 
shown to provide good protection against FeLV when administered intranasally 
(Poulet et al, 2003). As many diseases are transmitted via mucosal epithelium, 
application of vaccines via the intranasal route is preferable with the aim of 
stimulating strong mucosal immunity and eliminating the requirement for adjuvants 
that might be involved in formation of injection site sarcomas. It would therefore be 
advisable to investigate the infection of, and transgene expression in, feline cells of 
the respiratory system, with a view to developing a CAV-1 vector that can be 
administered intranasally. If the expression of appropriate transgenes is successful in 
vitro, a vaccine trial with experimental domestic cats using a CAV-1 vector 
expressing immunogens for feline viruses could be caiaied out.
Finally, the tropism of CAV-1 for feline cells may indicate a potential application as a 
gene therapy vector in cats in therapeutic or cytotoxic regimes. This would entail 
development of replication incompetent CAV-1 vectors expressing OFF for 
transductional studies in a wide range of feline cells.
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CHAPTER 4
Fibre Swapping in Canine Adenovirus type 1
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4.1 INTRODUCTION
In recent years a vast amount of research has focused on the modification of 
adenoviral tropism in order to deliver vectors to specific tissues. Adenovirus tropism 
is somewhat promiscuous, with many tissues expressing the required receptors for 
viral entry and attachment. However, an obvious drawback of this broad tissue range 
is the non-specific delivery and expression of transgenes in non-target cells e.g. HAd5 
has a natural tropism for the liver, spleen and lungs (Nakamura et al., 2003). The 
infection of non-target cells leads to decreased bioavailability of the vector for the 
target tissue, necessitating administration of high titres of the vector. For example, in 
1999 an 18-year-old man who had been treated with a replication deficient adenovirus 
expressing an ornithine-b anscarbamylase (OTC) transgene died due to a serious 
immune reaction to the administered vector (Marshall, 1999). The liver was the target 
for the transgene, however, as other organs were transduced the vector dose had to be 
increased to 3.8 x lO'^ virus particles; only 1% of these reached hepatic cells. It was 
this massive dose of vector that stimulated the lethal immune response. An additional 
concern is that transgene expression at ectopic sites may cause toxicity (Mahasreshti 
et al., 2003.
By increasing tissue-specificity, lower doses of vector can be used, increasing the 
safety profile of the vector, as well as production costs and labour. Target tissues that 
express unique receptors are particularly good candidates for adenoviral targeting. 
For example, moieties found only on tumour cells can be specifically targeted by 
adenoviruses (see later).
Complete understanding of the natural tropism of a virus is necessary for the 
development of a targeted vector based on that virus. The primary deteiminant of 
adenoviral tropism is the fibre. The fibres of HAds 2 and 5 have been thoroughly 
researched and are well characterised. The fibre is associated with the secondary 
determinant of adenovirus tropism, the penton base. This in turn interacts with hexon 
proteins to form the viral capsid. These capsid components are the major adenovirus 
immunogens.
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4.1.1 Adenovirus Fibre and Penton; the Main Determinants of Tropism
The fibre is a tiimeric protein comprised of an N-terminal tail, a long shaft domain, 
and a knob domain at the C-terminiis. The shaft has a left-handed triple ^-helical 
structure with 3-fold symmetry (Stouten et al, 1992), made up of repeating sequence 
motifs of 15 amino acids (the number of which varies between serotypes) that each 
have two short beta-strands and two beta-bends (Green et al, 1983) oriented along the 
axis (van Raaij et al, 1999). A hydrogen bonding network exists within and between 
these monomers (van Raaij et a l, 1999) and as a result the fibre shaft is stable and 
rigid. However, a flexible region of 5 amino acids links the shaft and the knob 
domain and allows movement in the fibre that is proposed to be necessary for receptor 
binding (van Raajit et al, 1999). Trimérisation of the fibre requires the knob domain 
and a small C-terminal portion of the shaft domain of at least 15 amino acids in length 
(Hong & Engler, 1996). In culture, purified fibre knob domains of HAd2 were shown 
to cross-link into trimers (Louis et al, 1994). Only tiimerised fibres are able to bind 
receptors (Stevenson et a l, 1995) and mutations in the HAd5 fibre gene that ablate 
fibre bimer formation prevent virus infectivity (Santis et al, 1999).
Receptor binding occurs in the fibre knob domain (Stevenson et al, 1995). The knob 
domain consists of three monomers in a propeller-like structure (Henry et al, 1994). 
Each of these monomers is composed of two P-sheets that are linked by loops and 
turns; one P-sheet is involved in receptor recognition and the other is proposed to be 
involved in trimérisation (Xia et al, 1994). The trimérisation of these monomers leads 
to the formation of a central depression that was originally hypothesised to be 
involved in receptor binding (Xia et al, 1994). However, crystallisation of the 
HAdl2 fibre in complex with the N-terminal domain of human CAR revealed that 
CAR binds the fibre at the interface between adjacent knob monomers (Bewley et al, 
1999) and circular dichroism spectroscopy of HAd5 fibre mutants was used to show 
that the binding sites are positioned on the underside of the knob near the shaft 
domain (Kirby et al, 2000). The knob domain is also responsible for 
haemagglutination (Eiz et al, 1997, Eiz & Pring-Akerblom, 1997), the clumping
143
together of blood cells that occurs when adenovirus suspensions are added to blood. 
Haemagglutination inhibition tests are used to determine the presence of anti­
adenovirus antibodies and to divide the adenoviruses into serologically distinct 
subgi’oups; there are 6 subgioups of HAds: A to F (Rosen, 1960). As the knob 
domain is involved in both receptor and antibody recognition, it is not surprising that 
it is highly variable, for example, the knob domains of HAd31 (subgioup A) and 
HAd3 (subgioup B) have only 28.9% identity (Pring-Akerblom & Adrian, 1995). 
The fibre shaft also influences HAd tropism; in experiments where fibre shafts from 
different serotypes have been swapped the length of the shaft has been shown to be an 
important factor in determining tropism, independent of CAR and integrin binding 
(Shayakhmetov & Lieber, 2000, Koizumi et a l, 2003, Nakamura et al, 2003).
The N-terminal of fibre interacts with the penton base specifically and with high 
affinity, although this interaction is reversible for the disassembly of the virus during 
infection (Boudin & Boulanger, 1981). As its name suggests, the penton base is made 
up of 5 monomers and has 5-fold symmeby (Stewart et al, 1991). The penton has 
two main functions. As part of the capsid, the penton is important in the virion 
structure and it is also involved in the secondary binding of adenoviruses to cellular 
receptors. Following fibre binding to primary receptors, penton-receptor interactions 
mediate internalisation into host cells (Wickham et al, 1993).
Once adenoviruses have gained entry to host cells the fibre is put to further use. Hong 
& Engler found that the fibre gene houses a nuclear localisation signal (Hong & 
Engler, 1991). Purified HAd2 fibre proteins were found to accumulate in the nucleus 
of cells and deletion of 4 amino acids of the nuclear localisation signal from the HAd2 
fibre gene resulted in accumulation of mutant fibre proteins in the cytoplasm. Fusion 
of this nuclear localisation motif to a |3-galactosidase gene allowed expression in the 
nucleus. As a result the fibre is thought to play a role in the intracellular bafficking of 
adenoviruses (Miyazawa et al, 1999).
The penton also has other roles in adenovirus infection. Domains of HAd2 penton 
monomers have been identified that are involved in nuclear localisation (Karayan et 
al, 1997) and the rounding of adenovirus infected cells during c.p.e. has been 
attributed to the penton (Bai et a l, 1993).
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4.1.1.1 Adenovirus-Receptor Interactions
The primary receptor for all the HAds except those of subgroup B (Roelvink et al., 
1998) is CAR, which is bound by the fibre protein (Bergelson et ah, 1997). In 
addition, a number of animal adenoviruses have been shown to bind to CAR 
homologues (section 1.4.4). CARs are widespread in the tissues of most species and 
therefore CAR binding adenoviruses have a broad tissue tropism. Fechner et al, 
found high levels of variation between CAR levels in different tissues of mice, with 
the highest levels found in the liver (Fechner et al, 1999). This diversity of CAR 
expression has also been demonstrated in vitro in human cell-lines, with the levels of 
CAR expression differing between cell types from the same tissue source (Havenga et 
al, 2002).
It has been shown that the targeting of adenoviruses in vivo is not as predicted by in 
vitro results; tmnsgene expression was found to be broader than that predicted by 
tissue CAR expression (Fechner et al, 1999). As such the influence of other factors, 
whether cellular or viral, must be seriously considered in the development of gene 
therapy vectors.
The HAd5 fibre was shown to bind the MHC-I heavy chain by phage display library 
screening (Hong et al, 1997). MHC-I was therefore proposed to be a primary 
receptor for HAd5. However, when McDonald et al, investigated HAd5 infection of 
non-permissive cells that expressed MHC-I allele HLA-A2, no virus uptake was 
demonstrated. (McDonald et al, 1999). Davison et al, also showed that MHC-I 
allele HLA-A2 is not a high-affinity receptor for HAd5 in hamster cells (Davison et 
al, 1999).
Integiins are found on a high percentage of human tissues at comparable levels 
(Fechner et al, 1999). Normal extracellular proteins use these integiins for cell 
adhesion (reviewed by Ruoslahti 1996). The HAd2 and HAd5 pen tons were found to 
interact, via an ROD motif, with oty-integrins (Wickham et al, 1993), which allows 
internalisation of the virus via endocytic vacuoles. This penton RGD motif is 
conserved in many adenovirus serotypes (Mathias et al, 1994). Goldman & Wilson
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highlighted the importance of penton-integrin interactions by showing that, whereas 
undifferentiated airways epithelia express high levels of av-integrins, more mature 
epithelial cells do not express the av-integrins and as such are almost completely 
resistant to HAd transfer (Goldman & Wilson, 1995).
More recently heparan sulphate glycosaminoglycans have been highlighted as 
mediators of HAd2 and HAd5 binding (Dechecchi et al, 2000, Dechecchi et al,
2001). Binding by both of these viruses was blocked completely by preincubation 
with both heparin and soluble CAR, whereas only partial inhibition was observed 
when HAd2 and HAd5 were incubated with either heparin or soluble CAR 
(Dechecchi et al, 2001).
4.1.2 Modifying Adenovirus Tropism
Tropism modification strategies to date have included redirecting adenoviruses either 
by modifying adenovirus capsid components or by ablating natural tropism and 
redirecting vectors with additional molecules.
4.1.2.1 Retargeting using exogenous complexes
Fibre-receptor interactions have been prevented by using either anti-fibre antibodies 
or synthetic CAR receptors, or by coating adenovirus particles with polymers. These 
molecules are co-linked to either antibodies that recognise specific ligands or receptor 
binding ligands that redirect fibre binding. The retargeting of HAd based vectors in 
this way has been achieved by a number of research gi'oups.
Coating adenovirus vectors with polymers such as poly-[N-(2- 
hydroxypropyl)methacrylamide] (pHPMA) and polyethylene glycol (PEG) has been 
shown not only ablate nonnal viral tropism but also protect the vectors from immune 
responses (Fisher et a l, 2001, Croyle et al, 2001). The chemical incorporation of 
targeting ligands onto the surface of such polymer coated vectors allows specific 
binding of vectors to receptor bearing cells (Fisher et al, 2001).
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An anti-epidermal growth factor receptor (EGFR) antibody bound to a truncated 
version of the CAR receptor blocked normal HAd5 binding and redirected binding to 
EGFR overexpressing cancer cells in vitro (Dmitriev et al, 2000). Kashentseva et al, 
also ablated normal HAd5 tropism by fusing soluble CAR domains with proteins 
specific for oncoprotein c-erbB-2 (Kashentseva et al, 2002). These bispecific 
molecules bound to c-erbB-2 and enhanced gene transfer to tumour cell-lines by up 
to 17-fold compared with HAd alone.
Another group developed a bispecific antibody that consisted of an anti-fibre antibody 
fused to an anti-EpCAM antibody. EpCAM is expressed on tumours of various tissues 
to a much higher degi'ee than in normal tissues. Targeting by this method conferred 
specificity to cancer cell-lines and was independent of CAR expression (Haisma et 
al, 1999).
The use of polymer coated adenoviruses has gieat potential, as this not only allows 
retargeting of the vector to specific cells, but also masks it from the immune system. 
However, more in vivo work is required as clearance of such polymers in non-viral 
vectors by plasma proteins has been demonstrated (Dash et al, 1999). The use of 
bispecific molecules to target adenoviral tiopism and ablate normal receptor binding 
is more technically challenging, which increases both labour and costs. Where 
targeting molecule binding to vectors is incomplete, normal tissue distribution would 
be observed. As such it would be important that the ratio of adenovirus vectors to 
bispecific molecule was optimised prior to administration. Another important 
consideration is that the introduction of another component may evoke further 
immune responses and therefore clearance of the vector.
4.1.2.2 Retargeting via the insertion o f peptides into the HI loop o f the fibre
knob region
The fibre knob domain consists of two ^-sheets; the exposed receptor binding p-sheet 
consists of P-strands designated G, H, I and D, and the other P-sheet, which is 
involved in trimérisation, is composed of P-sbands J, C, B and A (Xia et al, 1994). 
These P-stiands only make up 35% of the monomer, the other 65% is made up of P-
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loops and turns. The 6 main loops are designated AB, CD, GH, HI and IJ. As 
discussed in the previous section, integiins are receptors found on many cell types and 
RGD motifs specifically attach to these integiins. Incorporating an RGD motif in the 
HI loop of a HAd5 vector targeted it to integiins on both CAR negative and CAR 
positive cells (Okada et a l, 2001). As such, the transfection efficiency with this 
vector was increased in dendritic cells, which did not express CAR, as well as CAR 
expressing colon and melanoma cells when compared with an equivalent untargeted 
HAd5 vector. Another HAd5 vector with an RGD motif inserted into the HI loop 
improved gene transfer to ovarian cancer cell-lines by up to 471-fold (Vanderkwaak 
et al, 1999).
Peptides for binding to specific cell-types can be identified by screening phage 
display libraries. For example, the SIGYPLP peptide was shown to bind endothelial 
cells (Nicklin et al, 2000). Inclusion of SIGYPLP in the HAd5 fibre improved the 
transduction of endothelial cells by 19-fold compared with other non-targeted HAd5 
vectors (Nicklin et al, 2001). The screening of phage display libraries was also used 
to isolate motifs with the ability to bind the human transferrin receptor (hTR), a 
receptor found on human brain microcapillary endothelium (Xia et al, 2000). 
Insertion of the isolated motif into the HI loop of the HAd5 knob domain resulted in 
between 2 and 34-fold increased gene transfer to hTR expressing cell-lines in vitro.
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4.1.2.3 Retargeting by fibre or fibre knob swapping between adenoviruses o f
different serotypes
Many groups have demons tinted the retargeting of adenoviruses by the swapping of 
fibre genes, or portions of them, with those of other adenoviruses. The infection 
profile of group B HAds is distinct from the other HAd groups and group B HAds 
recognise a receptor other than CAR (Bergelson et al, 1997, Roelvink et al, 1998). 
Chimaeric HAd5 vectors carrying subgroup B HAd (11, 35, 16 and 51) fibres 
transduced smooth muscle cells with a higher efficiency than HAd5 vectors (Havenga 
et al, 2001). In situ these chimeras transduced cultured blood vessels (coronary 
arteries) and the tmnsduction of endothelial cells with an Adl6 fibre carrying HAd5 
was much more effective than with the HAd5 based vector. Other HAd5-group B 
fibre chimeras were able to transduce CAR negative synoviocytes with up to 10-fold 
efficiency compared with an entirely HAd5 based vectors (Goossens et al, 2001). 
Dendritic cells are also CAR negative and retargeting of HAd5 with a group B fibre 
improved bansduction efficiency (Rea et al, 2001).
The exchange of fibre genes between HAds and an animal adenovirus has also been 
investigated. Unlike HAd5, OAV does not have an RGD motif in the penton and 
therefore does not bind to integiins (Vrati et al, 1996). Whereas OAV is unable to 
infect human 293 cells, a recombinant ovine adenovirus that housed a chimeric fibre 
incoiporating the CAR binding domain of the HAd5 fibre (Xu & Both, 1998) 
bansduced 293 cells.
4.1.2.4 Other attempts at retargeting
Other proteins found on the surface of adenovirus capsids may also be targets for the 
insertion of retargeting ligands. As a proof of principle, Dmitriev et a l, engineered 
HAd vectors with modifications to the plX protein, a minor stabilising capsid protein 
(Dmitriev et al, 2002). The modified pIX was linked at its C-terminal to a Flag 
epitope and heparan sulphate binding motif, consisting of a polylysine sequence. The 
modified proteins were incorporated into the capsid and heterologous sequences were
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displayed on the capsid surface. These viruses were able to bind to heparin-coated 
beads and recognise cellular heparan sulphate receptors. As such, this domain has 
potential for retargeting of adenoviruses if used in conjunction with other 
modifications.
Another capsid protein that could be modified for adenovirus retargeting is the 
penton. LDV peptide motifs recognise «4(31 integiins found on lymphocytes and 
monocytes; the replacement of the RGD motif of the HAd5 penton with the LDV 
motif redirected HAd5 binding to a4|3i integiin expressing cells (Wickham et al, 
1995).
By introducing an RGD motif into a protiuding loop of the HAd5 hexon peptide. 
Vigne et a l were able to create a recombinant vector that expressed a transgene in 
naturally refractory smooth muscle cells at a 10-fold lower concentiation than a vector 
unmodified in the hexon region (Vigne et a l 1999). In addition, 293 cells, which are 
highly permissive to wild-type HAd5, which were saturated with fibre knob domains, 
were also tiansduced by this vector and allowed tmnsgene expression.
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4.1.3 Objective
It has been demonstrated that CAV-1 can enter both feline and human cells (Chapter 
3). However, it has a wide tropism that could prove problematic for tissue-specific 
administration of CAV-1 based vectors and as such retargeting is required. This 
retargeting could be achieved by either ligand incorporation into capsid proteins or by 
blocking the native CAV-1 fibre binding region with bispecific molecules that 
recognise other cellular receptors. The development of such sti'ategies in HAds 2 and 
5 has taken many years and although technology has improved in this time, similar 
research in CAV-1 would be time consuming and labour intensive. An alternative to 
this would be to remove the CAV-1 fibre and replace it with other well characterised 
adenovirus fibres, or recombinant fibres, with known tissue affinities. A fibre 
swapping vector system was developed in order to investigate the possibility of such 
an approach. The fibre genes of CAV-2 and HAd5 were incoiporated into CAV-1 
and the tropism of the resultant vectors was investigated in a range of cell types.
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4.2 MATERIALS AND METHODS
4.2.1 Construction of shuttle plasmids
4.2.1.1 Construction of pCR2.1UD(-fib)
PCR amplification of Ufib and Dfib
The regions upstream and downstream of the CAV-1 fibre gene, Ufib and Dfib, 
respectively, were cloned from c l . l l l  CAV-1 DNA (Monison et al, 1997) using Tag 
PCR master mixes (section 2.2.2.2) at annealing temperatures of 55°C with the 
primers detailed below. The PCR products were analysed by agarose gel 
electi'ophoresis (section 2.2.1.5).
Primers for cloning Ufib and Dfib
Primers were designed, based on CAV-1 sequence determined by Morrison et al, in 
1997 (Table 4.1). In addition to CAV-1 sequence, Pme I restriction enzyme sites 
were added onto the 5’ ends of ufibpme and dfibpme. The U exon and fibre genes of 
CAV-1 are on opposite sb'ands and share a start codon. The insertion of a Pme I site 
between these two genes would have created another start codon 11 bases upstream of
the fibre start region, which would possibly have inhibited tianslation of the fibre
gene. Therefore, an extra thymidine nucleotide was incorporated between the Pme I 
site and the U exon sequence of ufibpme (see Figure 4.1).
Cloning of Ufib and Dfib
Ufib and Dfib were cloned into vector pCR2.1-TOPO® (section 2.1.1.4) (pCR2. lUfib 
and pCR2.1Dfib respectively) and transformed into One Shot® cells according to the 
manufacturer's instructions (section 2.1.2.1). The transformed cells were plated out 
on LB agar plates and incubated overnight at 31°C. The following day single and 
STET/lysosyme minipreparations of DNA were prepared (section 2.2.1.10).
Positive clones were screened for by digestion of pCR2.1Ufib were identified by 
digestion with Bam HI (section 2.2.1.2), which cuts the pCR2.1 vector backbone once 
and pCR2. lUfib once producing approximate fragments of either 250 bp and 4650 bp,
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CAV-1 region Primer
set
Primer sequence Tm(°C)
Product 
size ( bp)
Location on 
CAV-1
Region directly 
upstream of 
the fibre gene
ufib
ufibpme
5 ’ AGO GTT TAG GCG CTA ACT GG 
3 ’
5 ’ GTT TAA AC # ATG GCT TTG GTG 
TTG GTG A AC 3'
59.4
65.5
1052 24837-24856
25889-25857
Region directly 
downstream of 
the fibre gene
dfibpme
dfib
5 ’ GTT TAA ACA TAG AGT TTG CCC 
A AT G T A A A C G 3 ’
5 ’ ACA ACC TCC CAT GTG ACA GC 
3 ’
62.9
59.4
1031 27519-27541
28660-28531
Table 4.1 Primers for amplification of Ufib and Dfib. The thymidine residue 
introduced in the ufibpme primer sequence is highlighted in blue.
GTTCACCAACACCAAAGCCATAGTTTAAACAJGAAGCGGACACGAAGTGCTCT 
 ............U exon..............  > < Pme I > Met <............Fibre-------- -----------
Figure 4.1 Mapping of ufibpme primer
The ufibpme primer is highlighted in yellow, with the additional nucleotide highlighted 
in blue. Start codons of the U exon and Fibre gene are underlined.
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or 850 bp and 4050 bp depending on insert orientation. pCR2.1Dfib clones were 
screened for by Eco RI digestion (section 2.2.1.2), Eco RI cuts the pCR2.1 vector 
backbone twice on either side of the insert and cuts pCR2. IDfib once producing 
fragments of 300 bp, 700 bp and 3900 bp.
50 pi of bacterial culture from positive clones was used to inoculate 2.5 ml of L-broth 
in bijoux and QIAprep® minipreparations of DNA were prepared (section 2.2.1.10). 
The authenticity of Ufib and Dfib sequences were confirmed by LiCor (section
2.2.3.1) and ABI Prism (section 2.2.3.2) sequencing, respectively, using T7 forward 
and M l3 reverse primers (Table 4.2). Sequence data generated was analysed using 
the UW-GCG software package, homology between the nucleotide sequence and the 
CAV-1 genome was determined using the ‘Fasta’ progi'am.
Cloning Ufib and Dfib into one vector tpCR2.1UDt-fib))
The regions upsbeam and downstream of the CAV-1 fibre were linked by a Pme I 
site, as described below.
pCR2. lUfib was linearised by Pme I digestion and the DNA was purified using the 
QIAquick gel purification kit as follows. The agarose gel electrophoresis step was 
omitted and the DNA solution was diluted with 3 volumes of QG solution. The 
remainder of the purification was earned out according to the manufacturer’s 
instructions. DNA was eluted in 30ml of dH20. The linearised DNA was 
dephosphorylated (section 2.2.1.3) and then purified once again with the QIAquick 
gel purification kit as before. Fragment Dfib was isolated from pCR2. IDfib by 
digestion with Pme I and Eco RV, visualised by agarose gel electrophoresis (section
2.2.1.5) and gel purified (section 2.2.1.6). A ligation reaction was performed between 
linearised pCR2. lUfib and fragment Dfib (section 2.2.1.7). 5 pi of the ligation was 
tiansformed into Max Efficiency STBL2 cells according to the manufacturer's 
protocol. Transfoimed STBL2 cells were plated out on LB agar plates and incubated 
at 37°C overnight. The following day single colonies were selected and 
STET/lysosyme minipreparations of DNA were prepared (section 2.2.1.10). Positive
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Target
Sequence
Primer Primer sequence Tm
(°C)
Location on Target 
Sequence
CAV-1 
(upstream of 
UE3)
E3deliip 5’ GOO ATG A AT TGG TCA GGA A AG G 3 ’ 62 24689-24710
CAV-1
(within
fibre)
26396 5' CTT TAG GCC GAG CTT TC 3* 52.8 26380-26396
CAV-1
(within
fibre)
26643 5' GA AAT GCA GTG TCA GTG CG 3' 57.3 26643-26662
CAV-1
(within
fibre)
26738 5’ TGG ATA GGC GAA GOT CAA 3' 53.7 26721-26738
CAV-1
(within
fibre)
27001 5' CAA ACG TTA ACA CCT C 3' 46.6 27001-27015
CAV-1
(within
Ufib)
Fib I 5' GTG TCT CTA TGT CCA CAA GG 3' 57.3 25750-25770
CAV-1
(within
Dfib)
Fib2 5' GTA GCA TTA CAG CTC GAG TG 3’ 57.3 27600-27620
CAV-2
(within
fibre)
27181 5’ ACG AAC AGT TGC AAG CTG TCC 3' 59.8 27181-27201
CAV-2
(within
fibre)
27287 5' GTT GCC ACC AAA GCT CCG CTC 3’ 63.7 27287-27307
HAd5
(within
fibre)
31587 5' TAC TGC CAC TGG TAG CTT G 3' 62 31587-31605
HAd5
(within
fibre)
31731 5' AAT AGT CAC ACC TGG ACC AG 3’ 60 31712-31731
HAd5
(within
fibre)
32197 5' ACA GOT GCC ATT ACA GTA GG 3' 60 32197-32216
HAd5
(within
fibre)
32302 5' GTT TAG CAT CTT TCT CTG C 3' 54 32284-32302
pCR2.1-
TOPO
M13
reverse
5’ CAG GAA ACA GCT ATG AC 3' 50 pCR2.1-TOPO
pCR2.1-
TOPO
T7
forward
5’ TAA TAC GAC TCA CTA TAG GG 3’ 56 pCR2.1-TOPO
Table 4.2 Sequencing and PCR Primers
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pCR2.1UD(“fib) clones were confirmed by Eco RI digestion (section 2.2.1.2). In the 
correct orientation Eco RI digest of pCR2. lUD(-fib) produces fragments of DNA of 
approximate sizes 300 bp, 1700 bp and 3900 bp. 50 pi of bacterial culture from 
positive clones was used to inoculate 2.5 ml of L-broth and QIAprep® 
minipreparations were carried out (section 2,2.1.10).
4.2.1.2 Construction of pCR2.1UDCm^
pCR2.1UD(-fib) was linearised by digestion with Pme I (section 2.2.1.2) and purified 
using the QIAquick™ gel extraction kit (section 4,2.1.1). The linearised DNA was 
phosphorylated (section 2.2.1.3), followed by purification with the QIAquick™ gel 
extiaction kit (section 4.2.1.1). The chloramphenicol resistance cassette (Cm^) was 
excised from vector pSwapmeCm^ (constructed by Dr M.D. Morrison) by Pme I 
restriction enzyme digestion (section 2.2.1.2) and the appropriate fragment 
(approximately 1700 bp) was isolated by gel purification (section 2,2.1.6). A ligation 
reaction was carried out with linearised pCR2.1UD(-fib) vector and the Cm^ fragment 
(section 2.2.1.7). 5 pi of the ligation was transformed into Max Efficiency STBL2 
cells (section 2,2,1.9). Transformed STBL2 cells were plated out on LB agar plates 
containing 100 pg/ml chloramphenicol and incubated at 37°C overnight. The 
following day single colonies were selected and inoculated into 2.5ml of L-broth 
containing 100 pg/ml chloramphenicol and STET/lysosyme minipreparations of DNA 
were prepared (section 2.2.1.10). Positive pCR2.1UDCm^ clones were selected for 
by Pme I digestion, which produces fragments of approximate sizes 1700 bp and 5900 
bp. 50 pi of bacterial culture from positive clones was used to inoculate 2.5 ml of L- 
broth containing 100 pg/ml chloramphenicol and QIAprep® minipreparations were 
earned out (section 2.2.1.10).
4.2.1.3 Construction of pCR2.1UDfibCAV-l, pCR2.1VDfibCAV-2 and 
pCR2.1UdfibHAd5
PCR amplification of Adenovirus Fibre Genes
Fibre genes were amplified from CAV-1, CAV-2 and HAd5 using Taq PCR as 
described in section 2.2.2.2. The appropriate primers are detailed in Table 4.3. These 
corresponded to the 5’ and 3’ ends of the appropriate fibre gene and included Pme I
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Virus Primer Primer Sequence Tm
(°C)
Fibre location on 
virus
Product size (bp)
CAV-1 CAV-1 Fib5 
CAV-1 Fib3
5' GTT TAA ACC GCC ATG AAG CGG 
ACA CGA AGT GC 3'
5' GTT TAA ACT CAT TGA TTT TCC 
CCC ACA TAG 3’
70
64
25889-27520 1643
CAV-2 CAV-2 Fib5 
CAV-2 Fib3
5' GTT TAA ACC GCC ATG AAG CGG 
ACA CGA AGA GCT CTA 3'
5' GTT TAA ACT TAT TGA TTT TCG 
CCT ACA TAG G 3'
72
61
26592-28220 1640
HAd5 HAd5 Fib5 
HAd5 Flb3
5' GTT TAA ACC GCC ATG AAG CGC 
GCA AGA CCG TCT GAA GAT AC 3'
5' GTT TAA ACT TAT TCT TGG GCA 
ATG TAT G 3’
74
59
31042-28220 1757
Table 4.3 Primers for the amplification of CAV-1, CAV-2 and HAd5 fibre genes.
sites at either end. Four extra nucleotides (CGCC) were included between the 5' Pme 
I site and start codon to create a consensus Kozak sequence (CC(A/G)CCATGG) 
(Kozak 1986) (Figure 4.2). The PCR products were visualised by agarose gel 
electi'ophoresis (section 2.2.1.5).
CAV-1 Fib 5 5'-GTTTAAACCGCCATGAAGCGGACACGAAGTGC-3’
CAV-2 Fits 5'-GTTTAAACCGCCATGAAGCGGACACGAAGAGCTCTAC-3’
HAd5 Fib5 5'-GTTTAAACCGCCATGAAGCGCGCAAGACCGTCTGAAGATAC-3'
< Pme I > Met < -------------------- fibre DNA--------------------->
< KOZAK >
Figure 4.2 Fibre 5' primers
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Cloning of Adenovirus Fibre Genes into pCR2.1-TOPO®
PCR amplified CAV-1, CAV-2 and Had5 fibre genes were cloned into vector 
pCR2.1-TOPO® (pCR2.1FibCAV-l, pCR2. lFibCAV-2 and pCR2. lFibHAd5) and 
transformed into One Shot® cells (section 2.2.T9). The transformed cells were plated 
out on LB agar plates and incubated overnight at 37°C. The following day single 
colonies were selected and STET/lysosyme minipreparations were prepared (section
2.2.1.10). Positive clones were screened for by digestion with restriction enzyme Pme
I (section 2.2.1.2), which releases each of the fibre genes from the pCR2.1-TOPO® 
backbone producing fragments of approximately 3900 base pairs (pCR2.1) and 1600 
(CAV-1 and CAV-2) or 1700 (HAd5) base pairs. 50 pi of bacterial culture from 
positive clones was inoculated into 2.5 ml of L-broth and DNA was prepared by 
QIAprep® minipreparation (section 2.2.1.10). The authenticity of the fibre sequences 
was confirmed by ABI sequencing (section 2.2.3.2) using T7 forward and M13 
reverse primers and the appropriate internal primers. Internal primers for were 26396, 
26643, 26738 and 27001 for pCR2.IFibCAV-l, 27181 and 27287 for 
pCR2.1FibCAV-l, and 31587, 31731, 32197 and 32302 for pCR2.1FibHad5 (see 
Table 4.2). Sequence data generated was analysed using the UW-GCG software 
package, homology between the nucleotide sequence and the appropriate adenovirus 
genome was determined using the ‘Fasta’ program.
Insertion of adenovirus fibre genes into pCR2.1UD(-fib)
pCR2.IUD(-fib) was linearised with Pme I, phosphatased and purified as described in 
section 4.2.1.2. Fibre genes were excised from the appropriate vector, pCR2.1CAV- 
Ifib, pCR2.1CAV-2fib or pCR2.1HAd5fib, by Pme I restriction enzyme digestion 
(section 2.2.1.2) and the appropriate fibre fragments were isolated and purified by gel 
extraction (section 2.2.1.6). Ligation reactions were performed with linearised 
pCR2.1UD(-fib) vector and fibre fragments (section 2.2.1.7). 5 pi of the ligation was 
transformed into Max Efficiency STBL2 cells (section 2.2.1.9). Transformed STBL2 
cells were plated out on LB agar plates and incubated at 37°C overnight. The 
following day single colonies were selected and STET/lysosyme minipreparations 
were performed (section 2.2.1.10). Positive clones were selected for by digestion with 
the appropriate enzymes (section 2.2.1.2). Digestion of pCR2.1 UDFibCAV-1 with Afl
II yields bands of approximate size 1200 and 6800 bp in the correct orientation.
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Digestion of pCR2.1UDFibCAV-2 with Sal I yields bands of approximate size 600 
and 7100 bp in the coiTect orientation. Digestion of pCR2. lUDFibHAdS with Hpa I 
yields bands of approximate size 900 and 6700 bp in the conect orientation. 50 pi of 
bacterial culture from positive clones was used to inoculate 2.5 ml of L-broth and 
QIAprep® minipreparations were canied out (section 2.2.1.10).
4.2,1.4 Construction ofpCR2.1 UE3Dfib
pCR2. IDfib was linearised by digestion with Pme I and purified using the QIAquick 
gel extraction kit (section 4.2.1.1). Linearised pCR2. IDfib was then phosphatased 
(section 2.2.1.3), followed by purification with the QIAquick gel extiaction kit 
(section 4.2.1.1). Fragment UE3 was isolated from plasmid KXCm^ (Monison et al,
2002) by digestion with Kpnl and Pme I restriction enzymes (section 2.2.1.2). The 
Kpnl overhangs were blunted as described in section 2.2.1.4 and the appropriate 
fragment was isolated by gel extraction (section 2.2.1.6). Linearised pCR2. IDfib 
vector DNA and UE3 fragments were ligated together according to section 2.2.1.7. 
5 pi of the ligation was transformed into Max Efficiency STBL2 cells. Transformed 
STBL2 cells were plated out on LB agar and incubated at 37°C overnight. The 
following day single colonies were selected and STET/lysosyme minipreparations 
were performed (section 2.2.1.10). Digestion with Hpa I was performed to select for 
positive clones (section 2.2.1.2), Hpa I digestion of pCR2.1UE3Dfib yields bands of 
approximately 1300 and 4900 base pairs.. 50 pi of bacterial culture from positive 
clones was used to inoculate 2.5 ml of L-broth and QIAprep® minipreparations were 
carried out (section 2.2.1.10).
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4.2.2 Construction of Cosmids Containing Recombinant CAV-1
Genomes
4.2.2.1 Construction o f cosmid cAFibCAV-1 Cm^
A cosmid that contained the CAV-1 genome with the fibre gene deleted and replaced 
by a chloramphenicol resistance cassette (Cm^), flanked by Pme I restriction enzyme 
sites (Figure 4.3), was generated as follows.
Fragment UD(-fib)Cm’^  (section 4.2.1.2) was excised from pCR2.1UD(-fib)Cm^ by 
Pst I and Spe I restriction enzyme digestion (section 2.2.1.2). Pst I and Spe I 
digestion of pCR2.1UD(-fib)Cm^ yields bands of approximately 1200, 2700 and 3700 
base pairs. The 3700 bp fragment was isolated by gel extraction (section 2.2.1.6). 
Electrocompetent BJ5183 cells were cotransformed with cosmid FLR-CAV DNA and 
UD(-fib)Cm^ by electroporation (section 2.2.1.9). Electioporated cells were plated 
out on L broth plates containing 100 pg/ml choramphenicol and incubated at 37°C 
overnight. The following day individual colonies were selected and suspended in 2.5 
ml of L broth containing 100 pg/ml choramphenicol. STET/lysosyme 
minipreparations were performed (section 2.2.1.10). Positive clones were selected for 
by Hpa I restriction enzyme digestion (section 2.2.1.2). As BJ5183 cells are unstable 
for the maintenance of cosmid DNA, DNA from positive clones was transformed into 
Max Efficiency STBL2 cells (section 2.2.1.9). Transformed STBL2 cells were plated 
out on LB agar plates containing 100 pg/ml chloramphenicol and incubated at 37°C 
overnight. The following day single colonies were selected and inoculated into 2.5 ml 
of L broth containing 100 pg/ml chloramphenicol. Cosmid DNA was prepared from 
the bacterial cultures by the STET/lysosyme minipreparation method (section
2.2.1.10). Positive clones were selected for by restriction enzyme digestion with Hpa 
I (section 2.2.1.2). 1 ml of a fresh overnight culture from a positive clone was used to 
inoculate 400 ml of L broth containing 100 pg/ml chloramphenicol and DNA was 
prepared using the using Qiagen plasmid Mega Kit (section 2.2,1,11) following the 
instructions of the manufacturer. Glycerol stocks of the final construct were prepared 
and stored at -70°C (section 2.2.1.12).
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CosmidBackbone E3/U Exon
( 2 4 9 7 7 - 2 5 8 8 8
Wild Type CAV-1
CAV-1 Fibre 3 0 5 3 6  
( 2 5 8 8 9 - 2 7 5 2 0 )
Pmel
( 2 5 8 9 3 )
2 8 9 0 2
AFibCAV-1
Pme I Pmel
( 2 5 8 9 3 ) ( 2 7 5 3 6
CAV-1 Fibre 3 0 5 5 7  
( 2 5 9 0 1 - 2 7 5 3 2 )cPFibCAV-1
Pmel Pmel
( 2 5 8 9 3 ) ( 2 7 5 3 6 )
CAV-2 Fibre 3 0 5 5 4  
( 2 5 9 0 1 - 2 7 5 2 9 )
cPFib(C2)CAV-1
Pmel
( 2 5 8 9 3 )
Pmel
( 2 7 6 5 0 )
HAd5 Fibre 3 0 6 7 1  
( 2 5 9 0 1 - 2 7 6 4 6 )
cPFib(H5)CAV-1
Pmel
( 2 4 9 8 0 )
2 8 0 0 2
AE3AFibCAV-l
Figure 4.3 Maps of CAV-1 recombinant cosmid constructs
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4.2.2,2 Construction of cosmid cAFibCA V-1
A cosmid that had the fibre gene replaced by a unique Pme I restiiction enzyme site 
(Figure 4.3) was generated as follows.
Cosmid cAFibCAV-lCm^ was digested with Pme I (section 2.2.1.2) to remove the 
chloramphenicol resistance gene and purified using alcohol precipitation as follows. 
DNA in solution was precipitated by the addition of 0.1 volumes of 5 mM sodium 
chloride and 2 volumes of 100% ethanol, and incubation at -20°C for 30 minutes. The 
DNA was then pelleted by centrifugation at 14K for 15 minutes in a microcentrifuge. 
The surrounding liquid was removed and the DNA was air dried, then resuspended in 
20 pi of dH20. A ligation reaction was carried out on the purified DNA (section 
2.2.1.7). Elecbocompetent BJ5183 cells were cotransformed with cosmid AFibCAV- 
ICm^ DNA and fragment UD(-fib) as described in section 2.2.1.9. Electroporated 
cells were plated out on L broth plates and incubated at 37°C overnight. The 
following day individual colonies were selected and STET/lysosyme minipreparations 
were performed (section 2.2.1.10). Positive clones were selected for by Hpa I 
restriction enzyme digestion (section 2.2.1.2).
DNA from positive clones was transfonned into Max Efficiency STBL2 cells. 
Transformed STBL2 cells were plated out on LB agar plates and incubated at 37°C 
overnight. The following day single colonies were selected and used to inoculate 2.5 
ml of L broth. Cosmid DNA was prepared from the bacterial cultures by the 
STET/lysosyme minipreparation method (section 2.2.1.10) and digested with Hpa I 
(section 2.2.1.2) to check for positive clones. 1 ml of a fresh overnight culture from a 
positive clone was used to inoculate 400 ml of L broth containing 100 pg/ml 
chloramphenicol and DNA was prepared using the using Qiagen plasmid Mega Kit 
(section 2.2.1.11) following the instructions of the manufacturer. Glycerol stocks of 
the final constiuct were prepared and stored at -70°C (section 2.2.1.12).
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4.2.23 Construction of Cosmids cPFibCAV-1, cPFib(C2)CAV-l and
cPFib(H5)CAV-l)
The cotransformation of linearised FibCAV-1 with fibre recombinant shuttle vectors 
was used to generate cosmids containing fibre recombinant CAV-1 genomes (Figure 
4.3) as follows.
Cosmid AFibCAV-1 was linearised by digestion with Pme I (section 2.2.1.2) and 
purified by alcohol precipitation follows. DNA in solution was precipitated by the 
addition of 0.1 volumes of 5 mM sodium chloride and 2 volumes of 100% ethanol, 
and incubation at -20°C for 30 minutes. The DNA was then pelleted by centrifugation 
at 14K for 15 minutes in a microcentrifuge. The surrounding liquid was removed and 
the DNA was air dried, then resuspended in 20 pi of dH20. Fragments UDfibCAV-1, 
UDfibCAV-2 and UDfibHAd5 were excised from pCR2. lUDfibCAV-1, 
pCR2. lUDfibCAV-2 and pCR2.1UdfibHAd5 by Pst I and Spe I restriction enzyme 
digestion (section 2.2.1.2). Pst I and Spe I digestion of both pCR2.1 UDfibCAV-1 and 
pCR2.lUDfibCAV-2 yields bands of approximately 1200, 2700 and 3600 base pairs. 
Pst I and Spe I digestion of pCR2.1UdfibHAd5 yields bands of approximately 1200, 
2700 and 3800 base pairs. The 3600 and 3800 fragments were isolated from 
UDfibCA V-1 and UDfibCAV-2, and UDfibHAdS, respectively, by gel extraction 
(section 2.2.1.6). Electrocompetent BJ5183 cells were cotransformed with linearised 
cosmid AFibCAV-lCm^ DNA and either UDfibCA V-1, UDfibCAV-2 or UdfibHAd5 
fragments by electioporation, as described in section 2.2.1.9. Electroporated cells 
were plated out on L broth plates and incubated at 31°C overnight. The following day 
individual colonies were selected and STET/lysosyme minipreparations were 
performed (section 2.2.1.10). Positive clones were selected for by Hpa I restriction 
enzyme digestion (section 2.2.1.2).
DNA from positive clones was transformed into Max Efficiency STBL2 cells. 
Transformed STBL2 cells were plated out on LB agar plates and incubated at 37°C
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overnight. The following day single colonies were selected and used to inoculate 2.5 
ml of L broth. Cosmid DNA was prepared from the bacterial cultures by the 
STET/lysosyme minipreparation method (section 2.2.1.10) and digested with Hpa I 
(section 2.2.1.2) to check for positive clones. 1 ml of a fresh overnight culture bom a 
positive clone was used to inoculate 400 ml of L broth containing 100 pg/ml 
chloramphenicol and DNA was prepared using the using Qiagen plasmid Mega Kit 
(section 2.2.1.11) following the instructions of the manufacturer. Glycerol stocks of 
the final construct were prepared and stored at -70°C (section 2.2.1.12).
4.2.2.4 Construction of Cosmid cÆ3AFibCAV-l
A cosmid that contained the CAV-1 genome with the E3, U exon and fibre genes 
deleted and replaced by a Pme I restriction enzyme site (Figure 4.3) was generated as 
follows.
Cosmid AFibCAV-1 was linearised by digestion with Pme I and purified by alcohol 
precipitation (section 4.2.2.3). Fragment UE3Dfib was isolated from pCR2.1UE3Dfib 
by Pst I and Spe I restriction enzyme digestion (section 2.2.1.2). Pst I and Spe I 
digestion of pCR2.1UE3Dfib yields bands of approximately 1200, 2700 and 2700 
base pairs. The 2700 base pair fragment was isolated by gel extraction (section 
2.2.1.6). Electrocompetent BJ5183 cells were cotransformed with linearised cosmid 
AFibCAV-1 DNA and fragment UDE3Dfib as described in section 2.2.1.9. 
Electroporated cells were plated out on L broth plates and incubated at 37°C 
overnight. The following day individual colonies were selected and STET/lysosyme 
minipreparations were performed (section 2.2.1.10). Positive clones were selected for 
by Hpa I restriction enzyme digestion (section 2.2.1.2).
DNA from positive clones was transformed into Max Efficiency STBL2 cells. 
Transformed STBL2 cells were plated out on LB agar plates and incubated at 31°C 
overnight. The following day single colonies were selected and used to inoculate 2.5 
ml of L broth. Cosmid DNA was prepared from the bacterial cultures by the 
STET/lysosyme minipreparation method (section 2.2.1.10) and digested with Hpa I 
(section 2.2.1.2) to check for positive clones. 1 ml of a fresh overnight culture from a 
positive clone was used to inoculate 400 ml of L broth containing 100 pg/ml
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chloramphenicol and DNA was prepared using the using Qiagen plasmid Mega Kit 
(section 2.2.1.11) following the instructions of the manufacturer. Glycerol stocks of 
the final construct were prepared and stored at -70°C (section 2.2.1.12).
4.2.3 Generation of MDCK Fibre Complementation (pCI-NeoFib)
Cell-Line
4.2.3.1 Cloning ofCAV-1 Fibre Gene into an Expression Vector
The PCR amplified CAV-1 fibre gene was isolated by Pme I digestion of 
pCR2.1FibCAV-l and purified as described in section 4.2.1.2. Expression vector pCI- 
Neo (section 2.1.1.4) was linearised by digestion with Sma I (section 2.2.1.2) and 
purified using the QIAquick™ gel extraction kit (section 4.2.1.1). Linearised pCI-Neo 
was dephosphorylated as described in section 2.2.1.3 and purified using the 
QIAquick™ gel extraction kit (section 4.2.1.1). Linearised pCI-Neo DNA and the 
CAV-1 fibre fragment were ligated according to section 2.2.1.7. 5 pi of the ligation 
was transformed into Max Efficiency STBL2 cells and cells were plated out on LB 
agar plates and incubated at 37°C overnight. The following day single colonies were 
selected and STET/lysosyme minipreparations were performed (section 2.2.1.10). 
Positive clones were screened for by digestion with restriction enzyme Avr II (section
2.2.1.2) (Avril digestion of pCI-NeoFib in the coiTect orientation yields bands of 
approximate size 2800 and 4400 base pairs). 50 pi of bacterial culture from positive 
clones was used to inoculate 2.5 ml of L-broth and QIAprep® minipreparations were 
carried out (section 2.2.1.10). 1 ml of a fresh overnight culture from a positive clone 
was used to inoculate 400 ml of L broth containing 100 pg/ml chloramphenicol and 
DNA was prepared using the using Qiagen plasmid Mega Kit (section 2.2.1.11) 
following the instructions of the manufacturer. Glycerol stocks of the final construct 
were prepared and stored at -70°C (section 2.2.1.12).
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4.2.3.2 Transfection ofpCI-NeoFib into M DCK cells
MDCK cells in 25 cm^ tissue culture flasks were transfected with 0.5, 2 or 5 pg of the 
pCI-NeoFib plasmid using lipofectAMINE as detailed in section 2.2.4.5. The 
following day the transfected cells were subcultured using 2 ml of trypsin, and diluted 
with 8 ml of 5% MDCK medium containing 0.6mg/m! G418 to select for cells 
expressing neo^. A G418 kill curve for MDCKs revealed that the minimum 
concentration necessary to kill these cells is 0.6 mg/ml (unpublished data Dr M. D. 
Morrison, University of Glasgow. This was diluted 1:10 with 5% MDCK medium 
containing 0.6mg/ml G418, and 10 ml of this dilution was subcultured into 10cm 
diameter tissue culture dishes. G418 was added to medium to select for stably 
transfected cells. After 12 days isolated colonies of cells were tiypsinised and 
cultured in 6 well plates, and once confluent further subcultured into 25cm^ tissue 
culture flasks, in 5% MDCK medium containing 0.6 mg/ml G418. RNA was isolated 
from each cell-line using Centra’s Purescript® RNA isolation kit according to the 
manufacturer’s protocol. Positive cell-lines were identified by RT-PCR of RNA 
isolated from each cell-line using primers Fibl and Fib2 (Table 4.2) and Promega’s 
“Access” kit as described in section 2.2.2.3.
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4.2.4 Generation of Recombinant Canine Adenoviruses
Fsc I digestion of cosmids cAFibCAV-1, cAE3AFibCAV-l, cPFibCAV-1, 
cPFib(C2)CAV-l and cPFib(H5)CAV-l releases the reeombinant virus genome from 
the eosmid baekbone (see Figure 4.4). Between 0.5 and 5 pg of eaeh veetor was 
transfeeted into the appropriated eell-line as deseribed in seetion 2.2.4.5. AFibCAV-1, 
AE3AFibCAV-l, PFibCAV-1, PFib(C2)CAV-l and PFib(H5)CAV-l were transfeeted 
into MDCK eells. AFibCAV-1 and AE3AFibCAV-l were also transfected into pCI- 
NeoFib eells. The transfeeted cells were then monitored for e.p.e..
^  CAV-1 Genome5’ GCd GCC o q c  c ATlCAT CAA TAA TAT ACA GO 3 
3’ CGÇ CpG CCG CTA GTA GCC ATT ATA TGT CC 5’
Fse I site
Figure 4.4 Mapping of the junction between the eosmid baekbone and the CAV- 
genome in FLR-CAV. This map applies to both ends of the CAV-1 genome.
Transfection of eosmid ePFib(H5)CAV-l and the following experiments with 
PFib(H5)CAV-l were carried out in Category III Containment according to the 
standard operating procedures of the University of Glasgow and under GM (contained 
use) regulations..
4.2.4.1 Validation o f Recombinant Canine Adenoviruses by PCR
Medium was removed from transfeeted eells exhibiting e.p.e. and placed in serew-cap
1.5 ml eppendorf tubes. DNA was denatured by boiling the samples for 10 minutes. 
The denatured samples were diluted 1:100 in ddHiO and PCR and restriction enzyme 
digestion was carried out on samples and control samples as follows.
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PFibCAV-1
Tag PCR of virus isolated from 3 transfections of eosmid ePFibCAV-1, and 
pCR2.iUDFibCAV-l DNA (positive eontrol), was carried out using master mixes 
(section 2.2.2.2) with primers Fibl and Fib2 (Table 4.2). The amplified DNA was 
purified using the QIAquick gel extraction kit (seetion 4.2.1.1) and a 5 pi aliquot of 
eaeh sample was digested with Pme I (seetion 2.2.1,2), Samples of the amplified DNA 
and Pme I digested DNA were analysed by agarose gel electrophoresis (seetion
2.2.1.5).
PFib('C2)CAV-l
Tag PCR using master mixes (seetion 2.2,2,2) with Fibl and Fib2 primers was earned 
out on virus isolated from 4 transfections of eosmid ePFib(C2)CAV-l,
pCR2.1UDCAV-2Fib DNA (positive eontrol) and pCR2.1UDFibCAV-l DNA 
(negative eontrol). The amplified DNA was purified using the QIAquick gel 
extraction kit (seetion 4.2.1.1) and a 5 pi aliquot of eaeh sample was digested with 
each Pme I, Sal I and Nar I restriction enzymes (seetion 2.2.1.2). Samples of the 
amplified DNA and restriction digested DNA were analysed by agarose gel
electrophoresis (seetion 2.2.1.5).
PFibfH5)CAV-l
Tag PCR using master mixes (seetion 2.2.2.2) with Fibl and Fib2 primers was carried 
out on virus isolated from 4 transfections of eosmid ePFib(H5)CAV-l,
pCR2.1UDHAd5Fib DNA (positive control) and pCR2.1UDFibCAV-l DNA 
(negative eontrol). The amplified DNA was purified using the QIAquick gel 
extraction kit (seetion 4.2.1.1) and a 5 pi aliquot of eaeh sample was digested with 
eaeh Afl II, Hpa I and Neo I restriction enzymes (seetion 2.2,1.2). Samples of the 
amplified DNA and restriction digested DNA were analysed by agarose gel
electrophoresis (seetion 2 .2 .1 ,5).
AFibCAV-1
Tag PCR of cAFibCAV-1 virus, pCR2,lUD(-fib) DNA (positive control) and CAV-1 
(negative eontrol) was carried out using master mixes (seetion 2.2.2.2),and Fibl and 
Fib2 primers (Table 4.2). The amplified DNA was analysed by agarose gel 
electrophoresis (section 2.2.1.5).
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AE3AFibCAV-l
Taq PCR of isolated cAE3AFibCAV-l virus, pCR2. lUE3Dfib DNA (positive 
control), AE3Fib plasmid DNA and pCR2.1UD(-fib) DNA (negative control) was 
caiiied out using master mixes (section 2.2.2.2) and primers Fib2 and UEdelup (Table
4.2). The amplified DNA was analysed by agarose gel electrophoresis (section
2.2.1.5).
4.2A.2 Validation ofPFibCAVA.PFib(C2)CAV-l and PFib(H5)CAVA by
sequencing
The sequence authenticity of Ufib, Dfib and all fibre cassettes were confirmed by 
sequence analysis. No further PCR steps were involved in the derivation of 
recombinant viruses and all the subsequent steps were performed by traditional 
cloning without associated Taq error potential.
3 X 10*^  MDCK cells were subcultured in 175 cm^ tissue culture flasks and incubated 
at 37°C overnight. The following day the cells were infected with a sample of either 
PFibCAV-1, PFib(C2)CAV-l or PFib(H5)CAV-l from transfected cells exhibiting 
e.p.e.. Once the infected cells had reached 100% e.p.e. the cells were harvested and 
DNA was isolated using the DNeasy® Tissue Kit (Qiagen, UK) according to the 
manufacturer’s instructions. ABI Prism sequencing was performed on the DNA 
samples (section 2.2.3.2) using Fibl and Fib2 primers (Table 4.2) to confirm the DNA 
sequence at the junctions between cloned fibres and the CAV-1 backbone of the 
recombinant vectors. Sequence data generated was analysed using the UW-GCG 
software package, homology between the nucleotide sequence and the appropriate 
adenovirus genome was determined using the ‘Fasta’ progiam.
4.2.4,3 Production o f virus stocks
MDCK or pCI-NeoFib cells were subcultured in 175 cm^ tissue culture flasks until 
they had reached approximately 90% confluency. The cells were infected with 
samples of the medium from transfected cells exhibiting e.p.e. Once the infected cells
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had reached 100% e.p.e. they were scraped into the culture medium. The medium 
containing cells was placed in 50 ml falcon tubes and centrifuged at 1 K for 5 minutes 
at room temperature. The supernatant, except for 5 ml, was removed and retained. 
The cell pellets were resuspended in the remaining 5 ml of medium and subjected to 3 
freeze thaw cycles, followed by further centrifugation at 1 K for 5 minutes at room 
temperature. The supernatant was added to the initial retained medium, mixed, and 1 
ml aliquots were stored at -70°C. One vial was thawed and used to titre virus aliquots 
by the TCID50 method (section 2.2.4.6).
4.2.5 One-Step Growth Curves
MDCK were subcultured at 2 x 10  ^ cells, in 2 ml of medium, per well of a six-well 
tissue culture plate and incubated at 37°C overnight. The following day each well 
was infected with either CAV-1, PFibCAV-1, PFib(C2)CAV-l or PFib(H5)CAV-l at 
m.o.i. of 10 in 0.5 ml of the appropriate medium and incubated at 37°C for 1 hour. 
The medium containing virus was then removed, the cells were washed twice with 
PBS and 2 ml of the appropriate medium was added to each well. This was 
considered to be the 0 hour time point. At each time point the medium was removed 
and 1 ml aliquots were retained, the cells were washed twice with PBS and tiypsinised 
with 0.5 ml of trypsin. 2 wells were pooled for each sample. All samples were 
centrifuged at 14K for 10 minutes in order to pellet cell debris and then stored at - 
70°C. Cell-associated virus was isolated by subjecting the cellular samples to three 
cycles of freeze thawing, followed by centrifugation at 14K for 10 minutes. Infectious 
virus was titled using the TCID50 method detailed in section 2.2.4.6.
4.2.6 Cytotoxicity Assay
MDCK, A549, 293, CrFK, FEA, D17, pCI-NeoFib, CMLIO and A l l  cells (see 
section 2.1.3.1 for cell origins) were subcultured at 2 x 10  ^cells, in 2 ml of medium, 
per well of a six-well tissue culture plate and incubated at 37°C overnight. The
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following day each well was infected with either CAV-1, PFibCAV-1, PFib(C2)CAV- 
1 or PFib(H5)CAV-l at m.o.i. of 10 in 0.5 ml of the appropriate medium and 
incubated at 37°C for 1 hour. The medium containing virus was then removed and the 
cells were washed twice with PBS. The cells were then overlaid with 2 ml of 1% low 
melting temperature agarose in 5% MDCK gi'owth medium and incubated at 37°C for 
5 days. After 5 days viral plaques could be seen at each dilution of CAV-1 infected 
MDCK cells. Cells were stained overnight with 2 ml of 0.5% (w/v) crystal violet in 
9% (v/v) formaldehyde in dH20 at room temperature. The agarose was removed and 
excess stain was removed by washing the cells with H2O. The cells were examined 
by light microscopy and appropriate plates were photogiaphed using a PC scanner 
(Primax 9600 Profi) and MGI® Photosuite™ Starter Edition version 1.04.
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4.3 RESULTS
4.3.1 Construction and Production of Fibre Mutant CAV-1 Viruses
Fibre mutant CAV-1 based viruses were generated using the cotransformation strategy 
shown in Figure 4.5. The CAV-1 fibre gene was deleted from the CAV-1 genome in 
a eosmid backbone (FLR-CAV) and replaced with a chloramphenicol 
acetyltransferase (Cm^) gene flanked by Pme I restriction enzyme sites (cAFibCAV- 
ICm^) by homologous recombination of shuttle vector pCR2. lUDCm^ (see section 
4.2,1.2) with FLR-CAV. cAFibCAV-1, a eosmid with a unique Pme I restriction 
enzyme site replacing the fibre gene, was generated by Pme I digestion of cAFibCAV- 
ICm^, followed by religation. A eosmid containing the CAV-1 with deletions in the 
E3, U exon and fibre genes was also generated (cAE3AFibCAV-1 ).
The fibres of CAV-1, CAV-2 and Had5 were amplified by PCR and used in the 
construction of shuttle vectors pCR2.1 UDfibCAV-1, pCR2. lUDfibCAV-2 and 
pCR2. lUdfibHAd, respectively. Homologous recombination of these with 
c AFibCAV-1 generated cosmids cPFibCAV-1, cPFib(C2)CA V-1 and 
cPFib(H5)CAV-l, respectively, which contain Pme I sites flanked cloned CAV-1, 
CAV-2 and HAd5 fibres at the CAV-1 fibre locus, respectively.
Cosmids were digested with restriction enzyme Fsel to release the chimeric genome 
from the eosmid backbone (section 2.2.1.2). Transfection of Fsel digested cosmids 
PFibCAV-1, PFib(C2)CAV-l and PFib(H5)CAV-l into MDCK cells lead to the 
development of viral e.p.e. and the recovery of infectious particles. The stock titres of 
PFibCAV-1, PFib(C2)CAV-l and PFib(H5)CAV-l were 6.1 x 10  ^p.f.u./ml, 3.3 x lO"^  
p.f.u./ml and 1.2 x 10^  p.f.u./ml, respectively. Transfection of AFibCAV-1 and 
AE3AFibCAV-1 into MDCK cells resulted in no viral plaques. A cell-line that 
expressed the CAV-1 fibre stably was created by tiansfection of MDCK cells with 
pCI-NeoFib plasmid. This cell-line supported the transfection of Fsel digested 
cosmids cAFibCAV-1 and cAE3AFibCAV-1 and allowed the growth of the recovered
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UD(-Fib)Cm‘'
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cAFibCAV- 
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cAFibCAV-1
Digestion with Pme I 
to linearise cosmid
Fibre deleted cosmid
HR with 
UDFibAdx
cPtibCAV-1
cPfib(C2)CAV-l
cPfib(H 5)CAV-l
Recombinant fibre expressing
CAV-1 mQ PCR o f  sequence upstream o f  CAV-1 fibre
cosmid PCR o f  sequence downstream o f  CAV-1 fibre
# CAT UD(-fib)Cm ‘'
target UDFibAdx
0 Unique Pme I site HR Homologous Recombination in B.I5183 cellse fibre o f  adenovirus %
Figure 4.5 Strategy for production of CAV-1 recombinants (adapted from 
Chartier er a/., 1996).
Regions flanking the target were amplified by PCR and cloned into a “shuttle” vector 
with the chloramphenicol acetyltransferase (CmR) gene, flanked by unique restriction 
endonuclease (RE) sites (Pme I), inserted between them. This tripartite insert was 
cotransformed with cosmid FLR-CAV (contains wild-type CAV-1 genome flanked by 
Fsel sites) into recombinase proficient BJ5183 cells. Homologous recombination 
replaced the target with CmR and recombinants were selected for on chloramphenicol 
containing LB agar plates. The CmR gene was removed by Pmel digestion, followed 
by ligation and transformation into STBL2 cells. The appropriate fibre gene was then 
inserted into the Pme I site using shuttle vectors.
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fibre-deleted CAV-1 viruses. Stock titles of 7 x 10 and 2.9 x 10 p.f.u./ml were 
obtained for fibre mutant viruses AFibCAV-1 and AE3AFibCAV-l, respectively.
4.3.1.1 Validation o f Recombinant Canine Adenoviruses
The junctions between cloned fibres and CAV-1 backbone of PFibCAV-1, 
PFib(C2)CAV-l and PFib(H5)CAV-l viruses were sequenced to confirm sequence 
authenticity.
The coiTcct insertion or deletion in each vector was validated by PCR of viral DNA 
with the appropriate primers and, where appropriate, restiiction digestion of the 
amplified DNA.
Validation of PFibCAV-1
PCR of virus isolated from 3 transfections of cosmid PFibCAV-1 and 
pCR2. lUDFibCAV-1 DNA (positive contiol) with primers flanking the fibre region 
was used to verify the presence of the fibre gene. Pme I digestion of the amplification 
products verified the presence of Pme I restriction enzyme sites (Figure 4.6).
Validation of PFib(C2)CAV-l
Primers that flank the CAV-1 fibre region were used to amplify the fibre region of 
virus isolated from 4 transfections of cosmid PFib(C2)CAV-1, pCR2.1UDCAV-2Fib 
DNA (positive contiol) and pCR2. lUDFibCAV-1 DNA (negative control). Pme I 
digestion of the amplification products verified the presence of Pme I restriction 
enzyme sites. Digestion with restriction enzyme Pme I was used to verify the 
presence of Pme I sites and digestion with Sal I and Nar I was used to verify the 
presence of the CAV-2 and CAV-1 fibres, respectively (Figure 4.7).
Validation of PFib/H51CAV-l
Primers that flank the CAV-1 fibre region were used to amplify the fibre region of 
virus isolated from 4 transfections of cosmid PFib(H5)CAV-l, pCR2.1UDHAd5Fib 
DNA (positive control) and pCR2. lUDFibCAV-1 DNA (negative control). Digestion
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with restriction enzymes Afl II, Hpa I and Nco I was used to verify the presence of the 
Had5 or CAV-1 fibres (Figure 4.8).
Validation of AFibCAV-1
PCR of AFibCAV-1 virus, pCR2.1UD(-fib) (positive control) and CAV-1 virus 
(negative control) with primers Fibl and Fib2 was used to validate the deletion of the 
fibre gene from AFibCAV-1 (see Figure 4.9). Fibl and Fib2 are positioned 
approximately 200 bases on either side of the fibre gene in wild type CAV-1, 
therefore, in the absence of the fibre gene a product of approximately 400bp product 
was amplified. Wild type CAV-1 was used as a negative control to demonstiate the 
products expected from PCR with the same primers in the presence of the fibre gene.
Validation of AE3AFibCAV-1
PCR of isolated AE3AFibCAV-l virus, pCR2.1UE3Dfib DNA (positive control), 
pCR2.1UE3Dfib plasmid DNA and pCR2.1UD(-fib) DNA (negative control) with 
primers Fib2 and UEdelup was used to validate the deletion of the fibre gene from 
AE3AFibCAV-1 (Figure 4.10). Fib2 and UEdelup are positioned approximately 200 
bases from the fibre and E3 genes, respectively, in wild type CAV-1, therefore, in the 
absence of these genes a product of approximately 400bp product was amplified.
4.3.2 One-Step Growth Curves
To investigate the growth kinetics of fibre recombinant viruses PFibCAV-1, 
Pfib(C2)CAV-l and PFib(H5)CAV-l, MDCK cells were infected at a m.o.i. of 10 and 
incubated at 37°C over a period of 48 hours. Virus was isolated from the cells and the 
culture medium at the time points indicated in the figure legends. The titres were 
determined by the TCID50 method. Figures 4.11 and 4.12 show the total log TCID50 
values at each time point.
Although the amount of cell-associated PFib(C2)CAV-l virus that accumulated was 1 
log lower than CAV-1 and PFibCAV-1 over the time course, ANOVAs between the 
cell associated and extiacellular growth curves of CAV-1, PFibCAV-1 and
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Virus 1 
MW a b
Virus 2 Virus 3 pCR2.1UD
FibCAV-1 
a b a b a b
Figure 4.6 PCR of pFibCAV-1 virus. DNA was isolated from MDCK cells that 
showed viral e.p.e. after transfection with eosmid pFibCAV-l. The DNA was 
subjected to PCR with primers Fibl and Fib2 and digested with Pmel. PCR and Pmel 
digestion was carried out on pCR2. lUDFibCAV-1 DNA (positive eontrol) for 
comparison. MW = 1 Kb molecular weight marker.
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Figure 4.7 PCR of pFib(C2)CAV-l virus. Virus was isolated from MDCK eells 
that showed viral e.p.e. after transfeetion with eosmid pFib(C2)CAV-l. Four isolates 
of pFib(C2)CAV-l (Virus 1-4) were denatured subjected to PCR with primers Fibl 
and Fib2. The amplieons were digested with (a) Pmel, (b) Sail or (e) Nar I restriction 
enzymes. PCR and restriction enzyme digests were also carried out on 
pCR2.1UDFibCAV-2 DNA (positive eontrol) and pCR2.1 UDFibCAV-1 DNA 
(negative eontrol) for comparison. MW = 1 Kb molecular weight marker.
pCR2.1UD 
FibCAV-1 
MW a b e d
Virus Virus 2 pCR2.1UD
Fib(H5)CAV-l 
b e d a b e  d
Figure 4.8 PCR of pFib(H5)CAV-l virus. Virus was isolated from MDCK eells 
that showed viral e.p.e. after transfeetion with eosmid pFib(H5)CAV-l. Two isolates 
of pFib(H5)CAV-l (Virus 1 and Virus 2) were denatured and subjected to PCR with 
primers Fibl and Fib2. The amplieons (a) were digested with (b) A fill, (e) Hpal or (d) 
Neol restriction enzymes. PCR and restriction enzyme digests were also carried out 
on pCR2. IUDFibCAV-1 DNA (negative eontrol) and pCR2.1UDFibHAd5 (positive 
eontrol) for comparison. MW = 1 Kb molecular weight marker.
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AFibCAV-1 virus pCR2.1UD(-fib)
MW a b c a b c
CAV-1 virus
a b c
Figure 4.9 PCR of AFibCAV-1 virus. DNA was isolated from MDCK cells that 
showed viral e.p.e. after transfection with cosmid AFibCAV-1. The DNA was 
subjected to PCR with primers (a) Fibl and Fib2, (b) Fibl and 26396, and (e) Fib 2 
and 27001. PCR with the same primers was also carried out on pCR2.1 UD(-fib) DNA 
(positive eontrol) and CAV-1 virus (negative eontrol) for comparison. MW = 1 Kb 
molecular weight marker.
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Figure 4.10 PCR of AE3AFibCAV-l virus. DNA was isolated from MDCK cells 
that showed viral e.p.e. after transfeetion with eosmid AE3AFibCAV-l. PCR was 
also carried out on (a) AE3AFibCAV-l virus (b) pCR2.1UE3Dfib DNA (positive 
control), (e) AE3Fib plasmid DNA (negative eontrol), and (d) pCR2.lUD(-fib) DNA 
(negative eontrol) with primers Fib2 and UE3delup. MW = I Kb molecular weight 
marker.
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Cell-associated virus isolated from MDCK cells infected with CAV-1 
pFibCAV-1 or pFib(C2)CAV-1 at a m.o.i. of 10
oin
Time (hours)
Average PfibCAV-1 - a  Average Pfib(C2)CAV-1♦ Average WT
Extracellular virus isolated from MDCK cells infected with CAV-1 
pFibCAV-1 or pFib(C2)CAV-1 at a m.o.i. of 10
in
Time (hours)
Average PfibCAV-1 - - à - Average Pfib(C2)CAV-1♦ Average WT
Figure 4.11 One Step Growth Curves for CAV-1, PFibCAV-1 and 
PFIb(C2)CAV-l. MDCK cells were infected at a m.o.i. of 10 with either CAV- 
1, PFibCAV-1 or PFib(C2)CAV-l. Cell-associated and extracellular virus was 
isolated at 0, 6, 12, 15, 18, 24, 30, 36 and 48 hours p.i., TCIDso values arc 
presented.
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Cell-associated virus isolated from MDCK cells infected with CAV-1 o 
pFib(H5)CAV-1 at a m.o.i. of 10
Time (hours)
Pfib(H5)CAV-1♦ Wild-type CAV-1
Extracellular virus isolated from MDCK cells infected with CAV 
1 or pFib(H5)CAV-1 at a m.o.i. of 10
in
O)
Time (hours)
■ Pflb(H5)CAV-1♦ Wild-type CAV-1
Figure 4.12 One Step Growth Curves for CAV-1 and PFib(H5)CAV-l.
MDCK cells were infected at a m.o.i. o f 10 with cither CAV-1 or 
PFib(H5)CAV-l. Cell-associated and extracellular virus was isolated at 0, 4, 18, 
24, 30, 36 and 48 hours p.i., TCID50 values arc presented.
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PFib(C2)CAV-l returned P-values of 0.894 and 0.926, respectively, indicating no 
significant difference (Figure 4.11).
The growth kinetics of PFib(H5)CAV“l were also the same as CAV-1 (Figure 4.12). 
However, at 4 hours p.i. the decrease in cell-associated virus titles was 2 logs lower 
than CAV-1 and the accumulated cell-associated PFib(H5)CAV-l 48 hours p.i. was 
approximately 1.5 logs lower than CAV-1. The titre of PFib(H5)CAV-l in the 
growth medium 48 hours p.i. was 1.5 logs less than with CAV-1.
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4.3.3 Tropism of CAV-1 Recombinants
CAV-1 fibre recombinants that express GFP would be of benefit in order to fully 
investigate the effect of fibre pseudotyping. In the absence of such constructs 
preclinical investigations of CAV-1 recombinant ti'opism were performed through 
analysis of e.p.e. in various cell-lines.
There was no difference observed visually in the infection of human A549 and 293 
cells, feline FEA cells or canine D17, CMLIO or A72 cells (cell origins detailed in 
section 2.1.3.1) with PFib(C2)CAV-l and PFib(H5)CAV-l, compared with wild type 
CAV-1 (data not shown). At a m.o.i. of 0.1, there appeared to be approximately 10- 
fold decrease in amount of e.p.e. observed in PFib(C2)CAV-l infected MDCK cells, 
compared with CAV-1 infection (Figure 4.13). This was true of infection at m.o.i.s of 
0.01 and 0.001. The findings were similar in CrFK and pCI-NeoFib cells with 
PFib(C2)CAV-l (Figures 4.14 and 4.15).
Infection of MDCK cells with PFib(H5)CAV-l at a m.o.i. of 0.1 resulted in an 
approximate 100-fold decrease in the amount of e.p.e. compared with CAV-1 (Figure 
4.13). This was also ti'ue of the MDCK cells infected at 0.01 m.o.i. with 
PFib(H5)CAV-l. At a m.o.i. of 0,001 no viral e.p.e. was detected. However, there 
was only an approximately 10-fold decrease in the amount of e.p.e. observed in 
PFib(H5)CAV-l infection of both CrFK and pCI-NeoFib cells at each m.o.i. (Figures 
4.14 and 4.15).
pCI-NeoFib cells were investigated to determine whether expression of the CAV-1 
fibre would complement any deficiency in the recombinant viruses. Each of the 
viruses, including wild-type CAV-1, demonstrated increased levels of e.p.e. in pCI- 
NeoFib cells compared to MDCK cells.
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Figure 4.13 Cytotoxicity assay with fibre recombinant CAV-1 viruses in MDCK
cells. Cells were infected at a m.o.i. o f  0.1, 0.01 or 0.001 with (i) CAV -1, (ii)
pFib(C2)CAV-l and (iii) pFib(H 5)CA V -l.
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Figure 4.14 Cytotoxicity assay with fibre recombinant CAV-1 viruses in CrFK
cells. Cells were infected at a m.o.i. o f  0.1, 0.01 or 0.001 with (i) C A V -1 , (ii)
pFib(C 2)CAV -l and (iii) p F ib (H 5)C A V -l.
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Figure 4.15 Cytotoxicity assay with fibre recombinant CAV-1 viruses in pCl-
NeoFib cells. Cells were infected at a m.o.i. o f  0.1, 0.01 or 0.001 with (i) C AV -1, (ii)
pFib(C2)CAV-l and (iii) p F ib (H 5 )C A V -l.
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4.4 DISCUSSION
Like the HAds, CAV-1 has a broad tissue ti’opism in its canine host. It naturally 
replicates in endothelial cells of the vascular system and has been shown to cause 
disease in a wide range of tissues, primarily the respiratory system and liver, but 
including others such as the nervous system and eyes (Koptopoulos & Cornwell, 
1981). The ability to transduce and express genes in a wide range of cell and tissue 
types is undoubtedly one of most important features adenoviruses offer as gene 
therapy vectors. Nevertheless, the majority of proposed gene therapy protocols aim 
to treat diseases that require the delivery of vectors to specific target sites. The 
targeting of adenoviruses can be achieved through the modification of proteins 
involved in tropism.
The major determinants of adenoviral tropism are the fibre and pen ton proteins, which 
interact with each other specifically and with high affinity. It was demonstrated in 
1982 that isolated fibre and penton base proteins from different serotypes could 
interact with each other (Boudin & Boulanger, 1982). Several gi'oups have since 
showed the assembly of infectious adenovirus particles with fibre-penton chimeras 
(see section 4.1.2.3). It has also been shown that by the exchange of fibres, or 
domains of fibres, between HAds of different serotypes it is possible to significantly 
alter the tropism of the resultant vectors. Xu and Both described an OAV chimera that 
had the knob domain replaced by that of HAd5 (Xu & Both, 1998). The resultant 
OAV chimera could infect previously non-permissive human cells (Xu & Both,
1998). To date there is no published data on whole fibre swapping between 
adenoviruses native to different host species.
The addition of restriction enzyme sites on either side of the fibre gene did not 
significantly alter the giowth kinetics of PFibCAV-1 compared with wild-type CAV-1 
and, as such, a vector system that facilitates fibre swapping between CAV-1 and 
heterologous adenoviruses was produced. This vector system will potentially allow 
the insertion of fibres, both wild-type and modified, from a wide range of adenovirus 
serotypes into the fibre locus of CAV-1. The fibre of CAV-2 has 80.6% amino acid 
identity with that of CAV-1 and incoiporation of this fibre into CAV-1 resulted in an
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infectious virus that had growth kinetics with no significant difference to CAV-1. 
Insertion of the HAd5 fibre, which has only 26% amino acid identity with that of 
CAV-1, also yielded an infectious virus, although there was a significant reduction in 
both extracellular and cell-associated titles. Nevertheless, infectious PFib(H5)CAV-l 
particles were recovered to relatively high titres and the giowth kinetics were 
comparable to those of CAV-1.
The tropism of CAV-1 chimeras with CAV-2 and HAd5 fibres was assessed in 
various cell-lines. In particular, the exchange of the CAV-1 fibre with that of HAd5 
did not result in detectable cytotoxicity within A549 cells. Whereas HAd5 
productively infects A549 cells, wild type CAV-1 does not (Chapter 3). Presumably 
the block to PFib(H5)CAV-l infection of A549 cells is a consequence of events after 
the fibre-receptor interaction, as might occur in wild-type CAV-1 infection of these 
cells. It is possible that a secondary interaction analogous to penton-integiln 
interactions in HAds is required by CAV-1 for entry into the host cell and is 
unachievable in A549 cells. Perhaps irregular capsid assembly compromises A549 
infection by PFib(H5)CAV-l as there is only 50% identity between the CAV-1 and 
HAd5 tail domains. It is also known that HAd fibres are important in the intracellular 
trafficking of adenoviruses (Hong & Engler, 1991, Miyazawa et ah, 1999), however, 
the intracellular trafficking requirements of the CAV-1 fibre are unknown and these 
too may have an influence in this situation.
Plaque assays demonstrated that the tropism of CAV-1 was modified by the 
replacement of the native fibre with the fibre of either CAV-2 or HAd5. However, 
more in depth investigations are necessary to verify the integrity of modified viruses 
and their tropism. Similar chimeric CAV-1 vectors expressing GFP would be an 
invaluable tool in future work. In vivo investigations would also be necessary before 
considering the use of a fibre modified CAV-1 vector, as tropism in vitro is not 
always indicative of tropism in vivo (see section 4.1.1.1).
Transfection of MDCK cells with cosmid AFibCAV-1 yielded no viral plaques, 
therefore an MDCK-based cell-line was produced that expressed the CAV-1 fibre 
under the control of a CMV promoter (pCI-NeoFib). Transfection of this cell-line 
allowed the propagation of AFibCAV-1 virus and stocks were produced containing 7
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X 1 0  ^ p.f.u./ml, suggesting that the fibre supplied in trans by this method was 
functional. The production of AFibCAV-1 in pCI-NeoFib cells indicates that the 
CAV-1 fibre gene does not have to be supplied in cis for the assembly and 
encapsidation of infectious viral particles. However, the TCID50 method used to titie 
this virus does not provide information regarding the production of non-infectious 
particles. Two groups have reported the generation of fibreless HAd5 vectors in fibre 
complementing cell-lines and both found that there was a high particle to infectious 
virus ratio in stocks of these viruses (only one of every 1 0  ^particles were infectious) 
(Von Seggern et al, 1999, Legiand et al, 1999). Analysis of virus particles by 
caesium chloride gi'adients and electron microscopy showed that capsid assembly was 
normal, however, maturation of virions was impaired and this suggested that 
additional roles of the fibre were retarded by its removal. Such investigations with 
AFibCAV-1 should provide more information about the reduced numbers of 
infectious virions in stocks generated compared with wild type CAV-1 as a result 
possibly offer further insights into the functions of the CAV-1 fibre in the normal life 
cycle. In addition, Von Seggern et a l found that the RGD protrusions were angled 
more inwardly with fibreless HAd5 vectors than in wild type HAd5, this may have 
contributed to the decrease in infectivity as the removal of the fibre results in these 
viruses having an integiin-dependant entiy pathway. The mechanisms of secondary 
interactions with CAV-1 in its host species are unknown, therefore the mechanism of 
entry of AFibCAV-1 could further this knowledge. Although cytotoxicity was noted, 
the cytopathic effect observed in AFibCAV-1 infected pCI-NeoFib cells was not 
typical of adenovirus infection; the infected cells rounded but no clumping was 
observed. Viral packaging of AFibCAV-1 in pCI-NeoFib cells is clearly functional, 
however, infection with the resultant virus is impaired. The low titres of AFibCAV-1 
obtained restricted the investigations possible in this study. It would be necessary to 
determine whether alternative cell-lines could be produced to increase virus yield, 
which would allow further investigations into the mechanisms that are affected by the 
fibre deletion in AFibCAV-1. Virus stocks could also be concentiated and purified 
using caesium chloride gi’adients. The development of a AFibCAV-1 based vector 
carrying a reporter gene would also aid these studies.
Like HAds 2 and 5, the E3 region of CAV-1 is non-essential for replication in tissue 
culture (Monison et al, 2002). In HAds 2 and 5 this region functions in immune
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modulation of the host by several mechanisms. It blocks both MHC transport to host 
surface of the host cell (Bennet et al, 1999) and expression of the TNF receptor 
(Gooding et al, 1991, Shisler et al, 1997). E3 is also involved in internalisation of 
the cellular gi'owth factors by endosomes (Tollefson et al, 1991) and lysis of host 
cells for release of the progeny virus (Tollefson et al, 1996). The adenovirus U exon 
gene is found between the E3 and fibre encoding regions (Davison et al, 1993). The 
function of the U exon is undetermined, although it has been proposed to encode the 
N terminus of an, as yet, undefined protein (Davison et al, 2000). AE3FibCAV-l has 
a deletion that spans the E3, fibre and U exon genes of CAV-1. Like cosmid 
AFibCAV-1, transfection of MDCK cells with cosmid AE3FibCAV-l did not result in 
the formation of viral plaques but transfection of pCTNeoFib cells resulted in the 
isolation of AE3FibCAV-l virus particles. AE3FibCAV-l infection of MDCK cells 
showed no cytotoxicity and the cytopathic effect observed in AE3FibCAV-l infected 
pCI-NeoFib cells was similar to that of AFibCAV-1. It is not known whether the 
deletion of the U exon would affect either wild-type or heterologous fibre expression, 
this could be investigated by the production of an E3 and U exon deleted CAV-1 
vector with a functional fibre gene.
It has been demonstrated that the CAV-1 fibre can be replaced with heterologous 
adenovirus fibres and that tropism of these CAV-1 chimeras is altered. This work was 
intended as a proof of principle. The vector system developed could be applied in 
order to exchange the CAV-1 fibre with a wide range of adenovirus fibres. It would 
also allow the exchange of knob domains between CAV-1 and other adenoviruses. 
Human adenovirus tropism is well researched and modified fibre and knob domains 
have been created which allow specificity of binding in vivo. At present, there is little 
known about the domains within the CAV-1 fibre that deteimine tropism, and as such 
the use of modified human adenovirus fibres might allow the targeting of CAV-1 to 
selected ceil types. Redirection of fibre-deleted CAV-1 vectors with exogenous 
molecules is also a possible method of CAV-1 retargeting.
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CHAPTER 5
Neutralising Antibodies to CAV-1 and HAd5 Pseudotyped CAV-1 in Human Serum
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5.1 INTRODUCTION
The host immune response to adenoviruses is highly efficient. Infected cells are 
rapidly destroyed by the cellular response and the humoral response protects against 
re-infection with the same adenovirus serotype.
The intracellular expression of adenovirus gene products leads to the activation of 
cytotoxic T lymphocytes, which kill infected cells (Chirmule et al, 1999). Capsid 
proteins have also been shown to stimulate an anti-adenovirus cellular immune 
response (Yang et al, 1995). The action of CD4 helper cells is essential in the 
immune response to adenoviruses and their exclusion was found to prevent responses 
by CTLs and B cells, however, CD4 cells alone are insufficient in the clearance of 
adenovirus infected cells.
Neutralising antibodies are also elicited in response to capsid proteins, preventing re­
infection by that serotype. Detailed immunological testing in HAd pre-immunised 
lung cancer patients showed that anti-fibre antibodies emerged first followed by anti­
pen ton base and then anti-hexon antibodies (Gahery-Segard et al, 1998). Anti-fibre 
antibodies were found to have no neutralising effect on their own, however patients 
with anti-fibre and anti-penton base antibodies had significant neutralising activity 
and it was suggested that these antibodies had a synergistic effect. The mechanism 
suggested for this synergism was an initial uncoating of the adenovirus particles by 
anti-fibre antibody that then allowed access to the anti-penton base antibodies, and 
presumably anti-hexon antibodies. High proportions of the human population harbour 
neutralising antibodies to both HAd2 and HAd5 since they are endemic in the 
population, however, the data with regards to human adenoviruses neutralisation is 
conflicting (Horwitz, 1990). When Hoffman et al, analysed 15 serum samples from 
the USA for anti-HAd5 antibodies they found that they all had neutralising antibodies 
(Hofman et al, 1999) compared to a second American study that revealed that, 
although 97% of the population had antibodies to HAd5 capsid proteins, serum from 
only 55% of the subjects actually neutralised HAd5 infection in vitro (Chirmule et al,
1999). Similar to the results found by Chirmule et al, a French gioup found that 52% 
of human samples had neutralising antibodies to HAd5, although this was investigated
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using an E l deleted vector (Kremer et al, 2000). It is difficult to compare the 
published results as the experiments were canied out using different criteria and the 
materials and methods are often incomplete in the published papers.
This complex immune response to adenoviruses is the main limiting factor in the 
development of adenovirus based gene therapy vectors.
5.1.1 Sequential Administration of Adenovirus Vectors
It has been proposed that the problems posed to gene therapy by the endemic presence 
of the common HAds, and the immune response to HAds, may be overcome by the 
sequential administration of vectors based on non-cross-reactive adenovirus 
serotypes. Baboons that were administered with an E l deleted, liAAT expressing 
HAd5, followed by the equivalent HAd2, after expression from the HAd5 vector had 
been extinguished, showed no increase in the rate of elimination of transduced cells. 
This indicated that the HAd2 vector was able to evade the humoral response mounted 
against the HAd5 vector (Morral et al 1999). The sequential delivery of helper 
dependent HAds based on non-cross-reactive serotypes has also been demonstrated 
(Parks et al 1999). The immune responses elicited against a hdHAd2 were unable to 
neutralise a hdHAd5, whereas repeated tieatment with the same hdHAd2 reduced 
transgene expression by up to 100-fold. Non-cross-reactive serotypes might also 
include both chimeric and non-human adenoviruses. There is less chance of a pre­
existing immune response to animal adenoviruses in humans and in recent years this 
realisation has encouraged several research gi’oups to investigate adenoviruses that 
infect different species as human gene therapy vectors. The sequential delivery of a 
range of attenuated vectors of different serotypes should provide an adenovirus based 
gene therapy protocol that allows extended expression of transgenes in patients.
Moffatt et al, investigated cross-reactivity between BAV-3, PAV-3 and HAd5 
vectors (Moffatt et al, 2000). Mice immunised with BAV-3 and/or PAV-3 
demonstrated over 5000-fold transgene (p-gal) expression from a HAd5 based vector 
compared with mice immunised with HAd5 (Moffatt et al, 2000). Cross-
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neutralisation assays with sera from mice immunised either intianasally or 
intraperitoneally with BAV-3 and/or PAV-3 or HAd5 showed at least 30-fold higher 
antibody titres to homologous viruses compared with heterologous virus. The 
administration of OAV vectors to HAd5 immunised mice was also successful 
(Hofmann et ah, 1999),
5.1.2 Immune Responses to Animal Adenoviruses in Humans
Immune responses to CAV-2 and OAV have been investigated using human sera. 
Kremer et al, showed that 98% of subjects had no detectable neutralising antibodies 
to an E l deleted GFP expressing CAV-2, compared with 52% exhibiting neutialising 
antibodies against the E l deleted GFP expressing HAd5 vector (Kremer et al, 2000). 
15 random samples of human sera, which each contained antibodies against HAd5, 
contained no cross-reactive antibodies against OAV (Hofmann et al, 1999).
5.1.3 Objective
The primary aim of this investigation was to establish whether antibodies present in 
human sera were capable of neutralising CAV-1. A secondary aim was to establish 
whether a HAd5 pseudotyped CAV-1 vector (described in Chapter 5) was more 
sensitive to neutralisation as anti-fibre antibodies can play a role.
In addition, feline sera was analysed for both anti-CAV-1 and anti-HAd5 antibodies 
with a view to the use of CAV-1 as a vaccine vector in domestic cats (see Chapter 3 
for a review of published investigations regarding adenovirus infection in cats).
Anti-HAd5 antibody levels were determined for comparative puiposes.
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5.2 MATERIALS & METHODS
5.2.1 Adenovirus Neutralisation with Human Sera
50 serum samples from healthy conUol subjects were obtained from the Leukaemia 
Research Fund, Department of Veterinary Pathology, University of Glasgow. 
Neutralisation assays were caii'ied out on these samples to detect neutralising 
antibodies against CAV-1, HAd5 and pFib(H5)CAV-l as detailed in section 2.2.4.7.
5.2.2 Adenovirus Neutralisation with Feline Sera
50 random feline serum samples that had been routinely submitted to the Feline 
Diagnostic Laboratory, Department of Veterinary Pathology, University of Glasgow, 
were analysed to detect neutralising antibodies against CAV-1 and HAd5 as detailed 
in section 2.2.4.7.
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5.3 RESULTS
5,3.1 Pre-existing Neutralising Antibodies to CAV-1, HAd5 and
pFib(H5)CAV-l in Human Sera
50 samples of human sera were examined for neutralising activity against CAV-1, 
HAd5 and pFib(H5)CAV-l. 50% of these had a degiee of anti-CAV-1 activity, and 
74% had a neutralising effect on HAd5 (Table 5.1). However, neutralising antibody 
titres of less than 64 are considered to be ‘low’ and only subjects with titles of 64 or 
over are considered to be immune (based on CAV-1 vaccination trials, unpublished 
data from Professor H Thomson, Department of Veterinary Pathology, University of 
Glasgow). Considering this information, only 22% had significant anti-CAV-1 
activity compared with 46% anti-HAd5. There appeared to be no relationship 
between the samples that had anti-CAV-1 activity and those that had anti-HAd5 
activity.
74% of the samples demonstiated neutralising activity against pFib(H5)CAV-l, 
however, only 44% of the samples had neutralising antibody titres over 64. With the 
exception of one sample, all the serum samples that neutralised CAV-1 also 
neuhalised pFib(H5)CAV-l, whereas only 60% of the samples that neutralised HAd5 
neutralised pFib(H5)CAV-l. 13% of the samples that neutralised pFib(H5)CAV-l 
had both CAV-1 and HAd5 neutralising activity.
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T itre o f  N e u tr a lis in g  
A n tib o d ie s  to  :
T itre o f  N eu tra lis in g  
A n tib o d ie s  to  :
Sample
No. CAV-1 HAd-5 PFib(H5)CAV-1
Sample
No. CAV-1 HAd-5
PFib(H5)
C A V -1
1 45 256 128 26 0 91 32
2 23 32 23 27 0 0 0
3 0 0 0 28 724 362 512
4 128 181 512 29 0 128 64
5 0 128 181 30 0 32 0
6 23 0 0 31 181 512 512
7 181 32 128 32 32 724 512
8 512 16 128 33 0 32 0
9 0 128 32 34 0 181 91
10 0 181 91 35 16 23 23
11 16 128 32 36 128 23 64
12 0 128 23 37 0 11 0
13 45 32 128 38 0 91 128
14 32 45 11 39 45 91 32
15 362 0 128 40 0 128 45
16 0 0 0 41 60 23 23
17 0 181 128 42 0 128 181
18 0 362 512 43 16 0 0
19 0 0 0 44 16 0 0
20 0 128 32 45 32 0 11
21 0 91 91 46 256 0 128
22 0 0 0 47 0 0 0
23 256 32 256 48 0 128 256
24 181 16 128 49 0 0 0
25 362 32 91 50 32 181 32
Table 5.1 Neutralising Antibodies in Human Serum Samples 
50 human serum samples were analysed to determine the anti-CAV-1, HAd5 and 
PFib(H5)CAV-l neutralising antibodies. Shadowed cells contain antibody titres of 64 
or less, only sera with titres over 64 are considered to indicate immunity to the 
appropriate virus.
197
5.3.2 Pre-existing Neutralising Antibodies to CAV-1 and HAd5 in
Feline Sera
50 random samples of feline sera were analysed for neutralising antibodies against 
CAV-1 and HAd5. With the exception of samples 12, 26 and 35, none of the samples 
had detectable neutralising antibodies against CAV-1 or Had5. Samples 12 and 35 
had neutialising titres of 23 and 91, respectively, against HAd5. Sample 26 had a 
neutralising antibody titre of 23 against CAV-1. However, only animals with a titre 
of 64 or over are considered immune (based on unpublished data from Professor H 
Thomson, Department of Veterinary Pathology, University of Glasgow) and as such 
only one sample demonstrated the presence of any significant levels of neutialising 
antibodies and these were directed against HAd5.
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5.4 DISCUSSION
A high proportion of the population have neutialising antibodies to HAds 2 and 5, 
which could limit their use as gene therapy vectors. The use of less ubiquitous HAds 
and animal-derived adenoviruses may offer a solution to this problem. These 
adenoviruses are antigenically distinct from HAds 2 and 5 and exposure to them is 
limited, therefore humans are less likely to have immunity to them. There is variation 
between the published results regarding percentages of the population that have 
neutralising antibodies against the most ubiquitous of the human adenoviruses, type 5 
(section 5.1). Analysis of 50 samples of human sera revealed the presence of 
neutralising antibodies against HAd5 at significant levels in only 46% of the samples. 
Only 22% of the same samples had significant levels of neutialising antibodies 
against CAV-1.
Antibodies to CAV-1 and CAV-2 have been shown to be cross-reactive (Koptopoulos ?
& Cornwell, 1981, unpublished data). Ki'emer et ai, reported that 98% of subjects 
had no detectable neutralising antibodies to CAV-2 (Kremer et al, 2000). As such it |
might have been expected that a lower proportion of the sera tested in the presented 
Study would have neutralising antibodies against CAV-1. However, the experimental
protocol in Ki'emer’s experiment was based on GFP expression from a partially E l 
attenuated CAV-2 vector administered at high titres to human 911 cells. In essence, 
Kremer et a l investigated how CAV-2 vectors may be blocked by neutralising 
antibodies in a gene therapy setting. The neutialisation of CAV-1 demonstiated may 
not have been achieved by CAV-1 specific neutialising antibodies, for example, anti- 
HAd8 antibodies have previously been shown to neutralise CAV-1 (Smith et al, 
1970). It is also unknown whether the level of CAV-1 neutralisation shown here 
would affect vector efficacy in vivo. Further immunological investigations of human 
sera would provide more accurate information regarding CAV-1 neutralisation, for 
example, binding assays with the CAV-1 capsid proteins should determine whether 
the immune response in the tested sera is directed to specific proteins in these 
samples. Further work to determine the cross-neutralisation of CAV-1 by antibodies 
of other adenoviruses is also necessary.
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The fibre recombinant pFib(H5)CAV-l was neutralised by almost the same 
percentage of serum samples as HAd5. All but one of the samples that neuhalised 
CAV-1 were shown to neuhalise pFib(H5)CAV-l whereas only 12 of the 22 samples 
that had anti-HAd5 neutralising activity neutralised pFib(H5)CAV-l. This is to be 
expected as the hexon has been shown to be a major immunogen of adenoviruses 
(Gahery-Segard et al, 1998), although these results also confinn that fibre immunity 
is relevant to adenovirus neuhalisation in vitro. Although anti-fibre antibodies are 
involved in neutralisation in culture (Wolfhart, 1988) there have been reports of their 
ineffectiveness in vivo (Gall et al, 1996). It has been shown in humans that anti-fibre 
antibodies are not sufficient to neutralise adenovirus on their own, and that they 
require the presence of anti-penton antibodies (Gahery-Segard et al, 1998). The 
hypothesis is that adenovirus particles are initially uncoated by anti-fibre antibodies 
and this uncoating allow access to anti-penton antibodies, however, only 2 of the anti- 
HAd5 antibody containing samples that neutralised pFib(H5)CAV-l also contained 
significant levels of anti-CAV-1 antibodies. As such, in vivo immunological analyses 
of the pre-existing immunity of target patients would be necessary prior to the 
administration of any fibre recombinant vectors.
Another future field of investigation should be the determination of p.f.u. to particle 
ratios in each of the viruses investigated. It is possible that stocks of pFib(H5)CAV-l 
contain a higher proportion of defective particles (discussed in more detail in Chapter 
4). If this was the case, these particles would affect the titles returned by the 
neutialisation assay.
In conclusion, there is evidence that CAV-1 vectors are less likely to be neuhalised 
than HAd5 vectors in patients. Further studies would determine whether the level of 
CAV-1 neutralisation demonstrated here would be significant in a gene therapy 
setting.
It was expected that there would be little pre-existing immunity to CAV-1 found in 
the cat population, as it has no reservoir in the domestic canine community (see 
Chapter 1). It is therefore necessary to investigate the pre-existing immune response 
to CAV-1 in the feline population prior to the development of a CAV-1 based 
vaccine. Of 50 cats investigated, none had significant levels of neutralising antibodies
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against CAV-1 and only one cat had immunity to HAd5. In chapter 3 it was 
demonstrated that CAV-1 infects feline cells, DNA replication and transcription 
occurs, and a productive infection is established. Further to this, transgene expression 
was demonstrated in both feline cell-lines investigated using a GFP expressing CAV- 
1 based vector. These features of CAV-1, in conjunction with the lack of CAV-1 
neutralisation by feline sera demonstrated here, suggest that it is a worthwhile 
candidate for development as a vaccine vector for use in cats.
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CHAPTER 6
General Discussion
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Much of the development of adenoviruses as vectors has focused on the common 
HAds 2 and 5, mainly because there is so much known about these serotypes as they 
have been used as models for the elucidation of many eukaryotic cellular processes 
including DNA replication and transcription. However the development and 
application of these vectors has highlighted certain limitations including pre-existing 
immunity to these serotypes and a wide tropism hampering specific tissue targeting.
This work has investigated the suitability of CAV-1 as an alternative vector to HAd 2 
and 5 for the delivery of ti’ansgenes to cats and humans, for the purposes of 
vaccination and gene therapy. The essential criteria for any such vector include the 
following :
1. It must enter cells of the target host.
2. It must express transgenes within these cells.
3. It must be capable of targeting transgene expression to certain cells.
4. There must be low pre-existing immunity to the vector within the target host.
CAV-1 had been demonstiated to infect cells of heterologous host species (pig, 
racoon, ferret) (Emery & York, 1958, Bolin et al, 1958, Fieldsteel & Yoshihara, 
1957, reviewed in Koptopoulos & Cornwell, 1981). In the studies presented here 
more sensitive molecular techniques were used to investigate CAV-1 infection of both 
feline and human cell lines, to explore modification of tropism and to deteiTnine levels 
of neutralising antibodies to CAV-1 within feline and human serum.
Only circumstantial evidence for adenovirus infection of cats has been published and 
although CAV-1 infection of feline cells is productive in vitro, the results in Chapter 3 
demonstrate that there are no neutralising antibodies against CAV-1 in feline sera. 
There is clearly a block to natural CAV-1 infection in cats. At present in the UK, the 
routine vaccination of dogs with live CAV-2 may indirectly prevent CAV-1 infection 
of cats, however, adenovirus infection of cats was not documented before vaccination 
became commonplace. Wild type CAV-1 infection in the canine host begins in the 
respiratory epithelium. Viral replication leads to the release of progeny virus into the 
blood stream, which infect cells of the vascular endothelium and a range of organs. 
The feline cells investigated here were of kidney and embryonic fibroblast origin.
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Productive infection may not occur in other feline cells, for example, if CAV-1 
infection of feline respiratory epithelium was non-productive the spread of CAV-1 to 
permissive cells would be prevented. As such further investigations of wild-type 
CAV-1 infection in cats via natural routes would be necessary to determine suitable 
routes of administration of a CAV-1 based vaccine.
CAV-1 infection of human cells was studied in cells derived from tissues that one 
might expect to be infected by CAV-1 i.e. lung epithelium and kidney cells. 
However, despite entering these cells, the CAV-1 infectious cycle was incomplete. 
Infection of A549 cells was semi-productive, however, no infectious virus was 
generated in 293 cells. The block(s) to CAV-1 replication clearly occur at different 
stages of the virus life cycle in each of these cell-lines, and it is tempting to speculate 
that the block in 293 cells is at or before the packaging stage, while in A549 cells it 
might be that virus release from or lysis of cells is inefficient. Nevertheless, transgene 
expression was evident from AE3-GFP-CAV-1 in both cell-lines.
Like HAds, the application of CAV-1 for human gene therapy would require targeting 
of vectors. The CAV-1 genome was able to accommodate fibre genes from both 
CAV-2 and HAd5 and preliminary investigations suggested that the pseudotyping of 
CAV-1 altered its native hopism. The available vector system will allow the insertion 
of fibre genes from a catalogue of HAd5 fibre constructs, with known receptor 
binding capabilities, which could be used in conjunction with replication deficient 
CAV-1 vectors to target specific cell types.
An alternative to using heterologous adenovirus fibre constructs would be to modify 
the fibre of CAV-1, which would also be aided by the vector system described here. 
Inserting peptides with known receptor affinities into the receptor binding site of the 
fibre may confer tissue specificity onto the CAV-1 vector. In order to make such 
modifications, it will be necessary to establish the sites within the CAV-1 fibre that 
tolerate peptide insertion and permit effective expression of ligand binding properties 
of the peptide. The effect of such insertions on primary receptor binding would have 
to be established, for example, if native CAR binding is retained studies will be 
required to determine how native tropism might be ablated through further knob 
mutagenesis.
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Assuming that the modification of the CAV-1 fibre would allow the binding to 
specific receptors, the nature of CAV-1 penton interactions with cells must still be 
determined. The penton plays a critical role in both internalisation of adenoviruses 
and the efficient lysis of cells following virus replication and packaging into new 
particles. The results in Chapter 4 suggest that both of these events are diminished in 
human cells. Understanding the role of the penton in CAV-1 infection will therefore 
be important in the development of it as a vector. The penton can mediate infection in 
HAds with normal fibre binding ablated (Mizuguchi et al, 2002). It has also been 
shown that fibre-less HAd particles can be recovered that are still infectious (albeit it 
at a much lower efficiency) with cell entry achieved through penton interactions with 
cellular integrins (Von Seggern et al, 1999). These interactions are mediated through 
an ROD motif in the penton, however the CAV-1 penton lacks such a motif and as a 
result CAV-1 may employ a different strategy for internalisation. As it has been 
demonstrated that the penton contributes to the wide tissue tropism of HAd 2 and 5 
(due to widespread integrin expression), it will be important to determine if this is the 
case for CAV-1 based vectors. Future investigations with labelled fibre-less CAV-1 
will be important to determine the role of the penton base in viral infectivity.
Although it was demonstrated that CAV-1 can enter and express transgenes in cells of 
human origin, and has the potential to be targeted, this would be of little use if the 
vector encountered neuhalising antibodies upon administiation. Whereas 46% of 
human serum samples neutralised HAd5, only 22% of the same samples neutralised 
CAV-1. The hexon is the major adenovirus immunogen, and as such it was 
hypothesised that the immune profile of the HAd5 pseudotyped vector would be 
similar to that of CAV-1. All but one of the anti-CAV-1 samples neutralised the 
pseudotyped vector, however, a further 24% of samples also neutralised this vector. 
These findings indicate that anti-fibre antibodies may be a limiting factor in the use 
CAV-1 vectors pseudotyped with HAd fibres, although studies have shown that 
antibodies specific to fibre proteins are unable to neutralise HAds in vivo. As such in 
vivo immunological studies would be necessary to determine whether anti-HAdS fibre 
antibodies are significant to prevent CAV-1 based vector activity. In addition, it is 
likely that the neutralisation of this vector would be reduced in a gene therapy setting 
as the assay used here was extremely sensitive. The use of CAV-1 vectors that
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maintain the majority of the CAV-1 fibre would further reduce the likelihood of 
vector extinction by anti-HAd5 fibre antibodies.
In conclusion, CAV-1 is an excellent candidate for development as vector for use in 
both cats and humans. However for vaccination in cats it will be important to 
determine if CAV-1 can use natural routes for infection. For gene therapy purposes, 
which are presented here primarily from the perspective of human use but could 
equally apply to use in cats, future work on secondary interactions of the CAV-1 
penton and target cells will be necessary to determine whether this has to be addressed 
as far as targeting is concerned. Finally, the studies described here, although directed 
towards feline and human cells, have broader implications for CAV-1 vector use in 
other species.
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